


**CUMULATIVE
SUPPLEMENT 6
June 2011**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

**Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2011

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

Cumulative Supplement 6

June 2011

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

31st EDITION

**CUMULATIVE SUPPLEMENT 6
June 2011**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 30th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 31st Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
SHIONOGI PHARMA INC (SHIONOGI PHARMA)	SHIONOGI INC (SHIONOGI INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable

Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucml29689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2010</u>	<u>MAR 2011</u>	<u>JUN 2011</u>	<u>SEPT 2011</u>	<u>DEC 2011</u>
DRUG PRODUCTS LISTED	13838	14029	14309		
SINGLE SOURCE	2482 (17.9%)	2477 (17.7%)	2468 (17.2%)		
MULTISOURCE	11267 (81.4%)	11463 (81.7%)	11752 (82.1%)		
THERAPEUTICALLY EQUIVALENT	11107 (80.3%)	11301 (80.6%)	11592 (81.0%)		
NOT THERAPEUTICALLY EQUIVALENT	160 (1.2%)	162 (1.2%)	160 (1.1%)		
EXCEPTIONS ¹	89 (0.6%)	89 (0.6%)	89 (0.6%)		
NEW MOLECULAR ENTITIES APPROVED	8	6	8		
NUMBER OF APPLICANTS	752	768	784		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.

CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 31ST EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

1-1

ABIRATERONE ACETATE

TABLET; ORAL

ZYTIGA

+ CENTOCOR ORTHO 250MG N202379 001 Apr 28, 2011 Apr NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA MIRROR PHARMS 325MG;50MG;40MG A040864 001 Dec 01, 2008 Mar CAHN

AA 500MG;50MG;40MG A040883 001 Dec 23, 2008 Mar CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

AA WRASER PHARMS LLC 356.4MG;30MG;16MG A040688 001 Apr 03, 2007 Jan CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA BOCA PHARMA 300MG;5MG A090415 001 Jan 24, 2011 Feb CTEC

AB 300MG;5MG A090415 001 Jan 24, 2011 Jan NEWA

AA 300MG;7.5MG A090415 002 Jan 24, 2011 Feb CTEC

AB 300MG;7.5MG A090415 002 Jan 24, 2011 Jan NEWA

AA 300MG;10MG A090415 003 Jan 24, 2011 Feb CTEC

AB 300MG;10MG A090415 003 Jan 24, 2011 Jan NEWA

AA + MIKART 300MG;5MG A040658 001 Jan 19, 2006 Mar CRLD

AA 300MG;5MG A040658 001 Jan 19, 2006 Feb CTEC

AA + 300MG;7.5MG A040556 002 Mar 24, 2006 Feb CTEC

AA + 300MG;10MG A040556 001 Jun 23, 2004 Feb CTEC

@ RANBAXY 500MG;5MG A040825 001 Aug 16, 2007 May DISC

@ 500MG;10MG A040824 001 Aug 16, 2007 May DISC

@ RANBAXY LABS LTD 325MG;10MG A040826 001 Aug 16, 2007 May DISC

@ 750MG;7.5MG A040822 001 Aug 16, 2007 May DISC

LORTAB

AA UCB INC 500MG;5MG A087722 001 Jul 09, 1982 Jan CAHN

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

@ VINTAGE PHARMS 650MG;65MG A040507 001 Jul 30, 2003 Mar DISC

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET-N 100

@ XANODYNE PHARM 650MG;100MG N017122 002 Jan DISC

DARVOCET-N 50

@ XANODYNE PHARM 325MG;50MG N017122 001 Jan DISC

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

@ CORNERSTONE 325MG;100MG A076743 001 May 07, 2004 Mar DISC

@ 500MG;100MG A076750 001 Jun 28, 2004 Mar DISC

@ MIRROR PHARMS 650MG;100MG A077821 001 Feb 11, 2008 Apr DISC

AB 650MG;100MG A077821 001 Feb 11, 2008 Mar CAHN

@ TEVA 650MG;100MG A074119 001 Dec 19, 1994 Mar DISC

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

@	VINTAGE PHARMS	325MG;50MG	A074843	002	Feb 15, 2001	Mar	DISC
@		650MG;100MG	A074843	001	Feb 12, 1997	Mar	DISC

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC

MIOCHOL-E

>A>	+	BAUSCH AND LOMB	20MG/VIAL	N020213	001	Sep 22, 1993	Jun	CAHN
>D>	+	NOVARTIS	20MG/VIAL	N020213	001	Sep 22, 1993	Jun	CAHN

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

AB		MYLAN	200MG	A074977	001	Apr 13, 1998	Feb	CAHN
----	--	-------	-------	---------	-----	--------------	-----	------

TABLET; ORAL

ACYCLOVIR

AB		MYLAN	400MG	A074976	001	Apr 13, 1998	Feb	CAHN
AB			800MG	A074976	002	Apr 13, 1998	Feb	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

@	HOSPIRA	EQ 50MG BASE/ML	A075065	001	Feb 25, 1999	Feb	DISC
---	---------	-----------------	---------	-----	--------------	-----	------

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

XERESE

+	MEDA PHARMS	5%;1%	N022436	001	Jul 31, 2009	May	CTNA
---	-------------	-------	---------	-----	--------------	-----	------

ALBENDAZOLE

TABLET; ORAL

ALBENZA

>A>	+	COREPHARMA	200MG	N020666	001	Jun 11, 1996	Jun	CAHN
>D>	+	GLAXOSMITHKLINE LLC	200MG	N020666	001	Jun 11, 1996	Jun	CAHN

ALCAFTADINE

SOLUTION/DROPS; OPHTHALMIC

LASTACFT

>A>	+	ALLERGAN	0.25%	N022134	001	Jul 28, 2010	Jun	CAHN
>D>	+	VISTAKON PHARMS LLC	0.25%	N022134	001	Jul 28, 2010	Jun	CAHN

ALCLOMETASONE DIPROPIONATE

OINTMENT; TOPICAL

ACLOVATE

AB	+	NYCOMED US	0.05%	N018702	001	Dec 14, 1982	Mar	CAHN
----	---	------------	-------	---------	-----	--------------	-----	------

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

AB		MYLAN	EQ 35MG BASE	A078638	001	Aug 04, 2008	Feb	CAHN
AB			EQ 70MG BASE	A078638	002	Aug 04, 2008	Feb	CAHN
	@	SANDOZ	EQ 5MG BASE	A075871	001	Apr 22, 2009	Mar	DISC
	@		EQ 10MG BASE	A075871	002	Apr 22, 2009	Mar	DISC
	@		EQ 35MG BASE	A075871	004	Apr 22, 2009	Mar	DISC
	@		EQ 40MG BASE	A075871	003	Apr 22, 2009	Mar	DISC

TABLET; ORAL

ALENDRONATE SODIUM

@ SANDOZ

EQ 70MG BASE

A075871 005 Apr 22, 2009 Mar DISC

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB IPCA LABS LTD

100MG

A090637 001 Mar 16, 2011 Feb NEWA

AB 300MG

A090637 002 Mar 16, 2011 Feb NEWA

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB AUROBINDO PHARMA USA 0.5MG

A090871 001 Jun 07, 2011 May NEWA

AB 1MG

A090871 002 Jun 07, 2011 May NEWA

AB 2MG

A090871 003 Jun 07, 2011 May NEWA

AB 3MG

A090871 004 Jun 07, 2011 May NEWA

ALPROSTADIL

SUPPOSITORY; URETHRAL

MUSE

MEDA PHARMS

0.125MG

N020700 001 Nov 19, 1996 May CAHN

0.25MG

N020700 002 Nov 19, 1996 May CAHN

0.5MG

N020700 003 Nov 19, 1996 May CAHN

+

1MG

N020700 004 Nov 19, 1996 May CAHN

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

AB EPIC PHARMA LLC EQ 2.5MG BASE

A078552 001 Apr 08, 2009 Apr CAHN

AB EQ 5MG BASE

A078552 002 Apr 08, 2009 Apr CAHN

AB EQ 10MG BASE

A078552 003 Apr 08, 2009 Apr CAHN

AB HIKMA PHARMS EQ 2.5MG BASE

A077771 001 Apr 12, 2011 Mar NEWA

AB EQ 5MG BASE

A077771 002 Apr 12, 2011 Mar NEWA

AB EQ 10MG BASE

A077771 003 Apr 12, 2011 Mar NEWA

AB PURACAP PHARM EQ 2.5MG BASE

A078131 001 Sep 04, 2007 May CAHN

AB EQ 5MG BASE

A078131 002 Sep 04, 2007 May CAHN

AB EQ 10MG BASE

A078131 003 Sep 04, 2007 May CAHN

AB SECAN PHARMS EQ 5MG BASE

A090752 001 Apr 15, 2011 Apr NEWA

AB EQ 10MG BASE

A090752 002 Apr 15, 2011 Apr NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

>A> AB DR REDDYS LABS INC EQ 5MG BASE;40MG A090149 001 Jul 05, 2011 Jun NEWA

>A> AB EQ 10MG BASE;40MG A090149 002 Jul 05, 2011 Jun NEWA

>A> AB LUPIN PHARMS EQ 5MG BASE;40MG A078466 005 Jul 05, 2011 Jun NEWA

>A> AB EQ 10MG BASE;40MG A078466 006 Jul 05, 2011 Jun NEWA

>A> AB MYLAN EQ 5MG BASE;40MG A079047 001 Jul 05, 2011 Jun NEWA

>A> AB EQ 10MG BASE;40MG A079047 002 Jul 05, 2011 Jun NEWA

>A> AB TEVA PHARMS EQ 5MG BASE;40MG A077179 005 Jul 05, 2011 Jun NEWA

>A> AB EQ 10MG BASE;40MG A077179 006 Jul 05, 2011 Jun NEWA

>A> AB WATSON LABS INC EQ 5MG BASE;40MG A090364 001 Jul 05, 2011 Jun NEWA

>A> AB EQ 10MG BASE;40MG A090364 002 Jul 05, 2011 Jun NEWA

LOTREL

AB NOVARTIS EQ 5MG BASE;40MG

N020364 007 Apr 11, 2006 Jan CFTG

CAPSULE; ORAL

LOTREL

AB	+	NOVARTIS	EQ 10MG BASE;40MG	N020364 006	Apr 11, 2006	Jan	CFTG
----	---	----------	-------------------	-------------	--------------	-----	------

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

AB		AM ANTIBIOTICS	250MG	A062058 001		Feb	CDFR
AB			500MG	A062058 002		Feb	CDFR

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE, TABLET; ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

>A>	+	GASTROENTERO	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824 001	Feb 08, 2011	Jun	CAHN
-----	---	--------------	--	-------------	--------------	-----	------

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

>D>	+	DAVA PHARMS INC	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824 001	Feb 08, 2011	Jun	CAHN
	+		500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824 001	Feb 08, 2011	Feb	NEWA

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

>D>	AP	X GEN PHARMS	50MG/VIAL	A063206 001	Apr 29, 1992	Jun	CRLD
>A>	AP	+	50MG/VIAL	A063206 001	Apr 29, 1992	Jun	CRLD
>D>		FUNGIZONE					
>D>	AP	+	APOTHECON	50MG/VIAL	A060517 001	Jun	DISC
>A>		@	50MG/VIAL	A060517 001		Jun	DISC

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP		AUROBINDO PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090340 001	Sep 20, 2010	Apr	CAIN
AP			EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090349 001	Sep 20, 2010	Apr	CAIN
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090340 002	Sep 20, 2010	Apr	CAIN
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090349 002	Sep 20, 2010	Apr	CAIN
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090339 001	Sep 20, 2010	Apr	CAIN

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

AB		SANTOS BIOTECH	1MG	A078944 001	Jun 28, 2010	Feb	CAHN
----	--	----------------	-----	-------------	--------------	-----	------

ARGATROBAN

INJECTABLE; IV (INFUSION)

ARGATROBAN IN SODIUM CHLORIDE

>A>		EAGLE PHARMS	50MG/ML (50MG/ML)	N022434 001	Jun 29, 2011	Jun	NEWA
>A>		SANDOZ	125MG/125ML (1MG/ML)	N022485 001	May 09, 2011	May	NEWA

SOLUTION; IV (INFUSION)

ARGATROBAN IN DEXTROSE

@ SANDOZ

			125MG/125ML (1MG/ML)	N201743 001	May 09, 2011	May	DISC
--	--	--	----------------------	-------------	--------------	-----	------

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

>D>	@ PHARMERAL	325MG;50MG;40MG	A087048 002	Dec 09, 1983	Jun	CAHN
>A>	@ PURACAP PHARM	325MG;50MG;40MG	A087048 002	Dec 09, 1983	Jun	CAHN

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB	MIRROR PHARMS	325MG;200MG	A040832 001	Jan 07, 2010	Mar	CAHN
AB	PROSAM LABS	325MG;200MG	A040252 001	Dec 10, 1997	Feb	CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB	MIRROR PHARMS	325MG;200MG;16MG	A040860 001	Jan 07, 2010	Mar	CAHN
AB	PROSAM LABS	325MG;200MG;16MG	A040283 001	Dec 29, 1998	Feb	CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA	COASTAL PHARMS	325MG;4.8355MG	A091670 001	Mar 16, 2011	Feb	NEWA
AA	WATSON LABS	325MG;4.8355MG	A090084 001	Mar 22, 2011	Mar	NEWA
AA	PERCODAN					
AA	+ ENDO PHARMS	325MG;4.8355MG	N007337 007	Aug 05, 2005	Feb	CFTG

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	MYLAN	25MG	A074126 003	Aug 26, 1998	Feb	CAHN
AB		50MG	A074126 001	Mar 23, 1994	Feb	CAHN
AB		100MG	A074126 002	Mar 23, 1994	Feb	CAHN

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB	GLENMARK GENERICS	250MG;100MG	A091211 001	Jan 12, 2011	Jan	NEWA
AB	MALARONE					
AB	+ GLAXOSMITHKLINE	250MG;100MG	N021078 001	Jul 14, 2000	Jan	CFTG

AZILSARTAN MEDOXOMIL

TABLET; ORAL

EDARBI

	TAKEDA PHARMS	40MG	N200796 001	Feb 25, 2011	Feb	NEWA
+		80MG	N200796 002	Feb 25, 2011	Feb	NEWA

AZTREONAM

INJECTABLE; INJECTION

AZTREONAM

AP	BEDFORD	1GM/VIAL	A065286 001	Mar 23, 2011	Mar	NEWA
AP		2GM/VIAL	A065286 002	Mar 23, 2011	Mar	NEWA

BACITRACIN

OINTMENT; OPHTHALMIC

BACITRACIN

+	FERA PHARMS	500 UNITS/GM	A061212 001	Feb	CAHN
+	NYCOMED US	500 UNITS/GM	A061212 001	Jan	CAHN

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT	FERA PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764 002	Feb	CAHN
AT	NYCOMED US	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764 002	Jan	CAHN

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT	FERA PHARMS	500 UNITS/GM;10,000 UNITS/GM	A065022 001	Feb 27, 2002	Feb	CAHN
AT	NYCOMED US	500 UNITS/GM;10,000 UNITS/GM	A065022 001	Feb 27, 2002	Jan	CAHN

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

+	FERA PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166 002	Feb	CAHN
+	NYCOMED US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166 002	Jan	CAHN

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

AP	CNS THERAPS INC	0.05MG/ML	N022462 001	Nov 19, 2010	Feb	CTEC
AP		0.5MG/ML	N022462 002	Nov 19, 2010	Feb	CTEC
AP		2MG/ML	N022462 003	Nov 19, 2010	Feb	CTEC

Lioresal

AP	+	MEDTRONIC	0.05MG/ML	N020075 003	Nov 07, 1996	Feb	CTEC
AP	+		0.5MG/ML	N020075 001	Jun 17, 1992	Feb	CTEC
AP	+		2MG/ML	N020075 002	Jun 17, 1992	Feb	CTEC

TABLET; ORAL

BACLOFEN

AB	PROSAM LABS	10MG	A077089 001	Oct 31, 2007	Feb	CAHN
AB		20MG	A077088 001	Oct 31, 2007	Feb	CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB	PRINSTON PHARM LLC	5MG	A076118 001	Feb 11, 2004	May	CAHN
AB		10MG	A076118 002	Feb 11, 2004	May	CAHN
AB		20MG	A076118 003	Feb 11, 2004	May	CAHN
AB		40MG	A076118 004	Feb 11, 2004	May	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	5MG;6.25MG	A076612 001	Feb 11, 2004	Feb	CAHN
AB		10MG;12.5MG	A076612 002	Feb 11, 2004	Feb	CAHN

TABLET; ORALBENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	MYLAN	20MG;12.5MG	A076612 003	Feb 11, 2004	Feb	CAHN
AB		20MG;25MG	A076612 004	Feb 11, 2004	Feb	CAHN

BENZTROPINE MESYLATEINJECTABLE; INJECTIONBENZTROPINE MESYLATE

AP	LUITPOLD	1MG/ML	A091152 001	Mar 29, 2010	Feb	CAHN
----	----------	--------	-------------	--------------	-----	------

BETAMETHASONE VALERATELOTION; TOPICALBETAMETHASONE VALERATE

AB	STI PHARMA LLC	EQ 0.1% BASE	A070052 001	Jul 31, 1985	Apr	CAHN
----	----------------	--------------	-------------	--------------	-----	------

BICALUTAMIDETABLET; ORALBICALUTAMIDE

AB	ROXANE	50MG	A078285 001	Mar 24, 2011	Mar	NEWA
----	--------	------	-------------	--------------	-----	------

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINECAPSULE; ORALPYLERA

>A>	+	AXCAN	140MG;125MG;125MG	N050786 001	Sep 28, 2006	Jun	CAHN
>D>	+	AXCAN SCANDIPHARM	140MG;125MG;125MG	N050786 001	Sep 28, 2006	Jun	CAHN

BOCEPREVIRCAPSULE; ORALVICTRELIS

+	SCHERING	200MG	N202258 001	May 13, 2011	May	NEWA
---	----------	-------	-------------	--------------	-----	------

BRETYLIUM TOSYLATEINJECTABLE; INJECTIONBRETYLIUM TOSYLATE

>D>				N019030 001	Apr 29, 1986	Jun	DISC
>D>	+	HOSPIRA	50MG/ML	N019030 001	Apr 29, 1986	Jun	DISC
>A>	@		50MG/ML	N019030 001	Apr 29, 1986	Jun	DISC

BROMFENAC SODIUMSOLUTION/DROPS; OPHTHALMICBROMDAY

+	ISTA PHARMS INC	0.09%	N021664 002	Oct 16, 2010	Mar	CRLD
---	-----------------	-------	-------------	--------------	-----	------

BROMFENAC SODIUM

	COASTAL PHARMS	0.09%	A201211 001	May 11, 2011	Apr	NEWA
--	----------------	-------	-------------	--------------	-----	------

XIBROM

@	ISTA PHARMS INC	0.09%	N021664 001	Mar 24, 2005	Mar	DISC
---	-----------------	-------	-------------	--------------	-----	------

BUDESONIDECAPSULE; ORALBUDESONIDE

AB	MYLAN	3MG	A090410 001	May 16, 2011	May	NEWA
----	-------	-----	-------------	--------------	-----	------

ENTOCORT EC

AB	+	ASTRAZENECA	3MG	N021324 001	Oct 02, 2001	May	CFTG
----	---	-------------	-----	-------------	--------------	-----	------

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DUOCAINE

>D>	@ AMPHASTAR	EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML)	N021496 001	May 23, 2003	Jun	CAHN
>A>	@ AMPHASTAR PHARMS INC	EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML)	N021496 001	May 23, 2003	Jun	CAHN

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

APLENZIN

>D>	BIOVAIL LABS INTL	174MG	N022108 001	Apr 23, 2008	Jun	CAHN
>D>	+	348MG	N022108 002	Apr 23, 2008	Jun	CAHN
>D>		522MG	N022108 003	Apr 23, 2008	Jun	CAHN
>A>	VALEANT INTL	174MG	N022108 001	Apr 23, 2008	Jun	CAHN
>A>	+	348MG	N022108 002	Apr 23, 2008	Jun	CAHN
>A>		522MG	N022108 003	Apr 23, 2008	Jun	CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB1	ANCHEN PHARMS	100MG	A091459 001	Jun 09, 2011	May	NEWA
AB1		150MG	A091459 002	Jun 09, 2011	May	NEWA
AB2		150MG	A091520 001	Jun 09, 2011	May	NEWA
AB1		200MG	A091459 003	Jun 09, 2011	May	NEWA
AB1	WATSON LABS FLORIDA	100MG	A079095 001	Mar 24, 2009	May	CAHN
AB2		150MG	A079094 001	Mar 24, 2009	May	CAHN
AB1		150MG	A079095 002	Mar 24, 2009	May	CAHN
AB1		200MG	A079095 003	Mar 24, 2009	May	CAHN

CALCIPOTRIENE

SOLUTION; TOPICAL

CALCIPOTRIENE

AT	G AND W LABS INC	0.005%	A078468 001	Mar 24, 2011	Mar	NEWA
----	------------------	--------	-------------	--------------	-----	------

CALCIUM ACETATE

SOLUTION; ORAL

PHOSLYRA

+	FRESENIUS MEDCL	EQ 169MG CALCIUM/5ML	N022581 001	Apr 18, 2011	Apr	NEWA
---	-----------------	----------------------	-------------	--------------	-----	------

TABLET; ORAL

CALCIUM ACETATE

AB	PADDOCK LABS	EQ 169MG CALCIUM	A091561 001	Apr 13, 2011	Mar	NEWA
AB	ELIPHOS					
AB	+ CYPRESS PHARM	EQ 169MG CALCIUM	A078502 001	Nov 25, 2008	Mar	CTEC

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	PRINSTON PHARM LLC	12.5MG	A074477 001	Feb 13, 1996	May	CAHN
AB		25MG	A074477 002	Feb 13, 1996	May	CAHN
AB		50MG	A074477 003	Feb 13, 1996	May	CAHN
AB		100MG	A074477 004	Feb 13, 1996	May	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	NOSTRUM	100MG	A076697 001	May 20, 2011	May	NEWA
AB		200MG	A076697 002	May 20, 2011	May	NEWA
AB		300MG	A076697 003	May 20, 2011	May	NEWA

CARBATROL

AB	SHIRE	100MG	N020712 003	Sep 30, 1997	May	CFTG
AB		200MG	N020712 001	Sep 30, 1997	May	CFTG
AB	+	300MG	N020712 002	Sep 30, 1997	May	CFTG

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

@ JUBILANT CADISTA

100MG

A071940 001 Feb 01, 1988 Jan CAHN

CARBIDOPA; LEVODOPA

TABLET; ORAL

SINEMET

AB	MERCK SHARP DOHME	10MG;100MG	N017555 001		Jan	CAHN
AB		25MG;100MG	N017555 003		Jan	CAHN
AB	+	25MG;250MG	N017555 002		Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL

SINEMET CR

AB	MERCK SHARP DOHME	25MG;100MG	N019856 002	Dec 24, 1992	Jan	CAHN
AB	+	50MG;200MG	N019856 001	May 30, 1991	Jan	CAHN

CARBINOXAMINE MALEATE

TABLET; ORAL

CARBINOXAMINE MALEATE

AA	RIVERS EDGE PHARMS	4MG	A090756 001	May 27, 2011	May	NEWA
----	--------------------	-----	-------------	--------------	-----	------

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	MIRROR PHARMS	350MG	A040823 001	Oct 22, 2008	Mar	CAHN
AA	PROSAM LABS	350MG	A040188 001	Mar 07, 1997	Feb	CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065226 001	Apr 21, 2005	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065244 001	Aug 12, 2005	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065226 002	Apr 21, 2005	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065247 001	Aug 12, 2005	Jan	CAHN

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065369 001	Jun 18, 2007	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065369 002	Jun 18, 2007	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065369 003	Jun 18, 2007	Jan	CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

AP	HOSPIRA INC	EQ 500MG BASE/VIAL	A065290 001	Aug 11, 2006	Jan	CAHN
----	-------------	--------------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065290 002	Aug 11, 2006	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065293 001	Aug 10, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065293 002	Aug 10, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065290 003	Aug 11, 2006	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065292 001	Aug 10, 2006	Jan	CAHN

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065313 001	Jan 23, 2006	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065313 002	Jan 23, 2006	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065312 001	Feb 13, 2006	Jan	CAHN

CEFPODOXIME PROXETIL

TABLET; ORAL

CEFPODOXIME PROXETIL

AB	+ SANDOZ	EQ 200MG BASE	A065462 002	May 28, 2008	Jan	CRLD
	VANTIN					
	@ PHARMACIA AND UPJOHN	EQ 100MG BASE	N050674 001	Aug 07, 1992	Jan	DISC
	@	EQ 200MG BASE	N050674 002	Aug 07, 1992	Jan	DISC

CEFTAZIDIME

INJECTABLE; INJECTION

>A>	CEFTAZIDIME IN DEXTROSE CONTAINER					
>A>	B BRAUN	EQ 1GM BASE	N050823 001	Jun 13, 2011	Jun	NEWA
>A>	+	EQ 2GM BASE	N050823 002	Jun 13, 2011	Jun	NEWA

CEFTRIAOXONE SODIUM

INJECTABLE; IM-IV

CEFTRIAOXONE

AP	HOSPIRA INC	EQ 250MG BASE/VIAL	A065230 001	Aug 02, 2005	Jan	CAHN
AP		EQ 500MG BASE/VIAL	A065230 002	Aug 02, 2005	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A065230 003	Aug 02, 2005	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065230 004	Aug 02, 2005	Jan	CAHN

INJECTABLE; INJECTION

CEFTRIAOXONE

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A065231 001	Aug 02, 2005	Jan	CAHN
AP		EQ 2GM BASE/VIAL	A065231 002	Aug 02, 2005	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A065232 001	Aug 02, 2005	Jan	CAHN
AP	+ SANDOZ	EQ 10GM BASE/VIAL	A065168 001	May 17, 2005	Jan	CRLD

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB	ALKEM LABS LTD	EQ 250MG BASE	A065496 001	Jun 07, 2010	May	CAHN
AB		EQ 500MG BASE	A065496 002	Jun 07, 2010	May	CAHN
>A>	AB APOTEX	EQ 250MG BASE	A065069 001	Oct 02, 2002	Jun	CAHN
>A>	AB	EQ 500MG BASE	A065069 002	Oct 02, 2002	Jun	CAHN
>D>	AB APOTEX INC	EQ 250MG BASE	A065069 001	Oct 02, 2002	Jun	CAHN
>D>	AB	EQ 500MG BASE	A065069 002	Oct 02, 2002	Jun	CAHN

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

AB	HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	A065048 001	Jan 09, 2004	Mar	CTEC
AP	HOSPIRA INC	EQ 750MG BASE/VIAL	A065483 001	Oct 15, 2008	Jan	CAHN

INJECTABLE; INJECTION

CEFUROXIME SODIUM

AP	HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065503 001	Oct 15, 2008	Jan	CAHN
AP		EQ 1.5GM BASE/VIAL	A065483 002	Oct 15, 2008	Jan	CAHN
AP		EQ 7.5GM BASE/VIAL	A065484 001	Oct 15, 2008	Jan	CAHN

CEPHALEXIN

FOR SUSPENSION; ORAL

CEPHALEXIN

	@ ACS DOBFAR	EQ 100MG BASE/ML	A062117 001		Jan	CAHN
AB		EQ 125MG BASE/5ML	A062117 002		Jan	CAHN
AB	+	EQ 250MG BASE/5ML	A062117 003		Jan	CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT	LYNE	0.12%	A074291 001	Dec 28, 1995	Feb	CAHN
----	------	-------	-------------	--------------	-----	------

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

AA	NATCO PHARMA LTD	EQ 150MG BASE	A091621 001	Jan 21, 2011	Jan	NEWA
AA		EQ 300MG BASE	A090612 001	Jan 21, 2011	Jan	NEWA

>A> CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

>A> SOLUTION; ORAL

>A> ZUTRIPRO

>A>	+	CYPRESS PHARM	4MG/5ML;5MG/5ML;60MG/5ML	N022439 001	Jun 08, 2011	Jun	NEWA
-----	---	---------------	--------------------------	-------------	--------------	-----	------

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

AB	+	SANDOZ	EQ 4GM RESIN/PACKET	A074557 001	Aug 15, 1996	Apr	CRLD
----	---	--------	---------------------	-------------	--------------	-----	------

CHOLESTYRAMINE LIGHT

AB	+	SANDOZ	EQ 4GM RESIN/PACKET	A074558 001	Aug 15, 1996	Apr	CRLD
----	---	--------	---------------------	-------------	--------------	-----	------

QUESTRAN

@ BRISTOL MYERS

EQ 4GM RESIN/PACKET	N016640 001		Apr	DISC
---------------------	-------------	--	-----	------

@

EQ 4GM RESIN/SCOOPFUL	N016640 003		Apr	DISC
-----------------------	-------------	--	-----	------

QUESTRAN LIGHT

@ BRISTOL MYERS

EQ 4GM RESIN/PACKET	N019669 001	Dec 05, 1988	Apr	DISC
---------------------	-------------	--------------	-----	------

@

EQ 4GM RESIN/SCOOPFUL	N019669 003	Dec 05, 1988	Apr	DISC
-----------------------	-------------	--------------	-----	------

AB	+		EQ 4GM RESIN/PACKET	N019669 001	Dec 05, 1988	Mar	CRLD
----	---	--	---------------------	-------------	--------------	-----	------

CICLOPIROX

SHAMPOO; TOPICAL

CICLOPIROX

AT	TARO	1%	A090269 001	Feb 23, 2011	Feb	NEWA
----	------	----	-------------	--------------	-----	------

CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PROQUIN XR

@ DEPOMED INC

EQ 500MG BASE

N021744 001 May 19, 2005 May DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

>D>	@ ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A078166 002	Nov 27, 2007	Jun	CMFD
>A>	AB	212.6MG;EQ 287.5MG BASE	A078166 002	Nov 27, 2007	Jun	CMFD
>D>	@	425.2MG;EQ 574.9MG BASE	A078166 001	Nov 27, 2007	Jun	CMFD
>A>	AB	425.2MG;EQ 574.9MG BASE	A078166 001	Nov 27, 2007	Jun	CMFD

CISPLATIN

INJECTABLE; INJECTION

PLATINOL

>D>						
>D>	+ BRISTOL MYERS	50MG/VIAL	N018057 002		Jun	DISC
>A>	@	50MG/VIAL	N018057 002		Jun	DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB	MYLAN	EQ 10MG BASE	A077042 001	Nov 05, 2004	Apr	CAHN
AB		EQ 20MG BASE	A077042 002	Nov 05, 2004	Apr	CAHN
AB		EQ 40MG BASE	A077042 003	Nov 05, 2004	Apr	CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	MATRIX LABS LTD	EQ 75MG BASE	A091225 001	May 31, 2011	May	NEWA
AB		EQ 150MG BASE	A091225 002	May 31, 2011	May	NEWA
AB		EQ 300MG BASE	A091225 003	May 31, 2011	May	NEWA

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

CLINDAGEL

BT	+ GALDERMA LABS LP	EQ 1% BASE	N050782 001	Nov 27, 2000	Mar	CRLD
----	--------------------	------------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

@ COREPHARMA

EQ 1% BASE

A064108 001 Sep 27, 1996 Apr CAHN

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

OLUX

AB	+ STIEFEL LABS INC	0.05%	N021142 001	May 26, 2000	May	CAHN
----	--------------------	-------	-------------	--------------	-----	------

CREAM; TOPICAL

CLOBETASOL PROPIONATE

@ COREPHARMA

0.05%

A075338 001 Feb 09, 2001 Apr CAHN

CLOBETASOL PROPIONATE (EMOLLIENT)

@ COREPHARMA

0.05%

A075733 001 Aug 22, 2001 Apr CAHN

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

@ COREPHARMA

0.05%

A075057 001 Aug 12, 1998 Apr CAHN

SHAMPOO; TOPICAL

CLOBETASOL PROPIONATE

AB		ACTAVIS MID ATLANTIC	0.05%	A078854	001	Jun 07, 2011	May	NEWA
----	--	----------------------	-------	---------	-----	--------------	-----	------

CLOBEX

AB	+	GALDERMA LABS	0.05%	N021644	001	Feb 05, 2004	May	CFTG
----	---	---------------	-------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

AT		NYCOMED US	0.05%	A075391	001	Feb 08, 1999	Apr	CAHN
----	--	------------	-------	---------	-----	--------------	-----	------

SPRAY; TOPICAL

CLOBETASOL PROPIONATE

AT		PADDOCK LABS	0.05%	A090898	001	Jun 16, 2011	May	NEWA
----	--	--------------	-------	---------	-----	--------------	-----	------

CLOBEX

>D>	+	GALDERMA LABS LP	0.05%	N021835	001	Oct 27, 2005	Jun	CTEC
-----	---	------------------	-------	---------	-----	--------------	-----	------

>A>	AT	+	0.05%	N021835	001	Oct 27, 2005	Jun	CTEC
-----	----	---	-------	---------	-----	--------------	-----	------

		+	0.05%	N021835	001	Oct 27, 2005	May	CFTG
--	--	---	-------	---------	-----	--------------	-----	------

CLOCORTOLONE PIVALATECREAM; TOPICAL

CLODERM

>D>	+	DOW PHARM SCIENCES	0.1%	N017765	001		Jun	CAHN
-----	---	--------------------	------	---------	-----	--	-----	------

>A>	+	PROMIUS PHARMA LLC	0.1%	N017765	001		Jun	CAHN
-----	---	--------------------	------	---------	-----	--	-----	------

CLONIDINE HYDROCHLORIDEINJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

>A>	AP	APP PHARMS	1MG/10ML (0.1MG/ML)	A200673	001	Jul 08, 2011	Jun	NEWA
-----	----	------------	---------------------	---------	-----	--------------	-----	------

>A>	AP		5MG/10ML (0.5MG/ML)	A200673	002	Jul 08, 2011	Jun	NEWA
-----	----	--	---------------------	---------	-----	--------------	-----	------

	AP	WEST WARD	1MG/10ML (0.1MG/ML)	A200300	001	Jan 26, 2011	Jan	NEWA
--	----	-----------	---------------------	---------	-----	--------------	-----	------

	AP		5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Jan	NEWA
--	----	--	---------------------	---------	-----	--------------	-----	------

CODEINE SULFATE

>A>		SOLUTION; ORAL						
-----	--	----------------	--	--	--	--	--	--

>A>		CODEINE SULFATE						
-----	--	-----------------	--	--	--	--	--	--

>A>	+	ROXANE	30MG/5ML	N202245	001	Jun 30, 2011	Jun	NEWA
-----	---	--------	----------	---------	-----	--------------	-----	------

COLCHICINE; PROBENECIDTABLET; ORAL

PROBENECID AND COLCHICINE

AB		MIRROR PHARMS	0.5MG;500MG	A040618	001	May 13, 2008	Mar	CAHN
----	--	---------------	-------------	---------	-----	--------------	-----	------

COSYNTROPININJECTABLE; INJECTION

CORTROSYN

>D>	AP	+	AMPHASTAR	0.25MG/VIAL	N016750	001		Jun	CAHN
-----	----	---	-----------	-------------	---------	-----	--	-----	------

>A>	AP	+	AMPHASTAR PHARMS INC	0.25MG/VIAL	N016750	001		Jun	CAHN
-----	----	---	----------------------	-------------	---------	-----	--	-----	------

CYCLOBENZAPRINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL

AMRIX

AB		ANESTA AG	15MG	N021777	001	Feb 01, 2007	Apr	CFTG
----	--	-----------	------	---------	-----	--------------	-----	------

AB	+		30MG	N021777	002	Feb 01, 2007	Apr	CFTG
----	---	--	------	---------	-----	--------------	-----	------

CYCLOBENZAPRINE HYDROCHLORIDE

AB		MYLAN	15MG	A090738	001	Apr 18, 2011	Apr	NEWA
----	--	-------	------	---------	-----	--------------	-----	------

AB			30MG	A090738	002	Apr 18, 2011	Apr	NEWA
----	--	--	------	---------	-----	--------------	-----	------

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	JUBILANT CADISTA	5MG	A077563 001	Apr 19, 2006	Jan	CAHN
AB		10MG	A077563 002	Apr 19, 2006	Jan	CAHN
AB	KVK TECH	5MG	A078048 001	Feb 28, 2011	Feb	NEWA
AB		10MG	A078048 002	Feb 28, 2011	Feb	NEWA
AB	PROSAM LABS	5MG	A077291 001	Feb 03, 2006	Feb	CAHN
AB		10MG	A077209 001	Oct 04, 2005	Feb	CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

ENABLEX

	WARNER CHILCOTT LLC	EQ 7.5MG BASE	N021513 001	Dec 22, 2004	May	CAHN
+		EQ 15MG BASE	N021513 002	Dec 22, 2004	May	CAHN

DARUNAVIR ETHANOLATE

TABLET; ORAL

PREZISTA

@	TIBOTEC	EQ 300MG BASE	N021976 001	Jun 23, 2006	May	DISC
---	---------	---------------	-------------	--------------	-----	------

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION

DAUNOXOME

>A>	+	GALEN (UK)	EQ 2MG BASE/ML	N050704 002	Apr 08, 1996	Jun	CAHN
>D>	+	GILEAD	EQ 2MG BASE/ML	N050704 002	Apr 08, 1996	Jun	CAHN

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

@	COREPHARMA	75MG	N050261 001		May	CAHN
AB		150MG	N050261 002		May	CAHN
AB	+	300MG	N050261 003		May	CAHN

DEMECLOCYCLINE HYDROCHLORIDE

AB	VERSAPHARM	150MG	A065389 001	Dec 01, 2008	May	CAHN
AB		300MG	A065389 002	Dec 01, 2008	May	CAHN

DESLORATADINE

TABLET; ORAL

DESLORATADINE

AB	DR REDDYS LABS LTD	5MG	A078365 001	Mar 08, 2011	Feb	NEWA
----	--------------------	-----	-------------	--------------	-----	------

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOUR

AB	+	SCHERING	5MG;240MG	N021605 001	Mar 03, 2005	Apr	CFTG
----	---	----------	-----------	-------------	--------------	-----	------

DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR

AB	DR REDDYS LABS LTD	5MG;240MG	A078366 001	Apr 26, 2011	Apr	NEWA
----	--------------------	-----------	-------------	--------------	-----	------

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL

STIMATE

@	CSL BEHRING	0.15MG/SPRAY	N020355 001	Mar 07, 1994	May	DISC
---	-------------	--------------	-------------	--------------	-----	------

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

EMOQUETTE

AB	VINTAGE	0.15MG;0.03MG	A076675	001	Feb 25, 2011	Feb	NEWA
----	---------	---------------	---------	-----	--------------	-----	------

DESOXIMETASONE

GEL; TOPICAL

DESOXIMETASONE

AB	VERSAPHARM	0.05%	A090727	001	Mar 10, 2011	Feb	NEWA
----	------------	-------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

TOPICORT

+	TARO PHARMS NORTH	0.05%	N018594	001	Jan 17, 1985	May	CMFD
---	-------------------	-------	---------	-----	--------------	-----	------

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

>A>	LYNE	0.5MG/5ML	A090891	001	Jul 12, 2011	Jun	NEWA
-----	------	-----------	---------	-----	--------------	-----	------

AA	VINTAGE PHARMS	0.5MG/5ML	A091188	001	May 11, 2011	Apr	NEWA
----	----------------	-----------	---------	-----	--------------	-----	------

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	PFIZER	EQ 4MG PHOSPHATE/ML	A040803	001	Aug 29, 2008	May	CAHN
----	--------	---------------------	---------	-----	--------------	-----	------

AP		EQ 10MG PHOSPHATE/ML	A040802	001	Aug 29, 2008	May	CAHN
----	--	----------------------	---------	-----	--------------	-----	------

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT	FERA PHARMS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Feb	CAHN
----	-------------	---------------------------------------	---------	-----	--------------	-----	------

AT	NYCOMED US	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Jan	CAHN
----	------------	---------------------------------------	---------	-----	--------------	-----	------

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FOCALIN XR

	NOVARTIS	25MG	N021802	008	Apr 21, 2011	May	NEWA
--	----------	------	---------	-----	--------------	-----	------

		35MG	N021802	007	Apr 21, 2011	May	NEWA
--	--	------	---------	-----	--------------	-----	------

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

>A>	AB	COREPHARMA	5MG	N017078	001		Jun	CAHN
-----	----	------------	-----	---------	-----	--	-----	------

>A>	AB		10MG	N017078	002		Jun	CAHN
-----	----	--	------	---------	-----	--	-----	------

>A>	AB	+	15MG	N017078	003		Jun	CAHN
-----	----	---	------	---------	-----	--	-----	------

>D>	AB	SMITHKLINE BEECHAM	5MG	N017078	001		Jun	CAHN
-----	----	--------------------	-----	---------	-----	--	-----	------

>D>	AB		10MG	N017078	002		Jun	CAHN
-----	----	--	------	---------	-----	--	-----	------

>D>	AB	+	15MG	N017078	003		Jun	CAHN
-----	----	---	------	---------	-----	--	-----	------

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA	AMNEAL PHARMS	15MG/5ML;6.25MG/5ML	A090575	001	Feb 08, 2011	Jan	NEWA
----	---------------	---------------------	---------	-----	--------------	-----	------

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

>A>	AP	BAXTER HLTHCARE	5GM/100ML;75MG/100ML	N017634 004		Jun	CAHN
>D>	AP	BRISTOL MYERS SQUIBB	5GM/100ML;75MG/100ML	N017634 004		Jun	CAHN

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

>A>	AP	BAXTER HLTHCARE	5GM/100ML;150MG/100ML	N017634 001		Jun	CAHN
>D>	AP	BRISTOL MYERS SQUIBB	5GM/100ML;150MG/100ML	N017634 001		Jun	CAHN

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

>A>	AP	BAXTER HLTHCARE	5GM/100ML;224MG/100ML	N017634 003		Jun	CAHN
>D>	AP	BRISTOL MYERS SQUIBB	5GM/100ML;224MG/100ML	N017634 003		Jun	CAHN

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

>A>	AP	BAXTER HLTHCARE	5GM/100ML;300MG/100ML	N017634 002		Jun	CAHN
>D>	AP	BRISTOL MYERS SQUIBB	5GM/100ML;300MG/100ML	N017634 002		Jun	CAHN

DICLOFENAC SODIUM

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

AB		VALEANT INTL	100MG	A075492 001	Feb 11, 2000	Apr	CAHN
----	--	--------------	-------	-------------	--------------	-----	------

DIFLUPREDNATE

EMULSION; OPHTHALMIC

DUREZOL

+		ALCON PHARMS LTD	0.05%	N022212 001	Jun 23, 2008	May	CAHN
---	--	------------------	-------	-------------	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM CD

>D>	AB3	BIOVAIL	120MG	N020062 001	Aug 10, 1992	Jun	CAHN
>D>	AB3		180MG	N020062 002	Dec 27, 1991	Jun	CAHN
>D>	AB3		240MG	N020062 003	Dec 27, 1991	Jun	CAHN
>D>	AB3	+	300MG	N020062 004	Dec 27, 1991	Jun	CAHN
>D>	BC	+	360MG	N020062 005	Aug 24, 1999	Jun	CAHN
>A>	AB3	VALEANT INTL	120MG	N020062 001	Aug 10, 1992	Jun	CAHN
>A>	AB3		180MG	N020062 002	Dec 27, 1991	Jun	CAHN
>A>	AB3		240MG	N020062 003	Dec 27, 1991	Jun	CAHN
>A>	AB3	+	300MG	N020062 004	Dec 27, 1991	Jun	CAHN
>A>	BC	+	360MG	N020062 005	Aug 24, 1999	Jun	CAHN

DILTIAZEM HYDROCHLORIDE

AB3		VALEANT INTL	120MG	A075116 001	Dec 23, 1999	Apr	CAHN
AB3			180MG	A075116 002	Dec 23, 1999	Apr	CAHN
AB3			240MG	A075116 003	Dec 23, 1999	Apr	CAHN
AB3			300MG	A075116 004	Dec 23, 1999	Apr	CAHN

TIAZAC

>D>	AB4	BIOVAIL	120MG	N020401 001	Sep 11, 1995	Jun	CAHN
>D>	AB4		180MG	N020401 002	Sep 11, 1995	Jun	CAHN
>D>	AB4		240MG	N020401 003	Sep 11, 1995	Jun	CAHN
>D>	AB4		300MG	N020401 004	Sep 11, 1995	Jun	CAHN
>D>	AB4		360MG	N020401 005	Sep 11, 1995	Jun	CAHN
>D>	AB4	+	420MG	N020401 006	Oct 16, 1998	Jun	CAHN
>A>	AB4	VALEANT INTL	120MG	N020401 001	Sep 11, 1995	Jun	CAHN
>A>	AB4		180MG	N020401 002	Sep 11, 1995	Jun	CAHN
>A>	AB4		240MG	N020401 003	Sep 11, 1995	Jun	CAHN
>A>	AB4		300MG	N020401 004	Sep 11, 1995	Jun	CAHN
>A>	AB4		360MG	N020401 005	Sep 11, 1995	Jun	CAHN

CAPSULE, EXTENDED RELEASE; ORAL

TIAZAC

>A>	AB4	+	VALEANT INTL	420MG	N020401	006	Oct 16, 1998	Jun	CAHN
-----	-----	---	--------------	-------	---------	-----	--------------	-----	------

TABLET; ORAL

CARDIZEM

>D>	AB		BIOVAIL LABS INTL	30MG	N018602	001	Nov 05, 1982	Jun	CAHN
>D>	AB			60MG	N018602	002	Nov 05, 1982	Jun	CAHN
>D>	AB			90MG	N018602	003	Dec 08, 1986	Jun	CAHN
>D>	AB	+		120MG	N018602	004	Dec 08, 1986	Jun	CAHN
>A>	AB		VALEANT INTL	30MG	N018602	001	Nov 05, 1982	Jun	CAHN
>A>	AB			60MG	N018602	002	Nov 05, 1982	Jun	CAHN
>A>	AB			90MG	N018602	003	Dec 08, 1986	Jun	CAHN
>A>	AB	+		120MG	N018602	004	Dec 08, 1986	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

>D>	AB		BIOVAIL LABS INTL	120MG	N021392	001	Feb 06, 2003	Jun	CAHN
>D>	AB			180MG	N021392	002	Feb 06, 2003	Jun	CAHN
>D>	AB			240MG	N021392	003	Feb 06, 2003	Jun	CAHN
>D>	AB			300MG	N021392	004	Feb 06, 2003	Jun	CAHN
>D>	AB			360MG	N021392	005	Feb 06, 2003	Jun	CAHN
>D>	AB	+		420MG	N021392	006	Feb 06, 2003	Jun	CAHN
>A>	AB		VALEANT INTL	120MG	N021392	001	Feb 06, 2003	Jun	CAHN
>A>	AB			180MG	N021392	002	Feb 06, 2003	Jun	CAHN
>A>	AB			240MG	N021392	003	Feb 06, 2003	Jun	CAHN
>A>	AB			300MG	N021392	004	Feb 06, 2003	Jun	CAHN
>A>	AB			360MG	N021392	005	Feb 06, 2003	Jun	CAHN
>A>	AB	+		420MG	N021392	006	Feb 06, 2003	Jun	CAHN

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

AB			PROSAM LABS	25MG	A040542	001	Apr 21, 2006	Feb	CAHN
AB				50MG	A040542	002	Apr 21, 2006	Feb	CAHN
AB				75MG	A040542	003	Apr 21, 2006	Feb	CAHN

DISULFIRAM

TABLET; ORAL

ANTABUSE

AB			ODYSSEY PHARMS	250MG	A088482	001	Dec 08, 1983	Mar	CTEC
AB		+		500MG	A088483	001	Dec 08, 1983	Mar	CTEC

DISULFIRAM

AB			SIGMAPHARM LABS LLC	250MG	A091619	001	Mar 28, 2011	Mar	NEWA
AB				500MG	A091619	002	Mar 28, 2011	Mar	NEWA

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL

DIVALPROEX SODIUM

AB			MYLAN	EQ 125MG VALPROIC ACID	A090407	001	Mar 28, 2011	Mar	NEWA
----	--	--	-------	------------------------	---------	-----	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

AB			AUROBINDO PHARMA LTD	EQ 125MG VALPROIC ACID	A090554	001	Apr 21, 2011	Apr	NEWA
AB				EQ 250MG VALPROIC ACID	A090554	002	Apr 21, 2011	Apr	NEWA
AB				EQ 500MG VALPROIC ACID	A090554	003	Apr 21, 2011	Apr	NEWA
AB			UNICHEM LABS LTD	EQ 125MG VALPROIC ACID	A079163	001	Apr 05, 2011	Mar	NEWA
AB				EQ 250MG VALPROIC ACID	A079163	002	Apr 05, 2011	Mar	NEWA
AB				EQ 500MG VALPROIC ACID	A079163	003	Apr 05, 2011	Mar	NEWA

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

AB	WATSON LABS FLORIDA	EQ 500MG VALPROIC ACID	A079080	001	Feb 25, 2011	Feb	NEWA
----	---------------------	------------------------	---------	-----	--------------	-----	------

DOCETAXEL

INJECTABLE; INJECTION

DOCEFREZ

+	SUN PHARMA GLOBAL	20MG/VIAL	N022534	001	May 03, 2011	May	NEWA
---	-------------------	-----------	---------	-----	--------------	-----	------

+		80MG/VIAL	N022534	002	May 03, 2011	May	NEWA
---	--	-----------	---------	-----	--------------	-----	------

DOCETAXEL

>A>	ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011	Jun	NEWA
-----	-----------------	----------------------	---------	-----	--------------	-----	------

>A>		80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011	Jun	NEWA
-----	--	--------------------	---------	-----	--------------	-----	------

>D>	+	HOSPIRA INC	20MG/2ML (10MG/ML)	N022234	001	Mar 08, 2011	Jun	CTEC
-----	---	-------------	--------------------	---------	-----	--------------	-----	------

>A>	AP	+	20MG/2ML (10MG/ML)	N022234	001	Mar 08, 2011	Jun	CTEC
-----	----	---	--------------------	---------	-----	--------------	-----	------

		+	20MG/2ML (10MG/ML)	N022234	001	Mar 08, 2011	Mar	NEWA
--	--	---	--------------------	---------	-----	--------------	-----	------

>D>	+		80MG/8ML (10MG/ML)	N022234	002	Mar 08, 2011	Jun	CTEC
-----	---	--	--------------------	---------	-----	--------------	-----	------

>A>	AP	+	80MG/8ML (10MG/ML)	N022234	002	Mar 08, 2011	Jun	CTEC
-----	----	---	--------------------	---------	-----	--------------	-----	------

		+	80MG/8ML (10MG/ML)	N022234	002	Mar 08, 2011	Mar	NEWA
--	--	---	--------------------	---------	-----	--------------	-----	------

>D>	+		160MG/16ML (10MG/ML)	N022234	003	Mar 08, 2011	Jun	CTEC
-----	---	--	----------------------	---------	-----	--------------	-----	------

>A>	AP	+	160MG/16ML (10MG/ML)	N022234	003	Mar 08, 2011	Jun	CTEC
-----	----	---	----------------------	---------	-----	--------------	-----	------

		+	160MG/16ML (10MG/ML)	N022234	003	Mar 08, 2011	Mar	NEWA
--	--	---	----------------------	---------	-----	--------------	-----	------

>A>	AP	SANDOZ	20MG/2ML (10MG/ML)	N201525	001	Jun 29, 2011	Jun	NEWA
-----	----	--------	--------------------	---------	-----	--------------	-----	------

>A>	AP		80MG/8ML (10MG/ML)	N201525	002	Jun 29, 2011	Jun	NEWA
-----	----	--	--------------------	---------	-----	--------------	-----	------

>A>	AP		160MG/16ML (10MG/ML)	N201525	003	Jun 29, 2011	Jun	NEWA
-----	----	--	----------------------	---------	-----	--------------	-----	------

TAXOTERE

@	SANOFI AVENTIS US	40MG/ML	N020449	001	May 14, 1996	Mar	DISC
---	-------------------	---------	---------	-----	--------------	-----	------

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	ACTAVIS PHARMA	5MG	A090551	001	May 31, 2011	May	NEWA
----	----------------	-----	---------	-----	--------------	-----	------

AB		10MG	A090551	002	May 31, 2011	May	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	APOTEX	5MG	A078841	001	Jun 02, 2011	May	NEWA
----	--------	-----	---------	-----	--------------	-----	------

AB		10MG	A078841	002	Jun 02, 2011	May	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	AUROBINDO	5MG	A090056	001	May 31, 2011	May	NEWA
----	-----------	-----	---------	-----	--------------	-----	------

AB		10MG	A090056	002	May 31, 2011	May	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	CIPLA LTD	5MG	A077518	001	May 31, 2011	May	NEWA
----	-----------	-----	---------	-----	--------------	-----	------

AB		10MG	A077518	002	May 31, 2011	May	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	DR REDDYS LABS LTD	5MG	A201001	001	May 31, 2011	May	NEWA
----	--------------------	-----	---------	-----	--------------	-----	------

AB		10MG	A201001	002	May 31, 2011	May	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	HIKMA PHARMS	5MG	A090247	001	May 31, 2011	May	NEWA
----	--------------	-----	---------	-----	--------------	-----	------

AB		10MG	A090247	002	May 31, 2011	May	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	HUAHAI US INC	5MG	A200292	001	May 31, 2011	May	NEWA
----	---------------	-----	---------	-----	--------------	-----	------

AB		10MG	A200292	002	May 31, 2011	May	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	JUBILANT LIFE	5MG	A090768	001	May 31, 2011	May	NEWA
----	---------------	-----	---------	-----	--------------	-----	------

AB		10MG	A090768	002	May 31, 2011	May	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	MATRIX LABS LTD	5MG	A090521	001	May 31, 2011	May	NEWA
----	-----------------	-----	---------	-----	--------------	-----	------

AB		10MG	A090521	002	May 31, 2011	May	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	PLIVA HRVATSKA DOO	5MG	A090425	001	May 31, 2011	May	NEWA
----	--------------------	-----	---------	-----	--------------	-----	------

AB		10MG	A090425	002	May 31, 2011	May	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	ROXANE	5MG	A078662	001	May 31, 2011	May	NEWA
----	--------	-----	---------	-----	--------------	-----	------

AB		10MG	A078662	002	May 31, 2011	May	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	SANDOZ	5MG	A090290	001	May 31, 2011	May	NEWA
----	--------	-----	---------	-----	--------------	-----	------

AB		10MG	A090290	002	May 31, 2011	May	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	SUN PHARM INDS	5MG	A090493	001	May 31, 2011	May	NEWA
----	----------------	-----	---------	-----	--------------	-----	------

AB		10MG	A090493	002	May 31, 2011	May	NEWA
----	--	------	---------	-----	--------------	-----	------

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	TEVA	5MG	A077344 001	May 31, 2011	May	NEWA
AB		10MG	A077344 002	May 31, 2011	May	NEWA
AB	TORRENT PHARMS	5MG	A090686 001	May 31, 2011	May	NEWA
AB		10MG	A090686 002	May 31, 2011	May	NEWA
AB	WOCKHARDT	5MG	A091267 001	May 31, 2011	May	NEWA
AB		10MG	A091267 002	May 31, 2011	May	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

AB	SANDOZ	5MG	A091198 001	May 10, 2011	Apr	NEWA
AB		10MG	A091198 002	May 10, 2011	Apr	NEWA
AB	ZYDUS PHARMS USA INC	5MG	A090175 001	May 10, 2011	Apr	NEWA
AB		10MG	A090175 002	May 10, 2011	Apr	NEWA

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	IMPAX LABS INC	EQ 150MG BASE	A200065 001	Feb 17, 2011	Jan	NEWA
AB	MYLAN	40MG	A090855 001	Jul 01, 2010	Jan	CDFR
AB	+ PAR PHARM	EQ 150MG BASE	A065055 003	Jul 15, 2005	Feb	CTEC
AB	+	EQ 150MG BASE	A065055 003	Jul 15, 2005	Jan	CTEC

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

AB	WATSON LABS FLORIDA	EQ 50MG BASE	A062031 002	Oct 13, 1982	May	CAHN
AB		EQ 100MG BASE	A062031 001		May	CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

LORYNA

AB	SANDOZ	3MG;0.02MG	A079221 001	Mar 28, 2011	Mar	NEWA
----	--------	------------	-------------	--------------	-----	------

TABLET; ORAL-28

SYEDA

AB	SANDOZ	3MG;0.03MG	A090114 001	Mar 28, 2011	Mar	NEWA
----	--------	------------	-------------	--------------	-----	------

ENALAPRIL MALEATE

TABLET; ORAL

VASOTEC

>D>	AB	BIOVAIL LABS INTL	2.5MG	N018998 005	Jul 26, 1988	Jun	CAHN
>D>	AB		5MG	N018998 001	Dec 24, 1985	Jun	CAHN
>D>	AB		10MG	N018998 002	Dec 24, 1985	Jun	CAHN
>D>	AB	+	20MG	N018998 003	Dec 24, 1985	Jun	CAHN
>A>	AB	VALEANT INTL	2.5MG	N018998 005	Jul 26, 1988	Jun	CAHN
>A>	AB		5MG	N018998 001	Dec 24, 1985	Jun	CAHN
>A>	AB		10MG	N018998 002	Dec 24, 1985	Jun	CAHN
>A>	AB	+	20MG	N018998 003	Dec 24, 1985	Jun	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

VASERETIC

>D>	AB	BIOVAIL LABS INTL	5MG;12.5MG	N019221 003	Jul 12, 1995	Jun	CAHN
>D>	AB	+	10MG;25MG	N019221 001	Oct 31, 1986	Jun	CAHN
>A>	AB	VALEANT INTL	5MG;12.5MG	N019221 003	Jul 12, 1995	Jun	CAHN
>A>	AB	+	10MG;25MG	N019221 001	Oct 31, 1986	Jun	CAHN

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

LOVENOX

SANOFI AVENTIS US	300MG/3ML (100MG/ML)	N020164 009	Jan 23, 2003	Feb	CDFR
-------------------	----------------------	-------------	--------------	-----	------

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ELESTAT

AT + ALLERGAN	0.05%	N021565 001	Oct 16, 2003	Feb	CFTG
---------------	-------	-------------	--------------	-----	------

EPINASTINE HYDROCHLORIDE

AT CYPRESS PHARM	0.05%	A090870 001	Mar 14, 2011	Feb	NEWA
------------------	-------	-------------	--------------	-----	------

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

AP MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A090266 001	Apr 15, 2011	Apr	NEWA
-------------------	--------------------	-------------	--------------	-----	------

AP	200MG/100ML (2MG/ML)	A090266 002	Apr 15, 2011	Apr	NEWA
----	----------------------	-------------	--------------	-----	------

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYTHROMYCIN

AB ARBOR PHARMS INC	250MG	A062746 001	Dec 22, 1986	Jan	CAHN
---------------------	-------	-------------	--------------	-----	------

GEL; TOPICAL

E-GLADES

AT COREPHARMA	2%	A065009 001	Mar 18, 2002	Apr	CAHN
---------------	----	-------------	--------------	-----	------

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT + FERA PHARMS	0.5%	A062447 001	Sep 26, 1983	Feb	CAHN
------------------	------	-------------	--------------	-----	------

AT + NYCOMED US	0.5%	A062447 001	Sep 26, 1983	Jan	CAHN
-----------------	------	-------------	--------------	-----	------

SOLUTION; TOPICAL

ERYDERM

@ ARBOR PHARMS INC	2%	A062290 001		Jan	CAHN
--------------------	----	-------------	--	-----	------

ERYTHROMYCIN

@ COREPHARMA	2%	A064127 001	Feb 14, 1997	Apr	CAHN
--------------	----	-------------	--------------	-----	------

SWAB; TOPICAL

ERYTHROMYCIN

@ COREPHARMA	2%	A064128 001	Jul 03, 1996	Apr	CAHN
--------------	----	-------------	--------------	-----	------

TABLET; ORAL

ERYTHROMYCIN

ARBOR PHARMS INC	250MG	A061621 001		Jan	CAHN
------------------	-------	-------------	--	-----	------

+	500MG	A061621 002		Jan	CAHN
---	-------	-------------	--	-----	------

TABLET, COATED PARTICLES; ORAL

PCE

ARBOR PHARMS INC	333MG	N050611 001	Sep 09, 1986	Jan	CAHN
------------------	-------	-------------	--------------	-----	------

+	500MG	N050611 002	Aug 22, 1990	Jan	CAHN
---	-------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

E-MYCIN

@ ARBOR PHARMS INC	250MG	A060272 001		Jan	CAHN
--------------------	-------	-------------	--	-----	------

@	333MG	A060272 002		Jan	CAHN
---	-------	-------------	--	-----	------

ERY-TAB

+ ARBOR PHARMS INC	250MG	A062298 001		Jan	CAHN
--------------------	-------	-------------	--	-----	------

+	333MG	A062298 003	Mar 29, 1982	Jan	CAHN
---	-------	-------------	--------------	-----	------

+	500MG	A062298 002		Jan	CAHN
---	-------	-------------	--	-----	------

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL							
E.E.S.							
AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	N050207 001		Jan	CAHN	
ERYPED							
AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	N050207 003	Mar 30, 1987	Jan	CAHN	
+		EQ 400MG BASE/5ML	N050207 002		Jan	CAHN	
SUSPENSION; ORAL							
E.E.S. 200							
AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	A061639 001		Jan	CAHN	
E.E.S. 400							
AB	+	ARBOR PHARMS INC	EQ 400MG BASE/5ML	A061639 002	Jan	CAHN	
PEDIAMYCIN							
AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	A062304 001		Jan	CAHN	
PEDIAMYCIN 400							
AB	ARBOR PHARMS INC	EQ 400MG BASE/5ML	A062304 002		Jan	CAHN	
TABLET; ORAL							
E.E.S. 400							
BX	+	ARBOR PHARMS INC	EQ 400MG BASE	A061905 002	Aug 12, 1982	Jan	CAHN
	@		EQ 400MG BASE	A061905 001		Jan	CAHN
ERYTHROMYCIN ETHYLSUCCINATE							
BX	+	ARBOR PHARMS INC	EQ 400MG BASE	A061904 001		Jan	CAHN
TABLET, CHEWABLE; ORAL							
E.E.S.							
	@	ARBOR PHARMS INC	EQ 200MG BASE	N050297 002		Jan	CAHN
ERYPED							
	@	ARBOR PHARMS INC	EQ 200MG BASE	N050297 003	Jul 05, 1988	Jan	CAHN

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROCIN STEARATE

	@	ARBOR PHARMS INC	EQ 125MG BASE	A060359 002		Jan	CAHN
			EQ 250MG BASE	A060359 001		Jan	CAHN
+			EQ 500MG BASE	A060359 003		Jan	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ACTIVELLA

AB	NOVO NORDISK INC	0.5MG;0.1MG	N020907 002	Dec 28, 2006	Mar	CTEC	
ESTRADIOL AND NORETHINDRONE ACETATE							
AB	BRECKENRIDGE PHARM	0.5MG;0.1MG	A078324 002	Jun 09, 2011	May	NEWA	

ESTROPIPATE

CREAM; VAGINAL

OGEN

	@	PHARMACIA AND UPJOHN	1.5MG/GM	A084710 001		Apr	DISC
--	---	----------------------	----------	-------------	--	-----	------

ESZOPICLONE

TABLET; ORAL

>D>	ESZOPICLONE						
>D>	AB	TEVA	1MG	A091169 001	May 23, 2011	Jun	DISC
>A>		@	1MG	A091169 001	May 23, 2011	Jun	DISC
	AB		1MG	A091169 001	May 23, 2011	May	NEWA
>D>	AB		2MG	A091169 002	May 23, 2011	Jun	DISC
>A>		@	2MG	A091169 002	May 23, 2011	Jun	DISC

TABLET; ORAL

>D>		ESZOPICLONE							
	AB	TEVA	2MG	A091169	002	May 23, 2011	May	NEWA	
>D>	AB		3MG	A091169	003	May 23, 2011	Jun	DISC	
>A>		@	3MG	A091169	003	May 23, 2011	Jun	DISC	
	AB		3MG	A091169	003	May 23, 2011	May	NEWA	
		LUNESTA							
>D>	AB	SUNOVION PHARMS INC	1MG	N021476	001	Dec 15, 2004	Jun	CTEC	
>A>			1MG	N021476	001	Dec 15, 2004	Jun	CTEC	
	AB		1MG	N021476	001	Dec 15, 2004	May	CFTG	
>D>	AB		2MG	N021476	002	Dec 15, 2004	Jun	CTEC	
>A>			2MG	N021476	002	Dec 15, 2004	Jun	CTEC	
	AB		2MG	N021476	002	Dec 15, 2004	May	CFTG	
>D>	AB	+	3MG	N021476	003	Dec 15, 2004	Jun	CTEC	
>A>		+	3MG	N021476	003	Dec 15, 2004	Jun	CTEC	
	AB	+	3MG	N021476	003	Dec 15, 2004	May	CFTG	

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

		LEVONORGESTREL AND ETHINYL ESTRADIOL							
	AB	WATSON LABS	0.02MG;0.09MG	A079218	001	Jun 06, 2011	May	NEWA	
		LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL							
	AB	WATSON LABS	0.03MG,0.01MG;0.15MG,N/A	A078834	001	May 31, 2011	May	NEWA	
		LYBREL							
	AB	+	0.02MG;0.09MG	N021864	001	May 22, 2007	May	CFTG	
		SEASONIQUE							
	AB	+	0.03MG,0.01MG;0.15MG,N/A	N021840	001	May 25, 2006	May	CFTG	
		TABLET; ORAL-28							
		ORSYTHIA							
	AB1	VINTAGE PHARMS	0.02MG;0.1MG	A077099	001	May 11, 2011	Apr	NEWA	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

		BRIELLYN							
	AB	GLENMARK GENERICS	0.035MG;0.4MG	A090538	001	Mar 22, 2011	Mar	NEWA	
		TABLET, CHEWABLE; ORAL							
		NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
>D>	+	WARNER CHILCOTT	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jun	CAHN	
	+		0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jan	CRLD	
>A>	+	WATSON LABS INC	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jun	CAHN	

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

		LO LOESTRIN FE							
	+	WARNER CHILCOTT CO	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	May	CRLD	
		TABLET; ORAL-28							
		GILDESS FE 1.5/30							
	AB	VINTAGE	0.03MG;1.5MG	A077075	001	Apr 28, 2005	Jan	CTNA	
		GILDESS FE 1/20							
	AB	VINTAGE	0.02MG;1MG	A077077	001	May 20, 2005	Jan	CTNA	

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL

		NORGESTIMATE AND ETHINYL ESTRADIOL							
>A>	AB	GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A200494	001	Jun 17, 2011	Jun	NEWA	

TABLET; ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A090479	001	Mar 09, 2011	Feb	NEWA
----	-------------	---	---------	-----	--------------	-----	------

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

AB	VERSAPHARM	250MG	A040686	001	May 28, 2008	May	CAHN
----	------------	-------	---------	-----	--------------	-----	------

ETODOLAC

CAPSULE; ORAL

ETODOLAC

@ MYLAN

200MG

A075071 001 Sep 30, 1998 Feb CAHN

@

300MG

A075071 002 Sep 30, 1998 Feb CAHN

TABLET; ORAL

ETODOLAC

@ MYLAN

400MG

A075012 001 Sep 30, 1998 Feb CAHN

@

500MG

A075012 002 Sep 30, 1998 Feb CAHN

ETONOGESTREL

IMPLANT; IMPLANTATION

NEXPLANON

+ ORGANON USA INC 68MG/IMPLANT

N021529 002 May 31, 2011 May NEWA

ETRAVIRINE

TABLET; ORAL

INTELENCE

TIBOTEC

100MG

N022187 001 Jan 18, 2008 Jan CRLD

+ 200MG

N022187 002 Dec 22, 2010 Jan NEWA

EXEMESTANE

TABLET; ORAL

AROMASIN

AB + PHARMACIA AND UPJOHN 25MG

N020753 001 Oct 21, 1999 Mar CFTG

EXEMESTANE

AB ROXANE 25MG

A077431 001 Apr 01, 2011 Mar NEWA

>A> EZOGABINE

>A> TABLET; ORAL

>A> POTIGA

>A> VALEANT PHARMS 50MG

N022345 001 Jun 10, 2011 Jun NEWA

>A> 200MG

N022345 002 Jun 10, 2011 Jun NEWA

>A> 300MG

N022345 003 Jun 10, 2011 Jun NEWA

>A> + 400MG

N022345 004 Jun 10, 2011 Jun NEWA

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB AUROBINDO PHARMA LTD 125MG

A091114 001 Mar 21, 2011 Mar NEWA

AB 250MG

A091114 002 Mar 21, 2011 Mar NEWA

AB 500MG

A091114 003 Mar 21, 2011 Mar NEWA

AB MYLAN 125MG

A201333 001 Mar 24, 2011 Mar NEWA

AB 250MG

A201333 002 Mar 24, 2011 Mar NEWA

AB 500MG

A201333 003 Mar 24, 2011 Mar NEWA

AB ROXANE 125MG

A090128 001 Mar 21, 2011 Mar NEWA

TABLET; ORAL

	FAMCICLOVIR								
AB	ROXANE	250MG	A090128	002	Mar 21, 2011	Mar	NEWA		
AB		500MG	A090128	003	Mar 21, 2011	Mar	NEWA		
AB	WATSON LABS	125MG	A078278	001	Mar 21, 2011	Mar	NEWA		
AB		250MG	A078278	002	Mar 21, 2011	Mar	NEWA		
AB		500MG	A078278	003	Mar 21, 2011	Mar	NEWA		

FAMOTIDINE

INJECTABLE; INJECTION

	FAMOTIDINE								
AP	PFIZER	10MG/ML	A078641	001	Jun 25, 2008	May	CAHN		
	FAMOTIDINE PRESERVATIVE FREE								
AP	PFIZER	10MG/ML	A078642	001	Jun 25, 2008	May	CAHN		
	PEPCID								
	@ MERCK	10MG/ML	N019510	001	Nov 04, 1986	Jan	DISC		
	PEPCID PRESERVATIVE FREE								
	@ MERCK	10MG/ML	N019510	004	Nov 04, 1986	Jan	DISC		
	PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER								
	@ MERCK	0.4MG/ML	N020249	001	Feb 18, 1994	Jan	DISC		

TABLET; ORAL

	FAMOTIDINE								
AB	MYLAN	20MG	A075457	001	Apr 18, 2001	Feb	CAHN		
AB		40MG	A075457	002	Apr 18, 2001	Feb	CAHN		

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

	DUEXIS								
+	HORIZON PHARMA	26.6MG;800MG	N022519	001	Apr 23, 2011	Apr	NEWA		

FENOFIBRATE

TABLET; ORAL

	FENOGLIDE								
	SHORE THERAP	40MG	N022118	001	Aug 10, 2007	Feb	CAHN		
+		120MG	N022118	002	Aug 10, 2007	Feb	CAHN		

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

	FENTANYL-100								
AB	MALLINCKRODT INC	100MCG/HR	A077154	004	Feb 09, 2011	Jan	NEWA		
	FENTANYL-25								
AB	MALLINCKRODT INC	25MCG/HR	A077154	001	Feb 09, 2011	Jan	NEWA		
	FENTANYL-50								
AB	MALLINCKRODT INC	50MCG/HR	A077154	002	Feb 09, 2011	Jan	NEWA		
	FENTANYL-75								
AB	MALLINCKRODT INC	75MCG/HR	A077154	003	Feb 09, 2011	Jan	NEWA		

FENTANYL CITRATE

>A>	SPRAY, METERED; NASAL								
>A>	LAZANDA								
>A>	ARCHIMEDES	100MCG	N022569	001	Jun 30, 2011	Jun	NEWA		
>A>	+	400MCG	N022569	002	Jun 30, 2011	Jun	NEWA		

TABLET; SUBLINGUAL

	ABSTRAL								
	PROSTRAKAN INC	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	Jan	NEWA		
		EQ 0.2MG BASE	N022510	002	Jan 07, 2011	Jan	NEWA		

TABLET; SUBLINGUAL

ABSTRAL

	PROSTRAKAN INC	EQ 0.3MG BASE	N022510 003	Jan 07, 2011	Jan	NEWA
+		EQ 0.4MG BASE	N022510 004	Jan 07, 2011	Jan	NEWA
		EQ 0.6MG BASE	N022510 005	Jan 07, 2011	Jan	NEWA
		EQ 0.8MG BASE	N022510 006	Jan 07, 2011	Jan	NEWA

FIDAXOMICIN

TABLET; ORAL

DIFICID

+	OPTIMER PHARMS	200MG	N201699 001	May 27, 2011	May	NEWA
---	----------------	-------	-------------	--------------	-----	------

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

AB	AMNEAL PHARM	50MG	A078423 001	Mar 07, 2011	Feb	NEWA
AB		100MG	A078423 002	Mar 07, 2011	Feb	NEWA
AB		150MG	A078423 003	Mar 07, 2011	Feb	NEWA
AB		200MG	A078423 004	Mar 07, 2011	Feb	NEWA
AB	MYLAN	50MG	A076042 001	Jul 29, 2004	Feb	CAHN
AB		100MG	A076042 002	Jul 29, 2004	Feb	CAHN
AB		150MG	A076042 003	Jul 29, 2004	Feb	CAHN
AB		200MG	A076042 004	Jul 29, 2004	Feb	CAHN

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON

>D>	VALEANT	250MG	N017001 001		Jun	CFTG
>A>	AB	250MG	N017001 001		Jun	CFTG
>D>	+	500MG	N017001 002		Jun	CFTG
>A>	AB +	500MG	N017001 002		Jun	CFTG
>A>	FLUCYTOSINE					
>A>	SIGMAPHARM LABS LLC	250MG	A201566 001	Jun 28, 2011	Jun	NEWA
>A>	AB	500MG	A201566 002	Jun 28, 2011	Jun	NEWA

FLUDARABINE PHOSPHATE

TABLET; ORAL

OFORTA

+	SANOFI AVENTIS US	10MG	N022273 001	Dec 18, 2008	Apr	CMFD
	@	10MG	N022273 001	Dec 18, 2008	Jan	DISC

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	+	FEINSTEIN	20-200mCi/ML	N021870 001	Aug 19, 2005	Feb	CTEC
AP		PETNET	20-200mCi/ML	A079086 001	Feb 25, 2011	Feb	NEWA

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP	PFIZER	0.5MG/5ML (0.1MG/ML)	A078595 001	May 13, 2008	May	CAHN
AP		1MG/10ML (0.1MG/ML)	A078595 002	May 13, 2008	May	CAHN

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

SYNALAR

>D>	AT	+	MEDICIS	0.01%	N012787 004		Jun	CAHN
>D>	AT	+		0.025%	N012787 005		Jun	CAHN
>D>	AT	+		0.025%	N012787 002		Jun	CAHN
>A>	AT	+	MEDIMETRIKS PHARMS	0.01%	N012787 004		Jun	CAHN
>A>	AT	+		0.025%	N012787 005		Jun	CAHN
>A>	AT	+		0.025%	N012787 002		Jun	CAHN

SYNALAR-HP

>D>	@	MEDICIS		0.2%	N016161 002		Jun	CAHN
>A>	@	MEDIMETRIKS PHARMS		0.2%	N016161 002		Jun	CAHN

OINTMENT; TOPICAL

SYNALAR

>D>	AT	+	MEDICIS	0.025%	N013960 001		Jun	CAHN
>A>	AT	+	MEDIMETRIKS PHARMS	0.025%	N013960 001		Jun	CAHN

SOLUTION; TOPICAL

SYNALAR

>D>	AT	+	MEDICIS	0.01%	N015296 001		Jun	CAHN
>A>	AT	+	MEDIMETRIKS PHARMS	0.01%	N015296 001		Jun	CAHN

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

AP		SANDOZ		2.5GM/50ML (50MG/ML)	A091299 001	May 02, 2011	Apr	NEWA
AP				5GM/100ML (50MG/ML)	A091299 002	May 02, 2011	Apr	NEWA
		@ VALEANT		500MG/10ML (50MG/ML)	N012209 001		Mar	DISC

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB1		ALEMBIC PHARMS LTD		EQ 10MG BASE	A090223 001	Mar 19, 2009	Apr	CAHN
AB1				EQ 20MG BASE	A090223 002	Mar 19, 2009	Apr	CAHN
AB				EQ 40MG BASE	A090223 003	Mar 19, 2009	Apr	CAHN

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

>D>	+	WATSON PHARMS		0.05%	N012806 002		Jun	DISC
>A>	@			0.05%	N012806 002		Jun	DISC

OINTMENT; TOPICAL

CORDRAN

>D>	+	WATSON PHARMS		0.025%	N012806 004		Jun	DISC
>A>	@			0.025%	N012806 004		Jun	DISC
>D>	+			0.05%	N012806 001		Jun	DISC
>A>	@			0.05%	N012806 001		Jun	DISC

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB		MYLAN		125MG	A076224 001	May 09, 2003	Feb	CAHN
----	--	-------	--	-------	-------------	--------------	-----	------

FLUTICASONE PROPIONATE

LOTION; TOPICAL

CUTIVATE

AB + NYCOMED US 0.05% N021152 001 Mar 31, 2005 Apr CFTG

FLUTICASONE PROPIONATE

AB GLENMARK GENERICS 0.05% A090759 001 May 02, 2011 Apr NEWA

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

@ MYLAN 50MG A075950 001 Oct 15, 2001 Feb CAHN

@ 100MG A075950 002 Oct 15, 2001 Feb CAHN

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA + AMNEAL PHARM 1MG A040625 001 Jul 21, 2005 Apr CAHN

AA JUBILANT CADISTA 1MG A040514 001 Jun 14, 2005 Jan CAHN

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA

>D> + GLAXOSMITHKLINE 2.5MG/0.5ML N021345 001 Dec 07, 2001 Jun CFTG

>A> AP + 2.5MG/0.5ML N021345 001 Dec 07, 2001 Jun CFTG

>D> + 5MG/0.4ML N021345 002 May 28, 2004 Jun CFTG

>A> AP + 5MG/0.4ML N021345 002 May 28, 2004 Jun CFTG

>D> + 7.5MG/0.6ML N021345 003 May 28, 2004 Jun CFTG

>A> AP + 7.5MG/0.6ML N021345 003 May 28, 2004 Jun CFTG

>D> + 10MG/0.8ML N021345 004 May 28, 2004 Jun CFTG

>A> AP + 10MG/0.8ML N021345 004 May 28, 2004 Jun CFTG

>A> FONDAPARINUX SODIUM

>A> AP DR REDDYS LABS LTD 2.5MG/0.5ML A091316 001 Jul 11, 2011 Jun NEWA

>A> AP 5MG/0.4ML A091316 002 Jul 11, 2011 Jun NEWA

>A> AP 7.5MG/0.6ML A091316 003 Jul 11, 2011 Jun NEWA

>A> AP 10MG/0.8ML A091316 004 Jul 11, 2011 Jun NEWA

FORMOTEROL FUMARATE

POWDER; INHALATION

FORADIL CERTIHALER

>D> + NOVARTIS 0.0085MG/INH N021592 001 Dec 15, 2006 Jun DISC

>A> @ 0.0085MG/INH N021592 001 Dec 15, 2006 Jun DISC

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

AB AUROBINDO PHARMA LTD 10MG A091163 001 Mar 30, 2011 Mar NEWA

AB 20MG A091163 002 Mar 30, 2011 Mar NEWA

AB 40MG A091163 003 Mar 30, 2011 Mar NEWA

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP + APP PHARMS EQ 50MG PHENYTOIN NA/ML A078052 001 Aug 06, 2007 Apr CRLD

AP PFIZER EQ 50MG PNENYTOIN NA/ML A078476 001 Mar 18, 2008 May CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB	MATRIX LABS LTD	100MG	A090158 001	Feb 14, 2011	Jan	NEWA
AB		300MG	A090158 002	Feb 14, 2011	Jan	NEWA
AB		400MG	A090158 003	Feb 14, 2011	Jan	NEWA
AB	MYLAN	100MG	A090158 001	Feb 14, 2011	May	CAHN
AB		300MG	A090158 002	Feb 14, 2011	May	CAHN
AB		400MG	A090158 003	Feb 14, 2011	May	CAHN

SOLUTION; ORAL

GABAPENTIN

AA	HI TECH PHARMA	250MG/5ML	A078974 001	Feb 18, 2011	Feb	NEWA
AA	+ PARKE DAVIS	250MG/5ML	N021129 001	Mar 02, 2000	Feb	CFTG

TABLET; ORAL

GABAPENTIN

AB	ZYDUS PHARMS USA INC	600MG	A078926 001	Feb 11, 2011	Jan	NEWA
AB		800MG	A078926 002	Feb 11, 2011	Jan	NEWA
BX	+ ABBOTT PRODS	300MG	N022544 001	Jan 28, 2011	Jan	NEWA
BX	+	600MG	N022544 002	Jan 28, 2011	Jan	NEWA

GRALISE

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL

HORIZANT

	+ GLAXO GRP LTD	600MG	N022399 001	Apr 06, 2011	Apr	NEWA
--	-----------------	-------	-------------	--------------	-----	------

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

	+ BAYER HLTHCARE	4.5354GM/7.5ML (604.72MG/ML)	N201277 001	Mar 14, 2011	Mar	NEWA
		6.0472GM/10ML (604.72MG/ML)	N201277 002	Mar 14, 2011	Mar	NEWA
		9.0708GM/15ML (604.72MG/ML)	N201277 003	Mar 14, 2011	Mar	NEWA
		18.1416GM/30ML (604.72MG/ML)	N201277 004	Mar 14, 2011	Mar	NEWA
		39.3068GM/65ML (604.72MG/ML)	N201277 005	Mar 14, 2011	Mar	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

AB	MYLAN	EQ 8MG BASE	A090900 001	Jan 24, 2011	Jan	NEWA
AB		EQ 16MG BASE	A090900 002	Jan 24, 2011	Jan	NEWA
AB		EQ 24MG BASE	A090900 003	Jan 24, 2011	Jan	NEWA
AB	SUN PHARMA GLOBAL	EQ 8MG BASE	A090178 001	Feb 02, 2011	Jan	NEWA
AB		EQ 16MG BASE	A090178 002	Feb 02, 2011	Jan	NEWA
AB		EQ 24MG BASE	A090178 003	Feb 02, 2011	Jan	NEWA

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

AB	AUROBINDO PHARMA LTD	EQ 4MG BASE	A090957 001	Mar 29, 2011	Mar	NEWA
AB		EQ 8MG BASE	A090957 002	Mar 29, 2011	Mar	NEWA
AB		EQ 12MG BASE	A090957 003	Mar 29, 2011	Mar	NEWA
AB	ZYDUS PHARMS USA INC	EQ 4MG BASE	A078898 001	Feb 17, 2011	Jan	NEWA
AB		EQ 8MG BASE	A078898 002	Feb 17, 2011	Jan	NEWA
AB		EQ 12MG BASE	A078898 003	Feb 17, 2011	Jan	NEWA

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE

+ HOSPIRA INC EQ 2GM BASE/VIAL A079183 001 Nov 15, 2010 Feb CRLD

GEMCITABINE HYDROCHLORIDE

AP APP PHARMS EQ 2GM BASE/VIAL A090242 003 May 16, 2011 May NEWA

AP FRESENIUS KABI ONCOL EQ 2GM BASE/VIAL A090799 003 May 16, 2011 May NEWA

+ HOSPIRA INC EQ 2GM BASE/VIAL A079183 001 Nov 15, 2010 May CTNA

AP TEVA PARENTERAL EQ 200MG BASE/VIAL A077983 002 Jan 25, 2011 Jan NEWA

AP EQ 1GM BASE/VIAL A077983 001 Jan 25, 2011 Jan NEWA

GEMZAR

AP + LILLY EQ 200MG BASE/VIAL N020509 001 May 15, 1996 Jan CFTG

AP + EQ 1GM BASE/VIAL N020509 002 May 15, 1996 Jan CFTG

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB BLU CARIBE 600MG A078012 001 Mar 26, 2007 Feb CAHN

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

AT FERA PHARMS EQ 0.3% BASE A065024 001 Jul 30, 2004 Feb CAHN

AT NYCOMED US EQ 0.3% BASE A065024 001 Jul 30, 2004 Jan CAHN

SOLUTION/DROPS; OPHTHALMIC

GENTAMICIN SULFATE

AT FERA PHARMS EQ 0.3% BASE A065121 001 Jan 30, 2004 Feb CAHN

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB MYLAN 1MG A077486 001 Feb 10, 2006 Feb CAHN

AB 2MG A077486 002 Feb 10, 2006 Feb CAHN

AB 4MG A077486 003 Feb 10, 2006 Feb CAHN

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB ZYDUS PHARMS USA INC 2.5MG;250MG A078905 001 Jan 31, 2011 Jan NEWA

AB 2.5MG;500MG A078905 002 Jan 31, 2011 Jan NEWA

AB 5MG;500MG A078905 003 Jan 31, 2011 Jan NEWA

GLUTAMINE

FOR SOLUTION; ORAL

NUTRESTORE

+ EMMAUS MEDCL 5GM/PACKET N021667 001 Jun 10, 2004 May CAHN

GLYBURIDE

TABLET; ORAL

GLYBURIDE

AB HERITAGE PHARMS INC 1.25MG A090937 001 Feb 28, 2011 May CAHN

AB 2.5MG A090937 002 Feb 28, 2011 May CAHN

AB 5MG A090937 003 Feb 28, 2011 May CAHN

AB INDICUS PHARMA 1.25MG A090937 001 Feb 28, 2011 Feb NEWA

AB 2.5MG A090937 002 Feb 28, 2011 Feb NEWA

TABLET; ORAL

	GLYBURIDE								
AB	INDICUS PHARMA	5MG	A090937	003	Feb 28, 2011	Feb	NEWA		

GRANISETRON

FILM, EXTENDED RELEASE; TRANSDERMAL

SANCUSO

>A>	+	PROSTRAKAN INC	3.1MG/24HR	N022198	001	Sep 12, 2008	Jun	CAHN	
>D>	+	STRAKAN	3.1MG/24HR	N022198	001	Sep 12, 2008	Jun	CAHN	

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

FULVICIN P/G

	@ ELORAC	125MG	A061996	001		Jan	CAHN		
--	----------	-------	---------	-----	--	-----	------	--	--

	@	250MG	A061996	002		Jan	CAHN		
--	---	-------	---------	-----	--	-----	------	--	--

FULVICIN P/G 165

	@ ELORAC	165MG	A061996	003	Apr 06, 1982	Jan	CAHN		
--	----------	-------	---------	-----	--------------	-----	------	--	--

FULVICIN P/G 330

	@ ELORAC	330MG	A061996	004	Apr 06, 1982	Jan	CAHN		
--	----------	-------	---------	-----	--------------	-----	------	--	--

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

AP	PFIZER	EQ 5MG BASE/ML	A078347	001	Sep 14, 2009	May	CAHN		
----	--------	----------------	---------	-----	--------------	-----	------	--	--

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP	SANDOZ	1,000 UNITS/ML	A091682	001	Jun 08, 2011	May	NEWA		
----	--------	----------------	---------	-----	--------------	-----	------	--	--

AP		5,000 UNITS/ML	A091659	001	Jun 08, 2011	May	NEWA		
----	--	----------------	---------	-----	--------------	-----	------	--	--

AP		5,000 UNITS/ML	A091682	002	Jun 08, 2011	May	NEWA		
----	--	----------------	---------	-----	--------------	-----	------	--	--

AP		10,000 UNITS/ML	A201002	001	Jun 08, 2011	May	NEWA		
----	--	-----------------	---------	-----	--------------	-----	------	--	--

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

	+	GE HEALTHCARE	100MG/VIAL	N022555	001	May 28, 2010	May	CAHN	
--	---	---------------	------------	---------	-----	--------------	-----	------	--

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AB	NOVEL LABS INC	1.5MG;5MG	A091528	001	Apr 20, 2011	Apr	NEWA		
----	----------------	-----------	---------	-----	--------------	-----	------	--	--

TUSSIGON

AB	+	KING PHARMS	1.5MG;5MG	A088508	001	Jul 30, 1985	Apr	CTEC	
----	---	-------------	-----------	---------	-----	--------------	-----	------	--

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG	A200645	001	Nov 30, 2010	Apr	CAHN		
----	--------------------	--------	---------	-----	--------------	-----	------	--	--

AB	JUBILANT CADISTA	12.5MG	A078391	001	Feb 11, 2008	Jan	CAHN		
----	------------------	--------	---------	-----	--------------	-----	------	--	--

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB	JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007	Jan	CAHN		
----	------------------	------	---------	-----	--------------	-----	------	--	--

AB		50MG	A040809	002	Sep 04, 2007	Jan	CAHN		
----	--	------	---------	-----	--------------	-----	------	--	--

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

>A>	@ SANOFI AVENTIS	12.5MG;75MG	N020758 001	Sep 30, 1997	Jun	CAHN
>A>		12.5MG;150MG	N020758 002	Sep 30, 1997	Jun	CAHN
>A>		12.5MG;300MG	N020758 003	Aug 31, 1998	Jun	CAHN
>A>	+	25MG;300MG	N020758 004	Mar 15, 2005	Jun	CAHN
>D>	@ SANOFI AVENTIS US	12.5MG;75MG	N020758 001	Sep 30, 1997	Jun	CAHN
>D>		12.5MG;150MG	N020758 002	Sep 30, 1997	Jun	CAHN
>D>		12.5MG;300MG	N020758 003	Aug 31, 1998	Jun	CAHN
>D>	+	25MG;300MG	N020758 004	Mar 15, 2005	Jun	CAHN

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB	PRINSTON PHARM LLC	12.5MG;10MG	A076230 001	Jul 01, 2002	May	CAHN
AB		12.5MG;20MG	A076230 002	Jul 01, 2002	May	CAHN
AB		25MG;20MG	A076230 003	Jul 01, 2002	May	CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	WATSON LABS	12.5MG;50MG	A200180 001	Jan 12, 2011	Jan	NEWA
AB		12.5MG;100MG	A200180 002	Jan 12, 2011	Jan	NEWA
AB		25MG;100MG	A200180 003	Jan 12, 2011	Jan	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	INVAGEN PHARMS	12.5MG;10MG	A201356 001	Apr 20, 2011	Apr	NEWA
AB		12.5MG;20MG	A201356 002	Apr 20, 2011	Apr	NEWA
AB		25MG;20MG	A201356 003	Apr 20, 2011	Apr	NEWA

>A> HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

>A> SOLUTION; ORAL

>A> REZIRA

>A>	+	CYPRESS PHARM	5MG/5ML;60MG/5ML	N022442 001	Jun 08, 2011	Jun	NEWA
-----	---	---------------	------------------	-------------	--------------	-----	------

HYDROCORTISONE

SOLUTION; TOPICAL

TEXACORT

+	TIBER LABS	2.5%	A081271 001	Apr 17, 1992	May	CAHN
---	------------	------	-------------	--------------	-----	------

TABLET; ORAL

HYDROCORTISONE

AB	COREPHARMA	5MG	A040646 001	Mar 30, 2007	Apr	CAHN
AB		10MG	A040646 002	Mar 30, 2007	Apr	CAHN
AB		20MG	A040646 003	Mar 30, 2007	Apr	CAHN

HYDROCORTISONE ACETATE

OINTMENT; OPHTHALMIC

HYDROCORTISONE ACETATE

@	FERA PHARMS	0.5%	A080828 001		Mar	CAHN
---	-------------	------	-------------	--	-----	------

HYDROFLUMETHIAZIDE

TABLET; ORAL

HYDROFLUMETHIAZIDE

@ PAR PHARM

50MG

A088850 001 May 31, 1985 May DISC

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

AB ELITE LABS

8MG

A076723 001 Oct 18, 2005 Feb CAHN

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

CYANOKIT

@ MERCK SANTE SAS

5GM/VIAL (5GM/KIT)

N022041 001 Apr 08, 2011 Apr DISC

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRINE

@ PHARMICS

1%

N000004 004 Jan CAHN

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

MAKENA

+ KV PHARM

1250MG/5ML (250MG/ML)

N021945 001 Feb 03, 2011 Feb NEWA

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

AP SANDOZ

1MG/ML

A091293 001 Mar 29, 2011 Mar NEWA

IFOSFAMIDE

INJECTABLE; INJECTION

IFOSFAMIDE

>A> AP BEDFORD LABS

1GM/20ML (50MG/ML)

A076619 001 Jun 29, 2011 Jun NEWA

>A> AP 3GM/60ML (50MG/ML)

A076619 002 Jun 29, 2011 Jun NEWA

ILOPERIDONE

TABLET; ORAL

FANAPT

NOVARTIS

2MG

N022192 002 May 06, 2009 Jan CAHN

4MG

N022192 003 May 06, 2009 Jan CAHN

6MG

N022192 004 May 06, 2009 Jan CAHN

8MG

N022192 005 May 06, 2009 Jan CAHN

10MG

N022192 006 May 06, 2009 Jan CAHN

ILOPROST

SOLUTION; INHALATION

VENTAVIS

>D> + ACTELION PHARMS LTD 20MCG/2ML (10MCG/ML)

N021779 001 Dec 29, 2004 Jun DISC

>A> @ 20MCG/2ML (10MCG/ML)

N021779 001 Dec 29, 2004 Jun DISC

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB	TARO	5%	A200173	001	Apr 15, 2011	Apr	NEWA
AB	TEVA PHARMS USA	5%	A200481	001	Apr 18, 2011	Apr	NEWA
AB	TOLMAR	5%	A091044	001	Feb 28, 2011	Feb	NEWA

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

AB	HETERO DRUGS LTD	25MG	A091240	001	Apr 12, 2011	Mar	NEWA
AB		50MG	A091240	002	Apr 12, 2011	Mar	NEWA

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

AB	+ SANDOZ	75MG	A074464	001	May 28, 1998	Jan	CTNA
----	----------	------	---------	-----	--------------	-----	------

IOFLUPANE I-123

SOLUTION; INTRAVENOUS

DATSCAN

	+ GE HLTHCARE INC	5MCI/2.5ML (2MCI/ML)	N022454	001	Jan 14, 2011	Jan	NEWA
--	-------------------	----------------------	---------	-----	--------------	-----	------

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200

@	HOSPIRA	41%	A074898	001	Dec 30, 1997	Feb	DISC
---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-200 IN PLASTIC CONTAINER

@	HOSPIRA	41%	A074636	001	Dec 30, 1997	Feb	DISC
---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-250

@	HOSPIRA	51%	A074898	002	Dec 30, 1997	Feb	DISC
---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-250 IN PLASTIC CONTAINER

@	HOSPIRA	51%	A074636	002	Dec 30, 1997	Feb	DISC
---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-300

@	HOSPIRA	61%	A074898	003	Dec 30, 1997	Feb	DISC
---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-300 IN PLASTIC CONTAINER

@	HOSPIRA	61%	A074636	003	Dec 30, 1997	Feb	DISC
---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-370

@	HOSPIRA	76%	A074898	004	Dec 30, 1997	Feb	DISC
---	---------	-----	---------	-----	--------------	-----	------

IOPAMIDOL-370 IN PLASTIC CONTAINER

@	HOSPIRA	76%	A074636	004	Dec 30, 1997	Feb	DISC
---	---------	-----	---------	-----	--------------	-----	------

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP	BIONICHE PHARMA	40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	May	NEWA
AP		100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	May	NEWA

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

LUITPOLD

	EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135	002	Mar 20, 2005	Apr	CMFD
--	--------------------------------------	---------	-----	--------------	-----	------

ISOSORBIDE DINITRATE

TABLET; ORAL

ISORDIL

>D>	AB	BIOVAIL	5MG	N012093 007	Jul 29, 1988	Jun	CAHN
>D>	AB		10MG	N012093 002	Jul 29, 1988	Jun	CAHN
>D>	AB		20MG	N012093 006	Jul 29, 1988	Jun	CAHN
>D>	AB	+	30MG	N012093 005	Jul 29, 1988	Jun	CAHN
>D>		+	40MG	N012093 001	Jul 29, 1988	Jun	CAHN
>A>	AB	VALEANT INTL	5MG	N012093 007	Jul 29, 1988	Jun	CAHN
>A>	AB		10MG	N012093 002	Jul 29, 1988	Jun	CAHN
>A>	AB		20MG	N012093 006	Jul 29, 1988	Jun	CAHN
>A>	AB	+	30MG	N012093 005	Jul 29, 1988	Jun	CAHN
>A>		+	40MG	N012093 001	Jul 29, 1988	Jun	CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

AB		TORRENT PHARMS	30MG	A200270 001	Jun 03, 2011	May	NEWA
AB			60MG	A200495 001	Jun 03, 2011	May	NEWA
AB			120MG	A200495 002	Jun 03, 2011	May	NEWA

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

AB		MIKAH PHARMA	2.5MG	A077169 001	Apr 24, 2006	Feb	CAHN
AB			5MG	A077169 002	Apr 24, 2006	Feb	CAHN

ITRACONAZOLE

INJECTABLE; INJECTION

SPORANOX

@ ORTHO MCNEIL JANSSEN 10MG/ML

N020966 001 Mar 30, 1999 May DISC

TABLET; ORAL

ONMEL

+ STIEFEL LABS INC 200MG

N022484 001 Apr 29, 2010 May CTNA

KETOCONAZOLE

GEL; TOPICAL

XOLEGEL

+ AQUA PHARMS 2%

N021946 001 Jul 28, 2006 May CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP PFIZER 15MG/ML

A078299 001 Jul 16, 2007 May CAHN

AP 30MG/ML

A078299 002 Jul 16, 2007 May CAHN

SPRAY, METERED; NASAL

SPRIX

+ LUITPOLD 15.75MG/SPRAY

N022382 001 May 14, 2010 May CAHN

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

COMBIVIR

AB + VIIV HLTHCARE 150MG;300MG

N020857 001 Sep 26, 1997 May CFTG

LAMIVUDINE AND ZIDOVUDINE

AB TEVA PHARMS 150MG;300MG

A079081 001 May 25, 2011 May NEWA

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB	ACTAVIS TOTOWA	25MG	A078669 001	Apr 08, 2011	Mar	NEWA
AB		100MG	A078669 002	Apr 08, 2011	Mar	NEWA
AB		150MG	A078669 003	Apr 08, 2011	Mar	NEWA
AB		200MG	A078669 004	Apr 08, 2011	Mar	NEWA
AB	ALEMBIC LTD	25MG	A090607 001	Jan 13, 2011	Jan	NEWA
AB		100MG	A090607 002	Jan 13, 2011	Jan	NEWA
AB		150MG	A090607 003	Jan 13, 2011	Jan	NEWA
AB		200MG	A090607 004	Jan 13, 2011	Jan	NEWA
AB	ALEMBIC PHARMS LTD	25MG	A090607 001	Jan 13, 2011	Apr	CAHN
AB		100MG	A090607 002	Jan 13, 2011	Apr	CAHN
AB		150MG	A090607 003	Jan 13, 2011	Apr	CAHN
AB		200MG	A090607 004	Jan 13, 2011	Apr	CAHN
AB	HIKMA PHARMS	25MG	A078134 001	Apr 19, 2011	Apr	NEWA
AB		100MG	A078134 002	Apr 19, 2011	Apr	NEWA
AB		150MG	A078134 003	Apr 19, 2011	Apr	NEWA
AB		200MG	A078134 004	Apr 19, 2011	Apr	NEWA

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB	JUBILANT LIFE	5MG	A200220 001	Feb 28, 2011	Feb	NEWA
AB		25MG	A200220 002	Feb 28, 2011	Feb	NEWA

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

AT	ALCON RES	0.005%	A091449 001	Mar 22, 2011	Mar	NEWA
AT	APOTEX	0.005%	A077697 001	Mar 22, 2011	Mar	NEWA
AT	BAUSCH AND LOMB	0.005%	A201006 001	Mar 22, 2011	Mar	NEWA
AT	LUITPOLD	0.005%	A200925 001	Mar 22, 2011	May	CAHN
AT	MYLAN	0.005%	A201786 001	Mar 22, 2011	Mar	NEWA
AT	PHARMAFORCE	0.005%	A200925 001	Mar 22, 2011	Mar	NEWA

XALATAN

AT	+ PHARMACIA AND UPJOHN	0.005%	N020597 001	Jun 05, 1996	Mar	CFTG
----	------------------------	--------	-------------	--------------	-----	------

LETROZOLE

TABLET; ORAL

LETROZOLE

AB	ACCORD HLTHCARE	2.5MG	A090934 001	Jun 03, 2011	May	NEWA	
AB	DR REDDYS LABS LTD	2.5MG	A091191 001	Jun 03, 2011	May	NEWA	
AB	ENDO PHARMS	2.5MG	A090789 001	Jun 03, 2011	May	NEWA	
AB	FRESENIUS KABI ONCOL	2.5MG	A090491 001	Jun 03, 2011	May	NEWA	
AB	IMPAX LABS	2.5MG	A091638 001	Jun 03, 2011	May	NEWA	
AB	INDICUS PHARMA	2.5MG	A201804 001	Jun 03, 2011	May	NEWA	
AB	KUDCO IRELAND	2.5MG	A091098 001	Jun 03, 2011	May	NEWA	
AB	NATCO PHARMA LTD	2.5MG	A200161 001	Jun 03, 2011	May	NEWA	
AB	ROXANE	2.5MG	A090838 001	Jun 03, 2011	May	NEWA	
AB	SUN PHARM INDS LTD	2.5MG	A091466 001	Jun 03, 2011	May	NEWA	
>D>	AB	SYNTHON PHARMS	2.5MG	A090196 001	Jun 03, 2011	Jun	DISC
>A>	@	2.5MG	A090196 001	Jun 03, 2011	Jun	DISC	
AB		2.5MG	A090196 001	Jun 03, 2011	May	NEWA	
AB	TEVA PHARMS	2.5MG	A090289 001	Jun 03, 2011	May	NEWA	

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

@ GENZYME

1MG/0.2ML

A075721 001 Nov 29, 2001 Apr DISC

LUPRON DEPOT

>A>	+	ABBOTT ENDOCRINE	22.5MG/VIAL	N020517 001	Dec 22, 1995	Jun	CAHN
>A>	+		30MG/VIAL	N020517 002	May 30, 1997	Jun	CAHN
>A>			45MG/VIAL	N020517 003	Jun 17, 2011	Jun	NEWA
>D>	+	ABBOTT LABS	22.5MG/VIAL	N020517 001	Dec 22, 1995	Jun	CAHN
>D>	+		30MG/VIAL	N020517 002	May 30, 1997	Jun	CAHN

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

AB		ACCORD HLTHCARE	250MG	A090843 001	Feb 14, 2011	Jan	NEWA
AB			500MG	A090843 002	Feb 14, 2011	Jan	NEWA
AB			750MG	A090843 003	Feb 14, 2011	Jan	NEWA
AB			1GM	A090843 004	Feb 14, 2011	Jan	NEWA
AB		AJANTA PHARMA	250MG	A201293 001	Jun 14, 2011	May	NEWA
AB			500MG	A201293 002	Jun 14, 2011	May	NEWA
AB			750MG	A201293 003	Jun 14, 2011	May	NEWA
AB			1GM	A201293 004	Jun 14, 2011	May	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB		DR REDDYS LABS LTD	5MG	A090392 001	Feb 24, 2011	Feb	NEWA
AB		GLENMARK GENERICS	5MG	A090385 001	Feb 24, 2011	Feb	NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

>D>	+	ORTHO MCNEIL PHARM	EQ 500MG/20ML (EQ 25MG/ML)	N020635 001	Dec 20, 1996	Jun	CFTG
>A>	AP	+	EQ 500MG/20ML (EQ 25MG/ML)	N020635 001	Dec 20, 1996	Jun	CFTG
>D>	+		EQ 750MG/30ML (EQ 25MG/ML)	N020635 004	Dec 20, 1996	Jun	CFTG
>A>	AP	+	EQ 750MG/30ML (EQ 25MG/ML)	N020635 004	Dec 20, 1996	Jun	CFTG
			LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
>D>	+	ORTHO MCNEIL PHARM	EQ 250MG/50ML (EQ 5MG/ML)	N020635 002	Dec 20, 1996	Jun	CFTG
>A>	AP	+	EQ 250MG/50ML (EQ 5MG/ML)	N020635 002	Dec 20, 1996	Jun	CFTG
>D>	+		EQ 500MG/100ML (EQ 5MG/ML)	N020635 003	Dec 20, 1996	Jun	CFTG
>A>	AP	+	EQ 500MG/100ML (EQ 5MG/ML)	N020635 003	Dec 20, 1996	Jun	CFTG
>D>	+		EQ 750MG/150ML (EQ 5MG/ML)	N020635 005	Dec 20, 1996	Jun	CFTG
>A>	AP	+	EQ 750MG/150ML (EQ 5MG/ML)	N020635 005	Dec 20, 1996	Jun	CFTG
>A>			LEVOFLOXACIN				
>A>	AP	AKORN	EQ 500MG/20ML (EQ 25MG/ML)	A091644 001	Jun 20, 2011	Jun	NEWA
>A>	AP		EQ 750MG/30ML (EQ 25MG/ML)	A091644 002	Jun 20, 2011	Jun	NEWA
>A>	AP	SAGENT PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	A200560 001	Jun 20, 2011	Jun	NEWA
>A>	AP		EQ 750MG/30ML (EQ 25MG/ML)	A200560 002	Jun 20, 2011	Jun	NEWA
>A>			LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
>A>	AP	ACS DOBFAR INFO SA	EQ 250MG/50ML (EQ 5MG/ML)	A090343 001	Jul 07, 2011	Jun	NEWA
>A>	AP		EQ 500MG/100ML (EQ 5MG/ML)	A090343 002	Jul 07, 2011	Jun	NEWA
>A>	AP		EQ 750MG/150ML (EQ 5MG/ML)	A090343 003	Jul 07, 2011	Jun	NEWA

SOLUTION; ORAL

LEVAQUIN

>D>	+	ORTHO MCNEIL JANSSEN	250MG/10ML	N021721 001	Oct 21, 2004	Jun	CFTG
-----	---	----------------------	------------	-------------	--------------	-----	------

SOLUTION; ORAL									
LEVAQUIN									
>A>	AA	+	ORTHO MCNEIL JANSSEN	250MG/10ML	N021721	001	Oct 21, 2004	Jun	CFTG
LEVOFLOXACIN									
>A>	AA		HI TECH PHARMA	250MG/10ML	A091678	001	Jun 20, 2011	Jun	NEWA
SOLUTION/DROPS; OPHTHALMIC									
LEVOFLOXACIN									
AT			HI TECH PHARMA	0.5%	A076826	001	Feb 10, 2011	Jan	NEWA
TABLET; ORAL									
LEVAQUIN									
>D>			ORTHO MCNEIL JANSSEN	250MG	N020634	001	Dec 20, 1996	Jun	CFTG
>A>	AB			250MG	N020634	001	Dec 20, 1996	Jun	CFTG
>D>				500MG	N020634	002	Dec 20, 1996	Jun	CFTG
>A>	AB			500MG	N020634	002	Dec 20, 1996	Jun	CFTG
>D>		+		750MG	N020634	003	Sep 08, 2000	Jun	CFTG
>A>	AB	+		750MG	N020634	003	Sep 08, 2000	Jun	CFTG
LEVOFLOXACIN									
>A>	AB		AUROBINDO PHARMA LTD	250MG	A201043	001	Jun 20, 2011	Jun	NEWA
>A>	AB			500MG	A201043	002	Jun 20, 2011	Jun	NEWA
>A>	AB			750MG	A201043	003	Jun 20, 2011	Jun	NEWA
>A>	AB		DR REDDYS LABS INC	250MG	A076710	001	Jun 20, 2011	Jun	NEWA
>A>	AB			500MG	A076710	002	Jun 20, 2011	Jun	NEWA
>A>	AB			750MG	A076710	003	Jun 20, 2011	Jun	NEWA
>A>	AB		GLENMARK GENERICS	250MG	A200250	001	Jun 20, 2011	Jun	NEWA
>A>	AB			500MG	A200250	002	Jun 20, 2011	Jun	NEWA
>A>	AB			750MG	A200250	003	Jun 20, 2011	Jun	NEWA
>A>	AB		LUPIN	250MG	A078424	001	Jun 20, 2011	Jun	NEWA
>A>	AB			500MG	A078424	002	Jun 20, 2011	Jun	NEWA
>A>	AB			750MG	A078424	003	Jun 20, 2011	Jun	NEWA
>A>	AB		MYLAN	250MG	A076276	001	Jun 20, 2011	Jun	NEWA
>A>	AB			500MG	A076276	002	Jun 20, 2011	Jun	NEWA
>A>	AB			750MG	A077097	001	Jun 20, 2011	Jun	NEWA
>A>	AB		SANDOZ	250MG	A077438	001	Jun 20, 2011	Jun	NEWA
>A>	AB			500MG	A077438	002	Jun 20, 2011	Jun	NEWA
>A>	AB			750MG	A077438	003	Jun 20, 2011	Jun	NEWA
>A>	AB		TEVA	250MG	A076361	001	Jun 20, 2011	Jun	NEWA
>A>	AB			500MG	A076361	002	Jun 20, 2011	Jun	NEWA
>A>	AB			750MG	A076361	003	Jun 20, 2011	Jun	NEWA
>A>	AB		TORRENT PHARMS	250MG	A090722	001	Jun 20, 2011	Jun	NEWA
>A>	AB			500MG	A090722	002	Jun 20, 2011	Jun	NEWA
>A>	AB			750MG	A090722	003	Jun 20, 2011	Jun	NEWA
>A>	AB		WOCKHARDT	250MG	A090367	001	Jun 20, 2011	Jun	NEWA
>A>	AB			500MG	A090367	002	Jun 20, 2011	Jun	NEWA
>A>	AB			750MG	A090367	003	Jun 20, 2011	Jun	NEWA

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)

FUSILEV

+	SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 20, 2011	Apr	NEWA
+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	N020140	003	Apr 20, 2011	Apr	NEWA

SOLUTION; IV (INFUSION)

FUSILEV

+	SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140	002	Apr 20, 2011	May	CDFR
---	-----------------	--	---------	-----	--------------	-----	------

SOLUTION; IV (INFUSION)

FUSILEV

+ SPECTRUM PHARMS EQ 250MG BASE/25ML (EQ 10MG BASE/ML) N020140 003 Apr 20, 2011 May CDFR

LEVONORGESTREL

TABLET; ORAL

PLAN B

@ TEVA WOMENS

AB + 0.75MG N021045 001 Jul 28, 1999 Feb CAHN
 0.75MG N021045 002 Aug 24, 2006 Feb CAHN

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVO-DROMORAN

@ VALEANT PHARM INTL

LEVORPHANOL TARTRATE

ROXANE

2MG N008720 001 Dec 19, 1991 Mar DISC
 2MG A074278 001 Mar 31, 2000 Mar CTEC

LEVOTHYROXINE SODIUM

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

>A> POWDER; INTRAVENOUS

>A> LEVOTHYROXINE SODIUM

>A> + APP PHARMS 100MCG/VIAL N202231 001 Jun 24, 2011 Jun NEWA
 >A> + 200MCG/VIAL N202231 002 Jun 24, 2011 Jun NEWA
 >A> + 500MCG/VIAL N202231 003 Jun 24, 2011 Jun NEWA

TABLET; ORAL

LEVO-T

ALARA PHARM

AB1, 0.025MG N021342 001 Mar 01, 2002 Feb CTEC
 AB2,
 AB3
 AB1, 0.05MG N021342 002 Mar 01, 2002 Feb CTEC
 AB2,
 AB3
 AB1, 0.075MG N021342 003 Mar 01, 2002 Feb CTEC
 AB2,
 AB3
 AB1, 0.088MG N021342 004 Mar 01, 2002 Feb CTEC
 AB2,
 AB3
 AB1, 0.1MG N021342 005 Mar 01, 2002 Feb CTEC
 AB2,
 AB3
 AB1, 0.112MG N021342 006 Mar 01, 2002 Feb CTEC
 AB2,
 AB3
 AB1, 0.125MG N021342 007 Mar 01, 2002 Feb CTEC
 AB2,
 AB3
 AB1, 0.137MG N021342 012 Dec 08, 2003 Feb CTEC
 AB2,
 AB3
 AB1, 0.15MG N021342 008 Mar 01, 2002 Feb CTEC
 AB2,
 AB3
 AB1, 0.175MG N021342 009 Mar 01, 2002 Feb CTEC
 AB2,
 AB3
 AB1, 0.2MG N021342 010 Mar 01, 2002 Feb CTEC
 AB2,
 AB3
 AB1, + 0.3MG N021342 011 Mar 01, 2002 Feb CTEC
 AB2,
 AB3

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

AT	NOVOCOL INC	5%	A040911 001	May 23, 2011	May	NEWA
----	-------------	----	-------------	--------------	-----	------

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL

LIDOCAINE HYDROCHLORIDE

AT	HI TECH PHARMA	2%	A040837 001	Mar 23, 2011	Mar	NEWA
----	----------------	----	-------------	--------------	-----	------

SYSTEM; INTRADERMAL

ZINGO

>D>	@ ANESIVA	0.5MG	N022114 001	Aug 16, 2007	Jun	CAHN
-----	-----------	-------	-------------	--------------	-----	------

>A>	@ POWDER PHARMS	0.5MG	N022114 001	Aug 16, 2007	Jun	CAHN
-----	-----------------	-------	-------------	--------------	-----	------

LINAGLIPTIN

TABLET; ORAL

TRADJENTA

+	BOEHRINGER INGELHEIM	5MG	N201280 001	May 02, 2011	May	NEWA
---	----------------------	-----	-------------	--------------	-----	------

LISINAPRIL

TABLET; ORAL

LISINAPRIL

AB	PRINSTON PHARM LLC	2.5MG	A076180 001	Jul 01, 2002	May	CAHN
----	--------------------	-------	-------------	--------------	-----	------

AB		5MG	A076180 002	Jul 01, 2002	May	CAHN
----	--	-----	-------------	--------------	-----	------

AB		10MG	A076180 003	Jul 01, 2002	May	CAHN
----	--	------	-------------	--------------	-----	------

AB		20MG	A076164 001	Jul 01, 2002	May	CAHN
----	--	------	-------------	--------------	-----	------

AB		30MG	A076164 002	Jul 01, 2002	May	CAHN
----	--	------	-------------	--------------	-----	------

AB		40MG	A076164 003	Jul 01, 2002	May	CAHN
----	--	------	-------------	--------------	-----	------

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB	GLENMARK GENERICS	450MG	A091616 001	Feb 14, 2011	Jan	NEWA
----	-------------------	-------	-------------	--------------	-----	------

LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM

AB	ALEMBIC PHARMS LTD	25MG	A090428 001	Oct 06, 2010	Apr	CAHN
----	--------------------	------	-------------	--------------	-----	------

AB		50MG	A090428 002	Oct 06, 2010	Apr	NEWA
----	--	------	-------------	--------------	-----	------

AB		100MG	A090428 003	Oct 06, 2010	Apr	CAHN
----	--	-------	-------------	--------------	-----	------

AB	HUAHAI US INC	25MG	A091497 001	Jun 06, 2011	May	NEWA
----	---------------	------	-------------	--------------	-----	------

AB		50MG	A091497 002	Jun 06, 2011	May	NEWA
----	--	------	-------------	--------------	-----	------

AB		100MG	A091497 003	Jun 06, 2011	May	NEWA
----	--	-------	-------------	--------------	-----	------

AB	MYLAN	25MG	A091590 001	Oct 06, 2010	Jan	NEWA
----	-------	------	-------------	--------------	-----	------

AB		50MG	A091590 002	Oct 06, 2010	Jan	NEWA
----	--	------	-------------	--------------	-----	------

AB		100MG	A091590 003	Oct 06, 2010	Jan	NEWA
----	--	-------	-------------	--------------	-----	------

LOTEPREDNOL ETABONATE

OINTMENT; OPHTHALMIC

LOTEMAX

+	BAUSCH AND LOMB	0.5%	N200738 001	Apr 15, 2011	Apr	NEWA
---	-----------------	------	-------------	--------------	-----	------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	12.5MG	A201451 001	Feb 23, 2011	Feb	NEWA
AA		25MG	A201451 002	Feb 23, 2011	Feb	NEWA
AA		50MG	A201451 003	Feb 23, 2011	Feb	NEWA
AA	JUBILANT CADISTA	12.5MG	A040659 001	Jun 04, 2010	Jan	CAHN
AA		25MG	A040659 002	Jun 04, 2010	Jan	CAHN

MELOXICAM

TABLET; ORAL

MELOXICAM

>D>	AB	ACTAVIS TOTOWA	7.5MG	A077938 001	Jul 19, 2006	Jun	CAHN
>D>	AB		15MG	A077938 002	Jul 19, 2006	Jun	CAHN
	AB	MYLAN	7.5MG	A077934 001	Jul 20, 2006	Feb	CAHN
	AB		15MG	A077934 002	Jul 20, 2006	Feb	CAHN
>A>	AB	PURACAP PHARM	7.5MG	A077938 001	Jul 19, 2006	Jun	CAHN
>A>	AB		15MG	A077938 002	Jul 19, 2006	Jun	CAHN

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE

@ SUN PHARMA GLOBAL

@

5MG

10MG

A090058 001

A090058 002

May 05, 2010

May 05, 2010

May

May

CAHN

CAHN

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

AP	BAXTER HLTHCARE CORP	10MG/ML	A081002 001	Jul 30, 1993	May	CAHN
----	----------------------	---------	-------------	--------------	-----	------

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

AA	ALEMBIC PHARMS LTD	200MG	A090122 001	Feb 18, 2009	May	CAHN
AA		400MG	A090122 002	Feb 18, 2009	May	CAHN
AA	TARO	200MG	A200998 001	May 23, 2011	May	NEWA
AA		400MG	A200998 002	May 23, 2011	May	NEWA

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

+ AQUA PHARMS

2%;0.01%

N020922 001

Dec 10, 1999

May

CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP	SANDOZ	500MG/VIAL	A091201 001	Mar 29, 2011	Mar	NEWA
AP		1GM/VIAL	A091201 002	Mar 29, 2011	Mar	NEWA
	MERREM					
AP	+ ASTRAZENECA	500MG/VIAL	N050706 003	Jun 21, 1996	Mar	CTNA
AP	+	1GM/VIAL	N050706 001	Jun 21, 1996	Mar	CTNA

MESALAMINE

ENEMA; RECTAL

ROWASA

>D>	AB	+	ALAVEN PHARM	4GM/60ML	N019618	001	Dec 24, 1987	Jun	CAHN
>A>	AB	+	MEDA PHARMS	4GM/60ML	N019618	001	Dec 24, 1987	Jun	CAHN

SFROWASA

>D>	AB		ALAVEN PHARM	4GM/60ML	N019618	002	Jun 20, 2008	Jun	CAHN
>A>	AB		MEDA PHARMS	4GM/60ML	N019618	002	Jun 20, 2008	Jun	CAHN

TABLET, DELAYED RELEASE; ORAL

ASACOL

>D>		+	WARNER CHILCOTT INC	400MG	N019651	001	Jan 31, 1992	Jun	CAHN
>A>		+	WARNER CHILCOTT LLC	400MG	N019651	001	Jan 31, 1992	Jun	CAHN

ASACOL HD

>D>		+	WARNER CHILCOTT INC	800MG	N021830	001	May 29, 2008	Jun	CAHN
>A>		+	WARNER CHILCOTT LLC	800MG	N021830	001	May 29, 2008	Jun	CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

	AB		MYLAN	500MG	A075973	001	Jan 25, 2002	Feb	CAHN
	AB			850MG	A075973	002	Jan 25, 2002	Feb	CAHN
	AB			1GM	A075973	003	Jan 25, 2002	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

FORTAMET

>D>	BX		ANDRX LABS LLC	500MG	N021574	001	Apr 27, 2004	Jun	CTEC
>A>	AB2			500MG	N021574	001	Apr 27, 2004	Jun	CTEC
>D>	BX	+		1GM	N021574	002	Apr 27, 2004	Jun	CTEC
>A>	AB	+		1GM	N021574	002	Apr 27, 2004	Jun	CTEC

GLUCOPHAGE XR

>D>	AB		BRISTOL MYERS SQUIBB	500MG	N021202	001	Oct 13, 2000	Jun	CTEC
>A>	AB1			500MG	N021202	001	Oct 13, 2000	Jun	CTEC

METFORMIN HYDROCHLORIDE

>D>	AB		ACTAVIS ELIZABETH	500MG	A076450	001	Oct 01, 2004	Jun	CTEC
>A>	AB1			500MG	A076450	001	Oct 01, 2004	Jun	CTEC
>D>	AB		AMNEAL PHARMS NY	500MG	A078596	001	Jan 03, 2008	Jun	CTEC
>A>	AB1			500MG	A078596	001	Jan 03, 2008	Jun	CTEC
>A>	AB1		APOTEX	500MG	A076706	001	Dec 14, 2004	Jun	CTEC
>A>	AB			750MG	A076706	002	Dec 29, 2005	Jun	CAHN
>D>	AB		APOTEX INC	500MG	A076706	001	Dec 14, 2004	Jun	CTEC
>D>	AB			750MG	A076706	002	Dec 29, 2005	Jun	CAHN
>D>	AB		IMPAX LABS	500MG	A076249	001	Jul 30, 2004	Jun	CTEC
>A>	AB1			500MG	A076249	001	Jul 30, 2004	Jun	CTEC
>A>	AB2		LUPIN LTD	500MG	A090692	001	Jun 29, 2011	Jun	NEWA
>A>	AB			1GM	A090692	002	Jun 29, 2011	Jun	NEWA
>D>	AB		MYLAN	500MG	A076650	001	Sep 13, 2005	Jun	CTEC
>A>	AB1			500MG	A076650	001	Sep 13, 2005	Jun	CTEC
>D>	AB		NEUROSCI INC	500MG	A078321	001	Apr 17, 2008	Jun	CTEC
>A>	AB1			500MG	A078321	001	Apr 17, 2008	Jun	CTEC
>D>	AB		NOSTRUM	500MG	A076756	001	Jul 26, 2006	Jun	CTEC
>A>	AB1			500MG	A076756	001	Jul 26, 2006	Jun	CTEC
>D>	AB		RANBAXY	500MG	A076413	001	Jun 18, 2004	Jun	CTEC
>A>	AB1		RANBAXY LABS LTD	500MG	A076413	001	Jun 18, 2004	Jun	CTEC
>D>	AB		SANDOZ	500MG	A076873	001	Dec 14, 2004	Jun	CTEC
>A>	AB1			500MG	A076873	001	Dec 14, 2004	Jun	CTEC
>D>	AB		SUN PHARM INDS (IN)	500MG	A077336	001	Feb 09, 2006	Jun	CTEC

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

>A>	AB1	SUN PHARM INDS (IN)	500MG	A077336	001	Feb 09, 2006	Jun	CTEC
>D>	AB	TEVA	500MG	A076269	001	Jun 18, 2004	Jun	CTEC
>A>	AB1		500MG	A076269	001	Jun 18, 2004	Jun	CTEC
>D>	AB	TORRENT PHARM	500MG	A090014	001	Dec 30, 2009	Jun	CTEC
>A>	AB1		500MG	A090014	001	Dec 30, 2009	Jun	CTEC
>D>	AB	WATSON LABS	500MG	A076818	001	Dec 14, 2004	Jun	CTEC
>D>	AB	WATSON LABS FLORIDA	500MG	A076172	001	Jun 16, 2004	Jun	CTEC
>A>	AB1		500MG	A076172	001	Jun 16, 2004	Jun	CTEC
>A>	AB1	WATSON LABS INC	500MG	A076818	001	Dec 14, 2004	Jun	CTEC
>D>	AB	ZYDUS PHARMS USA	500MG	A077060	001	Apr 20, 2005	Jun	CTEC
>A>	AB1		500MG	A077060	001	Apr 20, 2005	Jun	CTEC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

AB		TAKEDA GLOBAL	500MG;EQ 15MG BASE	N021842	001	Aug 29, 2005	Feb	CFTG
AB	+		850MG;EQ 15MG BASE	N021842	002	Aug 29, 2005	Feb	CFTG

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB		MYLAN	500MG;EQ 15MG BASE	A090406	001	Feb 25, 2011	Feb	NEWA
AB			850MG;EQ 15MG BASE	A090406	002	Feb 25, 2011	Feb	NEWA

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

>D>	AA	LANNETT	500MG	A084756	002	Mar 31, 2003	Jun	CAHN
>D>	AA		750MG	A084756	001		Jun	CAHN
>A>	AA	LANNETT HOLDINGS INC	500MG	A084756	002	Mar 31, 2003	Jun	CAHN
>A>	AA		750MG	A084756	001		Jun	CAHN
>D>		@ PHARMERAL	500MG	A084231	002		Jun	CAHN
>D>		@	750MG	A084471	001		Jun	CAHN
>A>		@ PURACAP PHARM	500MG	A084231	002		Jun	CAHN
>A>		@	750MG	A084471	001		Jun	CAHN

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHERGINE

AB	+	NOVARTIS	0.2MG	N006035	003		Apr	CTEC
AB		NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011	Apr	NEWA

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

AB		JUBILANT CADISTA	4MG	A040189	001	Oct 31, 1997	Jan	CAHN
AB			8MG	A040189	002	Oct 31, 1997	Jan	CAHN
AB			16MG	A040189	003	Jul 20, 2007	Jan	CAHN
AB			32MG	A040189	004	Jul 20, 2007	Jan	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

AP		HEMOPARM	EQ 40MG BASE/VIAL	A040793	001	Nov 25, 2008	Apr	CAHN
AP			EQ 125MG BASE/VIAL	A040827	001	Nov 25, 2008	Apr	CAHN
		@ HOSPIRA	EQ 500MG BASE/VIAL	A089173	001	Aug 18, 1987	Feb	DISC

INJECTABLE; INJECTION

A-METHAPRED

@ HOSPIRA

EQ 1GM BASE/VIAL

A089174 001 Aug 18, 1987 Feb DISC

METRONIDAZOLE

GEL; TOPICAL

METRONIDAZOLE

AB G AND W LABS INC 0.75%

A078178 001 Jan 19, 2011 Jan NEWA

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

>D> AP + GD SEARLE LLC 500MG/100ML

N018353 002 Jun CAHN

>A> AP + PFIZER 500MG/100ML

N018353 002 Jun CAHN

TABLET; ORAL

METRONIDAZOLE

AB ALEMBIC PHARMS LTD 250MG

A079067 001 Mar 13, 2009 May CAHN

AB 500MG

A079067 002 Mar 13, 2009 May CAHN

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

FLAGYL I.V.

>D> + GD SEARLE LLC EQ 500MG BASE/VIAL

N018353 001 Jun DISC

>A> @ PFIZER EQ 500MG BASE/VIAL

N018353 001 Jun DISC

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)

MYCAMINE

+ ASTELLAS 100MG/VIAL

N021506 003 Jun 27, 2006 Jan CRLD

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDOZALAM HYDROCHLORIDE

AP SAGENT STRIDES EQ 1MG BASE/ML

A090316 001 May 04, 2011 Apr NEWA

AP EQ 5MG BASE/ML

A090316 002 May 04, 2011 Apr NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

@ HOSPIRA EQ 1MG BASE/ML

A075884 001 May 28, 2002 Feb DISC

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

AB ACTAVIS ELIZABETH 15MG

A077959 001 Feb 14, 2011 Jan NEWA

AB 30MG

A077959 002 Feb 14, 2011 Jan NEWA

AB 45MG

A077959 003 Feb 14, 2011 Jan NEWA

MORPHINE SULFATE

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

+ EKR THERAP 10MG/ML (10MG/ML)

N021671 001 May 18, 2004 May CRLD

@ 15MG/1.5ML (10MG/ML)

N021671 002 May 18, 2004 May DISC

SOLUTION; ORAL

MORPHINE SULFATE

>A> LANNETT HOLDINGS INC 20MG/ML

N201517 001 Jun 23, 2011 Jun NEWA

MUPIROCIN

OINTMENT; TOPICAL

MUPIROCIN

AB	GLENMARK PHARMS	2%	A090480 001	Jun 08, 2011	May	NEWA
----	-----------------	----	-------------	--------------	-----	------

MUPIROCIN CALCIUM

CREAM; TOPICAL

BACTROBAN

+	GLAXOSMITHKLINE	EQ 2% BASE	N050746 001	Dec 11, 1997	Jan	CDFR
---	-----------------	------------	-------------	--------------	-----	------

NABUMETONE

TABLET; ORAL

NABUMETONE

AB	LUPIN LTD	500MG	A090445 001	Jan 12, 2011	Jan	NEWA
AB		750MG	A090445 002	Jan 12, 2011	Jan	NEWA
AB	WATSON LABS	500MG	A091083 001	Jun 13, 2011	May	NEWA
AB		750MG	A091083 002	Jun 13, 2011	May	NEWA

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

>A>	AP	IBI	EQ 1GM BASE/VIAL	A090002 001	Jun 30, 2011	Jun	NEWA
>A>	AP		EQ 2GM BASE/VIAL	A090002 002	Jun 30, 2011	Jun	NEWA
	AP	INSTITUTO BIOCHEMICO	EQ 10GM BASE/VIAL	A090005 001	Apr 20, 2011	Apr	NEWA
	AP	+ SANDOZ	EQ 10GM BASE/VIAL	A062527 004	Aug 02, 1984	Apr	CTEC

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB	ELITE LABS	50MG	A075274 001	May 26, 1999	Feb	CAHN
----	------------	------	-------------	--------------	-----	------

NAPROXEN

TABLET; ORAL

NAPROXEN

AB	MARKSANS PHARMA	250MG	A091416 001	Feb 14, 2011	Jan	NEWA
AB		375MG	A091416 002	Feb 14, 2011	Jan	NEWA
AB		500MG	A091416 003	Feb 14, 2011	Jan	NEWA

NARATRIPTAN

TABLET; ORAL

NARATRIPTAN

AB	APOTEX CORP	EQ 1MG BASE	A091373 001	Apr 22, 2011	Apr	NEWA
AB		EQ 2.5MG BASE	A091373 002	Apr 22, 2011	Apr	NEWA
AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552 001	Feb 14, 2011	Jan	NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB	INDICUS PHARMA	EQ 1MG BASE	A200502 001	Feb 28, 2011	Feb	NEWA
AB		EQ 2.5MG BASE	A200502 002	Feb 28, 2011	Feb	NEWA

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

AB	WATSON LABS	60MG	A077462 001	Mar 30, 2011	Mar	NEWA
AB		120MG	A077462 002	Mar 30, 2011	Mar	NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE; ORAL

VIRAMUNE XR

+	BOEHRINGER INGELHEIM	400MG	N201152 001	Mar 25, 2011	Mar	NEWA
---	----------------------	-------	-------------	--------------	-----	------

NICARDIPINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDENE SR

@	EKR THERAP	45MG	N020005 002	Feb 21, 1992	May	DISC
---	------------	------	-------------	--------------	-----	------

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB1	VALEANT INTL	30MG	A075269 001	Dec 04, 2000	Apr	CAHN
AB2		30MG	A075289 002	Feb 06, 2001	Apr	CAHN
AB2		60MG	A075289 001	Sep 27, 2000	Apr	CAHN
AB1		60MG	A075269 002	Dec 04, 2000	Apr	CAHN
AB1		90MG	A076070 001	Aug 16, 2002	Apr	CAHN

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

NISOLDIPINE

AB	MYLAN	8.5MG	A091001 001	Jan 26, 2011	Jan	NEWA
AB		17MG	A091001 002	Jan 26, 2011	Jan	NEWA
AB		25.5MG	A091001 003	Jan 26, 2011	Jan	NEWA
AB		34MG	A091001 004	Jan 26, 2011	Jan	NEWA
	SULAR					
AB	+ SHIONOGI PHARMA	8.5MG	N020356 008	Jan 02, 2008	Jan	CFTG
AB	+	17MG	N020356 007	Jan 02, 2008	Jan	CFTG
AB		25.5MG	N020356 006	Jan 02, 2008	Jan	CFTG
AB	+	34MG	N020356 005	Jan 02, 2008	Jan	CFTG

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTIN

AB	+ SHIONOGI INC	25MG/5ML	N009175 001		Apr	CFTG
----	----------------	----------	-------------	--	-----	------

NITROFURANTOIN

AB	AMNEAL PHARMS	25MG/5ML	A201679 001	May 11, 2011	Apr	NEWA
----	---------------	----------	-------------	--------------	-----	------

NITROGLYCERIN

OINTMENT; INTRA-ANAL

RECTIV

>A>						
>A>	+ PROSTRAKAN INC	0.4%	N021359 001	Jun 21, 2011	Jun	NEWA

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

AB	MYLAN	150MG	A075934 001	Jul 09, 2002	Feb	CAHN
AB		300MG	A075934 002	Jul 09, 2002	Feb	CAHN

NYSTATIN

SUSPENSION; ORAL

NYSTATIN

AA	VISTAPHARM	100,000 UNITS/ML	A065422 001	Mar 07, 2011	Feb	NEWA
----	------------	------------------	-------------	--------------	-----	------

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP	WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986 001	May 11, 2011	Apr	NEWA
----	---------------	------------------	-------------	--------------	-----	------

AP		EQ 1MG BASE/ML	A090986 002	May 11, 2011	Apr	NEWA
----	--	----------------	-------------	--------------	-----	------

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP	BIONICHE PHARMA USA	EQ 0.05MG BASE/ML	A079198 001	Feb 10, 2011	Jan	NEWA
----	---------------------	-------------------	-------------	--------------	-----	------

AP		EQ 0.1MG BASE/ML	A079198 002	Feb 10, 2011	Jan	NEWA
----	--	------------------	-------------	--------------	-----	------

AP		EQ 0.5MG BASE/ML	A079198 003	Feb 10, 2011	Jan	NEWA
----	--	------------------	-------------	--------------	-----	------

AP	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985 001	May 11, 2011	Apr	NEWA
----	---------------	-------------------	-------------	--------------	-----	------

AP		EQ 0.1MG BASE/ML	A090985 002	May 11, 2011	Apr	NEWA
----	--	------------------	-------------	--------------	-----	------

AP		EQ 0.5MG BASE/ML	A090985 003	May 11, 2011	Apr	NEWA
----	--	------------------	-------------	--------------	-----	------

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

AB	RANBAXY	4MG	A078602 001	Feb 24, 2011	Feb	NEWA
----	---------	-----	-------------	--------------	-----	------

AB		8MG	A078602 002	Feb 24, 2011	Feb	NEWA
----	--	-----	-------------	--------------	-----	------

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP	PFIZER	EQ 2MG BASE/ML	A078257 001	Apr 23, 2008	May	CAHN
----	--------	----------------	-------------	--------------	-----	------

AP	TEVA	EQ 2MG BASE/ML	A076876 001	Nov 22, 2006	Jan	CMFD
----	------	----------------	-------------	--------------	-----	------

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

AP	+ HOSPIRA	EQ 0.64MG BASE/ML	A077348 001	Feb 01, 2007	Apr	CRLD
----	-----------	-------------------	-------------	--------------	-----	------

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AP	PFIZER	EQ 2MG BASE/ML	A078244 001	Apr 23, 2008	May	CAHN
----	--------	----------------	-------------	--------------	-----	------

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 4MG BASE/5ML	A091483 001	Jan 31, 2011	Jan	NEWA
----	---------------	-----------------	-------------	--------------	-----	------

AA	SILARX	EQ 4MG BASE/5ML	A091342 001	Jan 27, 2011	Jan	NEWA
----	--------	-----------------	-------------	--------------	-----	------

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

AB	TARO	EQ 4MG BASE	A077729 001	Mar 28, 2011	Mar	NEWA
----	------	-------------	-------------	--------------	-----	------

AB		EQ 8MG BASE	A077729 002	Mar 28, 2011	Mar	NEWA
----	--	-------------	-------------	--------------	-----	------

AB		EQ 24MG BASE	A077729 003	Mar 28, 2011	Mar	NEWA
----	--	--------------	-------------	--------------	-----	------

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

>A>	ROCHE	EQ 6MG BASE/ML	N021246 002	Mar 21, 2011	Jun	NEWA
-----	-------	----------------	-------------	--------------	-----	------

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP	SANDOZ	50MG/10ML (5MG/ML)	A078817 001	Jan 24, 2011	Jan	NEWA
----	--------	--------------------	-------------	--------------	-----	------

AP		50MG/VIAL	A090849 001	Apr 28, 2011	Apr	NEWA
----	--	-----------	-------------	--------------	-----	------

AP		100MG/VIAL	A090849 002	Apr 28, 2011	Apr	NEWA
----	--	------------	-------------	--------------	-----	------

AP		100MG/20ML (5MG/ML)	A078817 002	Jan 24, 2011	Jan	NEWA
----	--	---------------------	-------------	--------------	-----	------

OXAPROZIN

TABLET; ORAL

OXAPROZIN

AB	MYLAN	600MG	A075847	001	Feb 28, 2001	Feb	CAHN
----	-------	-------	---------	-----	--------------	-----	------

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXECTA

>A>							
>A>	KING PHARMS R AND D	5MG	N202080	001	Jun 17, 2011	Jun	NEWA
>A>		7.5MG	N202080	002	Jun 17, 2011	Jun	NEWA

OXYCODONE HYDROCHLORIDE

AB	COASTAL PHARMS	5MG	A091313	001	Feb 18, 2011	Feb	NEWA
AB		15MG	A091313	002	Feb 18, 2011	Feb	NEWA
AB		30MG	A091313	003	Feb 18, 2011	Feb	NEWA
AB	RHODES PHARMS	5MG	A091490	001	Mar 09, 2011	Feb	NEWA
AB		10MG	A091490	002	Mar 09, 2011	Feb	NEWA
AB		15MG	A091490	003	Mar 09, 2011	Feb	NEWA
AB		20MG	A091490	004	Mar 09, 2011	Feb	NEWA
AB		30MG	A091490	005	Mar 09, 2011	Feb	NEWA

OXYMETHOLONE

TABLET; ORAL

ANADROL-50

+	MEDA PHARMS	50MG	N016848	001		May	CAHN
---	-------------	------	---------	-----	--	-----	------

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

AB	TEVA	5MG	A091443	002	Feb 15, 2011	Jan	NEWA
AB		10MG	A091443	001	Feb 15, 2011	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

@	ENDO PHARMS	7.5MG	N021610	005	Feb 29, 2008	Feb	DISC
---	-------------	-------	---------	-----	--------------	-----	------

@		15MG	N021610	006	Feb 29, 2008	Feb	DISC
---	--	------	---------	-----	--------------	-----	------

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

>A>	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	Jun	CAHN
>A>		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	Jun	CAHN
>A>		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Jun	CAHN
>A>		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Jun	CAHN
>A>	+	234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Jun	CAHN
>D>	ORTHO MCNEIL JANSSEN	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	Jun	CAHN
>D>		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	Jun	CAHN
>D>		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Jun	CAHN
>D>		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Jun	CAHN
>D>	+	234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Jun	CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

AP	MUSTAFA NEVZAT	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	May	CAHN
AP		90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	May	CAHN

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

PANCREAZE

>A>	JANSSEN PHARMS	17,500USP/ UNITS;4,200USP/ UNITS;10,000USP/ UNITS	N022523 001	Apr 12, 2010	Jun	CAHN
>A>		43,750USP/ UNITS;10,500USP/ UNITS;25,000USP/ UNITS	N022523 002	Apr 12, 2010	Jun	CAHN
>A>		70,000USP/ UNITS;16,800USP/ UNITS;40,000USP/ UNITS	N022523 004	Apr 12, 2010	Jun	CAHN
>A>	+	61,000USP/ UNITS;21,000USP/ UNITS;37,000USP/ UNITS	N022523 003	Apr 12, 2010	Jun	CAHN
>D>	ORTHO MCNEIL JANSSEN	17,500USP/ UNITS;4,200USP/ UNITS;10,000USP/ UNITS	N022523 001	Apr 12, 2010	Jun	CAHN
>D>		43,750USP/ UNITS;10,500USP/ UNITS;25,000USP/ UNITS	N022523 002	Apr 12, 2010	Jun	CAHN
>D>		70,000USP/ UNITS;16,800USP/ UNITS;40,000USP/ UNITS	N022523 004	Apr 12, 2010	Jun	CAHN
>D>	+	61,000USP/ UNITS;21,000USP/ UNITS;37,000USP/ UNITS	N022523 003	Apr 12, 2010	Jun	CAHN

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	ACTAVIS TOTOWA	EQ 20MG BASE	A090797 001	Feb 07, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090797 002	Feb 07, 2011	Jan	NEWA
AB	DR REDDYS LABS LTD	EQ 20MG BASE	A077619 001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A077619 002	Jan 19, 2011	Jan	NEWA
AB	KUDCO IRELAND	EQ 20MG BASE	A078281 001	Jan 20, 2011	Jan	NEWA
AB		EQ 40MG BASE	A078281 002	Jan 20, 2011	Jan	NEWA
AB	MATRIX LABS LTD	EQ 20MG BASE	A090970 001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090970 002	Jan 19, 2011	Jan	NEWA
AB	TORRENT PHARMS	EQ 20MG BASE	A090074 001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A090074 002	Jan 19, 2011	Jan	NEWA
AB	WOCKHARDT	EQ 20MG BASE	A091231 001	Jan 19, 2011	Jan	NEWA
AB		EQ 40MG BASE	A091231 002	Jan 19, 2011	Jan	NEWA

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

@	MONARCH PHARMS	EQ 250MG BASE	A062310 001		May	CAHN
---	----------------	---------------	-------------	--	-----	------

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

AB	MYLAN	EQ 37.5MG BASE	A091427 001	Apr 14, 2011	Apr	NEWA	
AB	PAXIL CR						
AB	+	GLAXOSMITHKLINE	EQ 37.5MG BASE	N020936 003	Dec 06, 2000	Apr	CTEC

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

AB	VALEANT INTL	400MG	A075028 001	Jul 20, 1998	Apr	CAHN
----	--------------	-------	-------------	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

AA	ELITE LABS	37.5MG	A200272 001	Jan 31, 2011	May	CAHN
AA	EPIC PHARMA LLC	37.5MG	A200272 001	Jan 31, 2011	Jan	NEWA

>A>	TABLET, ORALLY DISINTEGRATING; ORAL						
>A>	SUPRENZA						
>A>	CITIUS PHARMS	15MG	N202088	001	Jun 13, 2011	Jun	NEWA
>A>	+	30MG	N202088	002	Jun 13, 2011	Jun	NEWA

PHENYTOIN SODIUM

	INJECTABLE; INJECTION						
	PHENYTOIN SODIUM						
AP	X-GEN PHARMS	50MG/ML	A040573	001	Sep 13, 2006	May	CAHN

PILOCARPINE HYDROCHLORIDE

	SOLUTION; OPHTHALMIC						
	ISOPTO CARPINE						
	ALCON RES	1%	N200890	001	Jun 22, 2010	May	CTNA
		2%	N200890	002	Jun 22, 2010	May	CTNA
	+	4%	N200890	003	Jun 22, 2010	May	CTNA

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

	INJECTABLE; INJECTION						
	PIPERACILLIN AND TAZOBACTAM						
AP	AUROBINDO PHARMA LTD	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065498	001	May 23, 2011	May	NEWA
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065498	002	May 23, 2011	May	NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065498	003	May 23, 2011	May	NEWA
AP	HOSPIRA INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386	001	Sep 15, 2009	Jan	CAHN
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386	002	Sep 15, 2009	Jan	CAHN
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386	003	Sep 15, 2009	Jan	CAHN
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446	001	Sep 15, 2009	Jan	CAHN
AP	INSTITUTO BIOCHEMICO	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065523	001	May 31, 2011	May	NEWA
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065523	002	May 31, 2011	May	NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065523	003	May 31, 2011	May	NEWA
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A090498	001	May 31, 2011	May	NEWA

PIROXICAM

	CAPSULE; ORAL						
	PIROXICAM						
	@ MYLAN	10MG	A074043	001	Sep 22, 1992	Feb	CAHN
	@	20MG	A074043	002	Sep 22, 1992	Feb	CAHN

PODOFILOX

	SOLUTION; TOPICAL						
	PODOFILOX						
>D>	AT COLLEGIUM PHARM	0.5%	A090184	001	Jul 21, 2010	Jun	CAHN
>A>	AT PRECISION DERMAT	0.5%	A090184	001	Jul 21, 2010	Jun	CAHN

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

>D>	@	ALAVEN PHARM	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983 005	Oct 26, 1984	Jun	CAHN
>D>	@		227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983 004	Oct 26, 1984	Jun	CAHN
>D>	AA	+	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983 010	Jan 31, 1989	Jun	CAHN
>D>	AA	+	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983 007	Jun 12, 1987	Jun	CAHN
>D>	@		360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983 006	Oct 26, 1984	Jun	CAHN
>A>	@	MEDA PHARMS	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983 005	Oct 26, 1984	Jun	CAHN
>A>	AA	+	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983 010	Jan 31, 1989	Jun	CAHN
>A>			227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983 004	Oct 26, 1984	Jun	CAHN
>A>	AA	+	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983 007	Jun 12, 1987	Jun	CAHN
>A>	@		360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983 006	Oct 26, 1984	Jun	CAHN

COLYTE WITH FLAVOR PACKS

>D>	AA	+	ALAVEN PHARM	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983 012	Oct 08, 1998	Jun	CAHN
>A>	AA	+	MEDA PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983 012	Oct 08, 1998	Jun	CAHN

COLYTE-FLAVORED

>D>	AA	+	ALAVEN PHARM	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983 008	Nov 14, 1991	Jun	CAHN
>D>	AA	+		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983 009	Nov 14, 1991	Jun	CAHN
>A>	AA	+	MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983 008	Nov 14, 1991	Jun	CAHN
>A>	AA	+		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983 009	Nov 14, 1991	Jun	CAHN

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLMYCIN B SULFATE

>A>	AP		SAGENT STRIDES	EQ 500,000 UNITS BASE/VIAL	A090110 001	Jun 29, 2011	Jun	NEWA
-----	----	--	----------------	----------------------------	-------------	--------------	-----	------

PORFIMER SODIUM

>D> INJECTABLE; INJECTION

>D> PHOTOFRIN

>D>	+	AXCAN	75MG/VIAL	N020451 001	Dec 27, 1995	Jun	DISC
-----	---	-------	-----------	-------------	--------------	-----	------

>A>	@	PINNACLE BIOLGS	75MG/VIAL	N020451 001	Dec 27, 1995	Jun	DISC
-----	---	-----------------	-----------	-------------	--------------	-----	------

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB		PADDOCK LABS	8MEQ	A200185 001	May 18, 2011	May	NEWA
----	--	--------------	------	-------------	--------------	-----	------

AB			10MEQ	A200185 002	May 18, 2011	May	NEWA
----	--	--	-------	-------------	--------------	-----	------

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

MIRAPEX ER

>A>	BOEHRINGER INGELHEIM	2.25MG	N022421 006	Jun 17, 2011	Jun	NEWA
>A>		3.75MG	N022421 007	Jun 17, 2011	Jun	NEWA

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

@ VINTAGE PHARMS EQ 5MG BASE/5ML

A078416 001 Oct 31, 2007 May DISC

PREDNISONE

TABLET; ORAL

PREDNISONE

AB	JUBILANT CADISTA	1MG	A040611 001	Jun 06, 2005	Jan	CAHN
AB		5MG	A040362 002	Aug 29, 2001	Jan	CAHN
AB		10MG	A040362 001	Aug 29, 2001	Jan	CAHN
AB		20MG	A040362 003	Jun 29, 2005	Jan	CAHN

PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCOMP

AB	JUBILANT CADISTA	EQ 5MG BASE	A040268 001	Feb 27, 1998	Jan	CAHN
AB		EQ 10MG BASE	A040268 002	Feb 27, 1998	Jan	CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

AP	X-GEN PHARMS	25MG/ML	A040737 001	Apr 24, 2008	May	CAHN
AP		50MG/ML	A040737 002	Apr 24, 2008	May	CAHN

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

+ ROXANE 15MG

A080927 002 Jan CMFD

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON

@ XANODYNE PHARM 65MG

N010997 003 Jan DISC

PROPOXYPHENE HYDROCHLORIDE

@ TEVA 65MG

A088615 001 Oct 22, 1984 Mar DISC

@ VINTAGE PHARMS 65MG

A040908 001 Jul 17, 2009 Mar DISC

@ WEST WARD 65MG

A083501 001 Jan DISC

PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVON-N

@ XANODYNE PHARM 100MG

N016862 002 Jan DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	60MG	A090321 001	Mar 25, 2011	Mar	NEWA
AB		80MG	A090321 002	Mar 25, 2011	Mar	NEWA

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	120MG	A090321 003	Mar 25, 2011	Mar	NEWA
AB		160MG	A090321 004	Mar 25, 2011	Mar	NEWA

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

AB	MYLAN	60MG	A070213 005	Apr 08, 2011	Mar	NEWA
----	-------	------	-------------	--------------	-----	------

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

>A>	+	COREPHARMA	25MG	N008578 001		Jun	CAHN
>D>	+	GLAXOSMITHKLINE LLC	25MG	N008578 001		Jun	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

AB	MYLAN	EQ 5MG BASE	A076036 001	Jan 28, 2005	Feb	CAHN
AB		EQ 10MG BASE	A076036 002	Jan 28, 2005	Feb	CAHN
AB		EQ 20MG BASE	A076036 003	Jan 28, 2005	Feb	CAHN
AB		EQ 40MG BASE	A076036 004	Jan 28, 2005	Feb	CAHN

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

AB	AUROBINDO PHARMA LTD	1.25MG	A091604 001	Jun 08, 2011	May	NEWA
AB		2.5MG	A091604 002	Jun 08, 2011	May	NEWA
AB		5MG	A091604 003	Jun 08, 2011	May	NEWA
AB		10MG	A091604 004	Jun 08, 2011	May	NEWA

TABLET; ORAL

RAMIPRIL

>A>	AB	MATRIX LABS LTD	1.25MG	A090650 001	Jun 30, 2011	Jun	NEWA
>A>	AB		2.5MG	A090650 002	Jun 30, 2011	Jun	NEWA
>A>	AB		5MG	A090650 003	Jun 30, 2011	Jun	NEWA
>A>	AB		10MG	A090650 004	Jun 30, 2011	Jun	NEWA

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

@	MYLAN	EQ 150MG BASE	A075564 001	Oct 27, 2000	Feb	CAHN
@		EQ 300MG BASE	A075564 002	Oct 27, 2000	Feb	CAHN

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

AA	HI TECH PHARMA	EQ 15MG BASE/ML	A091078 001	Mar 22, 2011	Mar	NEWA
AA	TARO	EQ 15MG BASE/ML	A077476 001	Jun 13, 2011	May	NEWA

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

AB	MYLAN	EQ 150MG BASE	A074023 001	Aug 22, 1997	Feb	CAHN
AB		EQ 300MG BASE	A074023 002	Aug 22, 1997	Feb	CAHN

RIFAMPIN

INJECTABLE; INJECTION

RIFAMPIN

AP	PFIZER	600MG/VIAL	A065421 001	May 22, 2008	May	CAHN
----	--------	------------	-------------	--------------	-----	------

RIFAXIMIN

TABLET; ORAL

XIFAXAN

+ SALIX PHARMS 550MG N022554 001 Mar 24, 2010 Feb CRLD

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

+ TIBOTEC EQ 25MG BASE N202022 001 May 20, 2011 May NEWA

RISPERIDONE

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

>A>		JANSSEN PHARMS	12.5MG/VIAL	N021346 004	Apr 12, 2007	Jun	CAHN
>A>	+		25MG/VIAL	N021346 001	Oct 29, 2003	Jun	CAHN
>A>			37.5MG/VIAL	N021346 002	Oct 29, 2003	Jun	CAHN
>A>			50MG/VIAL	N021346 003	Oct 29, 2003	Jun	CAHN
>D>		ORTHO MCNEIL JANSSEN	12.5MG/VIAL	N021346 004	Apr 12, 2007	Jun	CAHN
>D>	+		25MG/VIAL	N021346 001	Oct 29, 2003	Jun	CAHN
>D>			37.5MG/VIAL	N021346 002	Oct 29, 2003	Jun	CAHN
>D>			50MG/VIAL	N021346 003	Oct 29, 2003	Jun	CAHN

SOLUTION; ORAL

RISPERDAL

>A>	AA	+	JANSSEN PHARMS	1MG/ML	N020588 001	Jun 10, 1996	Jun	CAHN
>D>	AA	+	ORTHO MCNEIL JANSSEN	1MG/ML	N020588 001	Jun 10, 1996	Jun	CAHN

RISPERIDONE

	AA		AMNEAL PHARMS	1MG/ML	A091384 001	May 25, 2011	May	NEWA
	AA		TARO	1MG/ML	A090347 001	Feb 07, 2011	Jan	NEWA

TABLET; ORAL

RISPERDAL

>A>	AB		JANSSEN PHARMS	0.25MG	N020272 008	May 10, 1999	Jun	CAHN
>A>	AB			0.5MG	N020272 007	Jan 27, 1999	Jun	CAHN
>A>	AB	+		1MG	N020272 001	Dec 29, 1993	Jun	CAHN
>A>	AB			2MG	N020272 002	Dec 29, 1993	Jun	CAHN
>A>	AB			3MG	N020272 003	Dec 29, 1993	Jun	CAHN
>A>	AB			4MG	N020272 004	Dec 29, 1993	Jun	CAHN
>A>		@		5MG	N020272 005	Dec 29, 1993	Jun	CAHN
>D>	AB		ORTHO MCNEIL JANSSEN	0.25MG	N020272 008	May 10, 1999	Jun	CAHN
>D>	AB			0.5MG	N020272 007	Jan 27, 1999	Jun	CAHN
>D>	AB	+		1MG	N020272 001	Dec 29, 1993	Jun	CAHN
>D>	AB			2MG	N020272 002	Dec 29, 1993	Jun	CAHN
>D>	AB			3MG	N020272 003	Dec 29, 1993	Jun	CAHN
>D>	AB			4MG	N020272 004	Dec 29, 1993	Jun	CAHN
>D>		@		5MG	N020272 005	Dec 29, 1993	Jun	CAHN

RISPERIDONE

	AB		CIPLA	0.25MG	A077543 001	May 18, 2011	May	NEWA
	AB			0.5MG	A077543 002	May 18, 2011	May	NEWA
	AB			1MG	A077543 003	May 18, 2011	May	NEWA
	AB			2MG	A077543 004	May 18, 2011	May	NEWA
	AB			3MG	A077543 005	May 18, 2011	May	NEWA
	AB			4MG	A077543 006	May 18, 2011	May	NEWA
		@	RATIOPHARM	0.25MG	A077784 001	Jun 08, 2010	Feb	DISC
		@		0.5MG	A077784 002	Jun 08, 2010	Feb	DISC
		@		1MG	A077784 003	Jun 08, 2010	Feb	DISC
		@		2MG	A077784 004	Jun 08, 2010	Feb	DISC

TABLET; ORAL

RISPERIDONE

@ RATIOPHARM

3MG

A077784 005 Jun 08, 2010 Feb DISC

@

4MG

A077784 006 Jun 08, 2010 Feb DISC

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

AB MYLAN

0.5MG

A091537 001 Mar 30, 2011 Mar NEWA

AB

1MG

A091537 002 Mar 30, 2011 Mar NEWA

AB

2MG

A091537 003 Mar 30, 2011 Mar NEWA

AB

3MG

A091537 004 Mar 30, 2011 Mar NEWA

AB

4MG

A091537 005 Mar 30, 2011 Mar NEWA

AB WATSON LABS FLORIDA

0.5MG

A076996 001 Apr 19, 2011 Apr NEWA

AB

1MG

A076996 002 Apr 19, 2011 Apr NEWA

AB

2MG

A076996 003 Apr 19, 2011 Apr NEWA

AB

3MG

A076996 004 Apr 19, 2011 Apr NEWA

AB

4MG

A076996 005 Apr 19, 2011 Apr NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP SAGENT STRIDES

50MG/5ML (10MG/ML)

A091458 001 Jul 28, 2010 Jan CAHN

AP

100MG/10ML (10MG/ML)

A091458 002 Jul 28, 2010 Jan CAHN

ROFLUMILAST

TABLET; ORAL

DALIRESP

+ FOREST RES INST INC

500MCG

N022522 001 Feb 28, 2011 Feb NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB PRINSTON PHARM LLC

EQ 0.25MG BASE

A078110 001 May 05, 2008 May CAHN

AB

EQ 0.5MG BASE

A078110 002 May 05, 2008 May CAHN

AB

EQ 1MG BASE

A078110 003 May 05, 2008 May CAHN

AB

EQ 2MG BASE

A078110 004 May 05, 2008 May CAHN

AB

EQ 3MG BASE

A078110 005 May 05, 2008 May CAHN

AB

EQ 4MG BASE

A078110 006 May 05, 2008 May CAHN

RUFINAMIDE

SUSPENSION; ORAL

BANZEL

+ EISAI INC

40MG/ML

N201367 001 Mar 03, 2011 Mar NEWA

SECOBARBITAL SODIUM

CAPSULE; ORAL

SECONAL SODIUM

+ MARATHON PHARMS

50MG

A086101 001 Oct 03, 1983 Jan CAHN

+

100MG

A086101 002 Oct 03, 1983 Jan CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

@ ROXANE

EQ 20MG BASE/ML

A076934 001 Jun 30, 2006 Mar DISC

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

@ IVAX SUB TEVA PHARMS

EQ 25MG BASE

A075719 003 Jun 30, 2006 Apr DISC

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

	@	IVAX SUB TEVA PHARMS	EQ 50MG BASE	A075719 001	Jun 30, 2006	Apr	DISC
	@		EQ 100MG BASE	A075719 002	Jun 30, 2006	Apr	DISC
AB		MYLAN	EQ 25MG BASE	A076540 001	Mar 20, 2007	Feb	CAHN
AB			EQ 50MG BASE	A076540 002	Mar 20, 2007	Feb	CAHN
AB			EQ 100MG BASE	A076540 003	Mar 20, 2007	Feb	CAHN
	@	ROXANE	EQ 25MG BASE	A076881 001	Feb 06, 2007	Mar	DISC
	@		EQ 50MG BASE	A076881 002	Feb 06, 2007	Mar	DISC
	@		EQ 100MG BASE	A076881 003	Feb 06, 2007	Mar	DISC

SINECATECHINS

OINTMENT; TOPICAL

VEREGEN

	+	MEDIGENE AG	15%	N021902 001	Oct 31, 2006	May	CAHN
--	---	-------------	-----	-------------	--------------	-----	------

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

FERRLECIT

AB	+	SANOFI AVENTIS US	62.5MG/5ML	N020955 001	Feb 18, 1999	Mar	CFTG
		SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE					
AB		GENERAMEDIX	62.5MG/5ML	A078215 001	Mar 31, 2011	Mar	NEWA

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F 18

	@	NIH NCI DCTD	10-200mCi/ML	N022494 001	Jan 26, 2011	Apr	DISC
	+		10-200mCi/ML	N022494 001	Jan 26, 2011	Jan	NEWA

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS

NITHIODOTE

	+	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML)	N201444 001	Jan 14, 2011	Feb	CTNA
		SODIUM NITRITE					
	+	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML)	N201444 001	Jan 14, 2011	Jan	NEWA

SODIUM POLYSTYRENE SULFONATE

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA		PADDOCK LABS	15GM/60ML	A090590 001	May 13, 2011	May	NEWA
----	--	--------------	-----------	-------------	--------------	-----	------

>D> SPECTINOMYCIN HYDROCHLORIDE

>D> INJECTABLE; INJECTION

>D> TROBICIN

>A>	@	PFIZER	EQ 2GM BASE/VIAL	N050347 001		Jun	DISC
>A>	@		EQ 4GM BASE/VIAL	N050347 002		Jun	CAHN
>D>	+	PHARMACIA AND UPJOHN	EQ 2GM BASE/VIAL	N050347 001		Jun	DISC
>D>	@		EQ 4GM BASE/VIAL	N050347 002		Jun	CAHN

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

	+	PARAPRO PHARMS	0.9%	N022408 001	Jan 18, 2011	Jan	NEWA
--	---	----------------	------	-------------	--------------	-----	------

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX STATDOSE

>D>	+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080 003	Dec 23, 1996	Jun	CFTG
>A>	AB	+	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080 003	Dec 23, 1996	Jun	CFTG
>A>		SUMATRIPTAN SUCCINATE					
>A>	AB	SUN PHARM INDS INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358 001	Jun 21, 2011	Jun	NEWA

TABLET; ORAL

SUMATRIPTAN SUCCINATE

@ ROXANE

EQ 25MG BASE

A078241 001 Aug 10, 2009 Mar DISC

@

EQ 50MG BASE

A078241 002 Aug 10, 2009 Mar DISC

@

EQ 100MG BASE

A078241 003 Aug 10, 2009 Mar DISC

>D> TACRINE HYDROCHLORIDE

>D> CAPSULE; ORAL

>D> COGNEX

>A>	@	SHIONOGI INC	EQ 10MG BASE	N020070 001	Sep 09, 1993	Jun	DISC
>A>	@		EQ 20MG BASE	N020070 002	Sep 09, 1993	Jun	DISC
>A>	@		EQ 30MG BASE	N020070 003	Sep 09, 1993	Jun	DISC
>A>	@		EQ 40MG BASE	N020070 004	Sep 09, 1993	Jun	DISC
>D>		SHIONOGI PHARMA	EQ 10MG BASE	N020070 001	Sep 09, 1993	Jun	DISC
>D>			EQ 20MG BASE	N020070 002	Sep 09, 1993	Jun	DISC
>D>			EQ 30MG BASE	N020070 003	Sep 09, 1993	Jun	DISC
>D>	+		EQ 40MG BASE	N020070 004	Sep 09, 1993	Jun	DISC

TELAPREVIR

TABLET; ORAL

INCIVEK

+	VERTEX PHARMS	375MG		N201917 001	May 23, 2011	May	NEWA
---	---------------	-------	--	-------------	--------------	-----	------

TELBIVUDINE

>D> SOLUTION; ORAL

>D> TYZEKA

>D>	+	NOVARTIS	100MG/5ML	N022154 001	Apr 28, 2009	Jun	DISC
>A>	@		100MG/5ML	N022154 001	Apr 28, 2009	Jun	DISC

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

AB	JUBILANT CADISTA	EQ 1MG BASE		A075317 001	Dec 20, 2004	Jan	CAHN
AB		EQ 2MG BASE		A075317 002	Dec 20, 2004	Jan	CAHN
AB		EQ 5MG BASE		A075317 003	Dec 20, 2004	Jan	CAHN
AB		EQ 10MG BASE		A075317 004	Dec 20, 2004	Jan	CAHN

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

AB	MYLAN	EQ 250MG BASE		A077136 001	Jul 02, 2007	Feb	CAHN
	@ ROXANE	EQ 250MG BASE		A077223 001	Jul 02, 2007	Feb	DISC

TERBUTALINE SULFATE

TABLET; ORAL

TERBUTALINE SULFATE

AB	+	IMPAX LABS	5MG	A075877	002	Jun 26, 2001	Jan	CRLD
----	---	------------	-----	---------	-----	--------------	-----	------

TESTOSTERONE

GEL, METERED; TRANSDERMAL

ANDROGEL

+	ABBOTT PRODS	1.62% (20.25MG/1.25GM ACTIVATION)	N022309	001	Apr 29, 2011	Apr	NEWA
---	--------------	-----------------------------------	---------	-----	--------------	-----	------

FORTESTA

+	ENDO PHARMS	10MG/0.5GM ACTIVATION	N021463	001	Dec 29, 2010	Mar	CPOT
---	-------------	-----------------------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; BUCCAL

STRIANT

>A>	+	ACTIENT PHARMS	30MG	N021543	001	Jun 19, 2003	Jun	CAHN
-----	---	----------------	------	---------	-----	--------------	-----	------

>D>	+	COLUMBIA LABS	30MG	N021543	001	Jun 19, 2003	Jun	CAHN
-----	---	---------------	------	---------	-----	--------------	-----	------

TETRABENAZINE

TABLET; ORAL

XENAZINE

>D>		BIOVAIL AMERICAS	12.5MG	N021894	001	Aug 15, 2008	Jun	CAHN
-----	--	------------------	--------	---------	-----	--------------	-----	------

>D>	+		25MG	N021894	002	Aug 15, 2008	Jun	CAHN
-----	---	--	------	---------	-----	--------------	-----	------

>A>		VALEANT INTL	12.5MG	N021894	001	Aug 15, 2008	Jun	CAHN
-----	--	--------------	--------	---------	-----	--------------	-----	------

>A>	+		25MG	N021894	002	Aug 15, 2008	Jun	CAHN
-----	---	--	------	---------	-----	--------------	-----	------

TETRACYCLINE HYDROCHLORIDE

FIBER, EXTENDED RELEASE; PERIODONTAL

ACTISITE

>D>		@ ON SITE	12.7MG/FIBER	N050653	001	Mar 25, 1994	Jun	CAHN
-----	--	-----------	--------------	---------	-----	--------------	-----	------

>A>		@ SCHIFF AND CO	12.7MG/FIBER	N050653	001	Mar 25, 1994	Jun	CAHN
-----	--	-----------------	--------------	---------	-----	--------------	-----	------

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

>A>	BC	ACTIENT PHARMS	100MG	A087942	001	Aug 22, 1983	Jun	CAHN
-----	----	----------------	-------	---------	-----	--------------	-----	------

>A>	BC		200MG	A087943	001	Aug 22, 1983	Jun	CAHN
-----	----	--	-------	---------	-----	--------------	-----	------

>A>	BC		300MG	A087944	001	Aug 22, 1983	Jun	CAHN
-----	----	--	-------	---------	-----	--------------	-----	------

>A>			400MG	A081034	001	Feb 28, 1992	Jun	CAHN
-----	--	--	-------	---------	-----	--------------	-----	------

>D>	BC	UCB INC	100MG	A087942	001	Aug 22, 1983	Jun	CAHN
-----	----	---------	-------	---------	-----	--------------	-----	------

>D>	BC		200MG	A087943	001	Aug 22, 1983	Jun	CAHN
-----	----	--	-------	---------	-----	--------------	-----	------

>D>	BC		300MG	A087944	001	Aug 22, 1983	Jun	CAHN
-----	----	--	-------	---------	-----	--------------	-----	------

>D>			400MG	A081034	001	Feb 28, 1992	Jun	CAHN
-----	--	--	-------	---------	-----	--------------	-----	------

SOLUTION; ORAL

THEOPHYLLINE

+	SILARX	80MG/15ML	A091156	001	Apr 13, 2011	Mar	NEWA
---	--------	-----------	---------	-----	--------------	-----	------

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

@	HOSPIRA	100MG/ML	A040079	001	May 03, 1996	May	DISC
---	---------	----------	---------	-----	--------------	-----	------

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

AB		MYLAN	250MG	A075161	001	Sep 13, 1999	Feb	CAHN
----	--	-------	-------	---------	-----	--------------	-----	------

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

>A>	AT	APOTEX INC	EQ 0.25% BASE	A075411 001	Sep 08, 2000	Jun	CAHN
>D>	AT	NOVEX	EQ 0.25% BASE	A075411 001	Sep 08, 2000	Jun	CAHN

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

AT		FERA PHARMS	0.3%	A065026 001	Sep 11, 2001	Mar	CAHN
----	--	-------------	------	-------------	--------------	-----	------

TOLCAPONE

TABLET; ORAL

TASMAR

>D>		VALEANT PHARM INTL	100MG	N020697 001	Jan 29, 1998	Jun	CRLD
>A>	+		100MG	N020697 001	Jan 29, 1998	Jun	CRLD
>D>	+		200MG	N020697 002	Jan 29, 1998	Jun	DISC
>A>	@		200MG	N020697 002	Jan 29, 1998	Jun	DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

AP		DR REDDYS LABS LTD	EQ 4MG BASE/VIAL	A201191 001	Mar 09, 2011	Feb	NEWA
AP		SAGENT PHARMS	EQ 4MG BASE/VIAL	A091284 001	Jan 26, 2011	Jan	NEWA

SOLUTION; INTRAVENOUS

TOPOTECAN

AP		HOSPIRA INC	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200582 001	Feb 02, 2011	Feb	NEWA
		SANDOZ	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N200199 001	Feb 25, 2011	Feb	NEWA
			EQ 3MG BASE/3ML (EQ 1MG BASE/ML)	N200199 002	Feb 25, 2011	Feb	NEWA
AP	+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200199 003	Feb 25, 2011	Feb	NEWA

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB		VINTAGE PHARMS	5MG	A090613 001	Mar 22, 2011	Mar	NEWA
AB			10MG	A090613 002	Mar 22, 2011	Mar	NEWA
AB			20MG	A090613 003	Mar 22, 2011	Mar	NEWA
AB			100MG	A090613 004	Mar 22, 2011	Mar	NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB		ZYDUS PHARMS USA INC	50MG	A090404 001	Jan 31, 2011	Jan	NEWA
----	--	----------------------	------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

ULTRAM ER

>D>	AB	+	BIOVAIL LABS INTL	100MG	N021692 001	Sep 08, 2005	Jun	CAHN
>D>	AB			200MG	N021692 002	Sep 08, 2005	Jun	CAHN
>D>	BC			300MG	N021692 003	Sep 08, 2005	Jun	CAHN
>A>	AB	+	VALEANT INTL	100MG	N021692 001	Sep 08, 2005	Jun	CAHN
>A>	AB			200MG	N021692 002	Sep 08, 2005	Jun	CAHN
>A>	BC			300MG	N021692 003	Sep 08, 2005	Jun	CAHN

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN

@	ALCON	0.004%	N021257	001	Mar 16, 2001	May	DISC
---	-------	--------	---------	-----	--------------	-----	------

TRAZODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OLEPTRO

>A>	+	ANGELINI LABOPHARM	150MG	N022411	001	Feb 02, 2010	Jun	CAHN
			300MG	N022411	002	Feb 02, 2010	May	CAHN
>D>	+	LABOPHARM	150MG	N022411	001	Feb 02, 2010	Jun	CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

AP	LUITPOLD	100MG/ML	A091330	001	Mar 08, 2011	May	CAHN	
AP	PHARMAFORCE	100MG/ML	A091330	001	Mar 08, 2011	Feb	NEWA	
TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE								
AP	LUITPOLD	100MG/ML	A091329	001	Mar 08, 2011	May	CAHN	
AP	PHARMAFORCE	100MG/ML	A091329	001	Mar 08, 2011	Feb	NEWA	

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

AB	NOVEL LABS INC	100MG	A091437	001	Jun 15, 2011	May	NEWA
----	----------------	-------	---------	-----	--------------	-----	------

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

AB	MIKAH PHARMA	EQ 25MG BASE	A077361	001	Aug 02, 2006	Feb	CAHN
AB		EQ 50MG BASE	A077361	002	Aug 02, 2006	Feb	CAHN
AB		EQ 100MG BASE	A077361	003	Aug 02, 2006	Feb	CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	ACTAVIS PHARMA	EQ 500MG BASE	A090370	001	Mar 16, 2011	Feb	NEWA
AB		EQ 1GM BASE	A090370	002	Mar 16, 2011	Feb	NEWA

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	PFIZER	EQ 500MG BASE/VIAL	A065397	001	Dec 30, 2008	May	CAHN
AP		EQ 1GM BASE/VIAL	A065397	002	Dec 30, 2008	May	CAHN
AP		EQ 5GM BASE/VIAL	A065432	001	Dec 30, 2008	May	CAHN
>A>	AP	EQ 10GM BASE/VIAL	A091469	001	Jul 01, 2011	Jun	NEWA

VANDETANIB

TABLET; ORAL

VANDETANIB

	IPR PHARMS INC	100MG	N022405	001	Apr 06, 2011	Apr	NEWA
+		300MG	N022405	002	Apr 06, 2011	Apr	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP	PFIZER	10MG/VIAL	A090243 001	May 11, 2010	May	CAHN
AP		20MG/VIAL	A090243 002	May 11, 2010	May	CAHN

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 37.5MG BASE	A200834 001	Apr 14, 2011	Apr	NEWA
AB		EQ 75MG BASE	A200834 002	Apr 14, 2011	Apr	NEWA
AB		EQ 150MG BASE	A200834 003	Apr 14, 2011	Apr	NEWA
AB	DR REDDYS LABS LTD	EQ 37.5MG BASE	A078421 001	May 06, 2011	Apr	NEWA
AB		EQ 75MG BASE	A078421 002	May 06, 2011	Apr	NEWA
AB		EQ 150MG BASE	A078421 003	May 06, 2011	Apr	NEWA
AB	MYLAN	EQ 37.5MG BASE	A078789 001	Jun 01, 2011	May	NEWA
AB		EQ 75MG BASE	A078789 002	Jun 01, 2011	May	NEWA
AB		EQ 150MG BASE	A078789 003	Jun 01, 2011	May	NEWA
>A>	ORCHID HLTHCARE	EQ 37.5MG BASE	A091123 001	Jul 11, 2011	Jun	NEWA
>A>		EQ 75MG BASE	A091123 002	Jul 11, 2011	Jun	NEWA
>A>		EQ 150MG BASE	A091123 003	Jul 11, 2011	Jun	NEWA
AB	TORRENT PHARMS LLC	EQ 37.5MG BASE	A090899 001	Jun 01, 2011	May	NEWA
AB		EQ 75MG BASE	A090899 002	Jun 01, 2011	May	NEWA
AB		EQ 150MG BASE	A090899 003	Jun 01, 2011	May	NEWA
AB	VALEANT INTL	EQ 37.5MG BASE	A090071 001	Apr 15, 2011	Apr	NEWA
AB		EQ 75MG BASE	A090071 002	Apr 15, 2011	Apr	NEWA
AB		EQ 150MG BASE	A090071 003	Apr 15, 2011	Apr	NEWA
AB	WOCKHARDT	EQ 37.5MG BASE	A078865 001	Apr 14, 2011	Apr	NEWA
AB		EQ 75MG BASE	A078865 002	Apr 14, 2011	Apr	NEWA
AB		EQ 150MG BASE	A078865 003	Apr 14, 2011	Apr	NEWA
AB	ZYDUS PHARMS USA INC	EQ 37.5MG BASE	A090174 001	Apr 14, 2011	Apr	NEWA
AB		EQ 75MG BASE	A090174 002	Apr 14, 2011	Apr	NEWA
AB		EQ 150MG BASE	A090174 003	Apr 14, 2011	Apr	NEWA

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VILIBRYD

	FOREST LABS INC	10MG	N022567 001	Jan 21, 2011	May	CAHN
		20MG	N022567 002	Jan 21, 2011	May	CAHN
+		40MG	N022567 003	Jan 21, 2011	May	CAHN
	TROVIS PHARMS	10MG	N022567 001	Jan 21, 2011	Jan	NEWA
		20MG	N022567 002	Jan 21, 2011	Jan	NEWA
+		40MG	N022567 003	Jan 21, 2011	Jan	NEWA

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCRISTINE SULFATE

	@ APP PHARMS	1MG/ML	A076401 001	Oct 28, 2003	Jan	DISC
--	--------------	--------	-------------	--------------	-----	------

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

AB	INVAGEN PHARMS	1MG	A090935 001	May 25, 2011	May	NEWA
AB		2MG	A090935 002	May 25, 2011	May	NEWA
AB		2.5MG	A090935 003	May 25, 2011	May	NEWA

TABLET; ORAL

WARFARIN SODIUM

AB	INVAGEN PHARMS	3MG	A090935 004	May 25, 2011	May	NEWA
AB		4MG	A090935 005	May 25, 2011	May	NEWA
AB		5MG	A090935 006	May 25, 2011	May	NEWA
AB		6MG	A090935 007	May 25, 2011	May	NEWA
AB		7.5MG	A090935 008	May 25, 2011	May	NEWA
AB		10MG	A090935 009	May 25, 2011	May	NEWA

ZIDOVUDINE

INJECTABLE; INJECTION

ZIDOVUDINE

AP	LUITPOLD	10MG/ML	A091457 001	May 06, 2010	Feb	CAHN
----	----------	---------	-------------	--------------	-----	------

TABLET; ORAL

ZIDOVUDINE

@ MATRIX LABS LTD

100MG

N200732 001	Feb 23, 2011	Feb	NEWA
-------------	--------------	-----	------

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOMETA

>A>

+ NOVARTIS

EQ 4MG BASE/100ML

N021223 003	Jun 17, 2011	Jun	NEWA
-------------	--------------	-----	------

>A>

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

AB	MYLAN	5MG	A078016 001	Apr 23, 2007	Feb	CAHN
AB		10MG	A078016 002	Apr 23, 2007	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

ZOLPIDEM TARTRATE

AB	ANCHEN PHARMS	6.25MG	A078148 002	Apr 14, 2011	Apr	NEWA
>A>	AB	SANDOZ	A090107 001	Jul 01, 2011	Jun	NEWA
>A>	AB		A090107 002	Jul 01, 2011	Jun	NEWA
AB	SYNTHON PHARMS	6.25MG	A078483 001	Apr 12, 2011	Apr	NEWA

OTC DRUG PRODUCT LIST - 31ST EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

2-1

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

SILARX	5MG/5ML	A091130	001	Apr 22, 2011	Apr	NEWA
TARO	5MG/5ML	A201546	001	May 20, 2011	May	NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SILARX	5MG/5ML	A091130	002	Apr 22, 2011	Apr	NEWA
TARO	5MG/5ML	A201546	002	May 20, 2011	May	NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+ CARDINAL HLTH	2%;70% (0.67ML)	N021555	001	Oct 07, 2002	Apr	CAHN
-----------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP SINGLE SWABSTICK

+ CARDINAL HLTH	2%;70% (1.75ML)	N021555	002	May 10, 2005	Apr	CAHN
-----------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP TRIPLE SWABSTICK

+ CARDINAL HLTH	2%;70% (5.25ML)	N021555	003	Jun 10, 2009	Apr	NEWA
-----------------	-----------------	---------	-----	--------------	-----	------

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

MYLAN	10MG	A075674	001	Dec 21, 2001	Feb	CAHN
-------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US	30MG/5ML	N201373	001	Jan 24, 2011	Jan	NEWA
---------------------	----------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US	30MG/5ML	N201373	002	Jan 24, 2011	Jan	NEWA
---------------------	----------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US	30MG	N021909	002	Jan 24, 2011	Jan	NEWA
---------------------	------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US	30MG	N021909	003	Jan 24, 2011	Jan	NEWA
---------------------	------	---------	-----	--------------	-----	------

TABLET; ORAL

ALLEGRA ALLERGY

SANOFI AVENTIS US	60MG	N020872	007	Jan 24, 2011	Jan	NEWA
-------------------	------	---------	-----	--------------	-----	------

+	180MG	N020872	010	Jan 24, 2011	Jan	NEWA
---	-------	---------	-----	--------------	-----	------

ALLEGRA HIVES

SANOFI AVENTIS US	60MG	N020872	008	Jan 24, 2011	Jan	NEWA
-------------------	------	---------	-----	--------------	-----	------

+	180MG	N020872	009	Jan 24, 2011	Jan	NEWA
---	-------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA ALLERGY

SANOFI AVENTIS US	30MG	N020872	005	Jan 24, 2011	Jan	NEWA
-------------------	------	---------	-----	--------------	-----	------

CHILDREN'S ALLEGRA HIVES

SANOFI AVENTIS US	30MG	N020872	006	Jan 24, 2011	Jan	NEWA
-------------------	------	---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	30MG	A076502	004	Apr 12, 2011	Mar	NEWA
--------------------	------	---------	-----	--------------	-----	------

TEVA	30MG	A076447	004	Apr 13, 2011	Mar	NEWA
------	------	---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011	Mar	NEWA
--------------------	------	---------	-----	--------------	-----	------

TEVA	30MG	A076447	005	Apr 13, 2011	Mar	NEWA
------	------	---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011	Mar	NEWA
--------------------	------	---------	-----	--------------	-----	------

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	180MG	A076502 008	Apr 12, 2011	Mar	NEWA
TEVA	60MG	A076447 006	Apr 13, 2011	Mar	NEWA
	180MG	A076447 008	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	60MG	A076502 007	Apr 12, 2011	Mar	NEWA
	180MG	A076502 009	Apr 12, 2011	Mar	NEWA
TEVA	60MG	A076447 007	Apr 13, 2011	Mar	NEWA
	180MG	A076447 009	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US	60MG;120MG	N020786 002	Jan 24, 2011	Jan	NEWA
---------------------	------------	-------------	--------------	-----	------

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US	180MG;240MG	N021704 002	Jan 24, 2011	Jan	NEWA
---------------------	-------------	-------------	--------------	-----	------

>A> FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A> DR REDDYS LABS LTD	180MG;240MG	A079043 002	Jun 22, 2011	Jun	NEWA
------------------------	-------------	-------------	--------------	-----	------

IBUPROFEN

TABLET; ORAL

IBUPROFEN

AVEMA PHARMA	200MG	A076460 001	Nov 26, 2003	May	CAHN
MARKSANS PHARMA	200MG	A091237 001	Feb 08, 2011	Jan	NEWA
	200MG	A091239 001	Feb 01, 2011	Jan	NEWA
MERRO PHARM	200MG	A070985 001	Oct 02, 1987	Jan	CAHN
SVADS HOLDINGS SA	200MG	A079129 001	Mar 28, 2011	Mar	NEWA
	200MG	A091355 001	Apr 04, 2011	Mar	NEWA

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION

NOVOLIN N

+ NOVO NORDISK INC	100 UNITS/ML	N019959 001	Jul 01, 1991	Jan	CRLD
--------------------	--------------	-------------	--------------	-----	------

LEVONORGESTREL

TABLET; ORAL

PLAN B

+ TEVA WOMENS	0.75MG	N021045 002	Aug 24, 2006	Feb	CAHN
---------------	--------	-------------	--------------	-----	------

LOPERAMIDE HYDROCHLORIDE

SUSPENSION; ORAL

LOPERAMIDE HYDROCHLORIDE

PERRIGO R AND D	1MG/7.5ML	A091292 001	May 20, 2011	May	NEWA
-----------------	-----------	-------------	--------------	-----	------

MINOXIDIL

AEROSOL, FOAM; TOPICAL

MINOXIDIL

PERRIGO ISRAEL	5%	A091344 001	Apr 28, 2011	Apr	NEWA
----------------	----	-------------	--------------	-----	------

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

MARKSANS PHARMA	EQ 200MG BASE	A090545 001	Mar 16, 2011	Feb	NEWA
RANBAXY LABS LTD	EQ 200MG BASE	A091183 001	May 20, 2011	May	NEWA

POTASSIUM IODIDE

TABLET; ORAL

IOSAT

ANBEX

65MG

N018664 002 May 12, 2011 Apr NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

MYLAN

EQ 75MG BASE

A075497 001 Jan 14, 2000 Feb CAHN

PERRIGO R AND D

EQ 150MG BASE

A091429 001 May 11, 2011 Apr NEWA

EQ 150MG BASE

A091429 002 May 11, 2011 Apr NEWA

>A>

SVADS HOLDINGS SA

EQ 150MG BASE

A200536 001 Jun 28, 2011 Jun NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 6 JUNE 2011

NO JUNE 2011 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2011 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N202379 001	5604213	Feb 18, 2014	DS DP U-1126		NCE	Apr 28, 2016
<u>ADAPALENE - DIFFERIN</u>						
N021753 001	7868044	Mar 12, 2023	U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	>A> 7964202	Sep 01, 2024	DP U-1078			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 001					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 002					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 003					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N022545 004					NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 001	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 002	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 003	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 004	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N200045 005	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	5250542	Mar 29, 2016	DS DP U-878			
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE</u>						
A078381 005					PC	Jul 02, 2011
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE</u>						
A078381 006					PC	Jul 02, 2011
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10</u>						
N021303 001	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15</u>						
N021303 006	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20</u>						
N021303 002	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25</u>						
N021303 004	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30</u>						
N021303 003	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5</u>						
N021303 005	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021436 001					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021436 002					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021436 003					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021436 004					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021436 005					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021436 006					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021713 001					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021729 002					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021729 003					I-633	Feb 16, 2014
<u>ARIPIPRAZOLE - ABILIFY</u>						
N021866 001					I-633	Feb 16, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 001					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 002					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 003					D-130	Feb 04, 2014
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N021567 004					D-130	Feb 04, 2014
<u>AZILSARTAN MEDOXOMIL - EDARBI</u>						
N200796 001	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AZILSARTAN MEDOXOMIL - EDARBI</u>						
N200796 002	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZITHROMYCIN - ZMAX</u>						
N050797 001	7887844	Feb 14, 2024	DP			
<u>BOCEPREVIR - VICTRELIS</u>						
N202258 001	7012066	Feb 22, 2022	DS DP U-1128		NCE	May 13, 2016
	7772178	Nov 11, 2027	DP U-1128			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	7897646	Sep 09, 2018	U-1118			
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 001	5326570	Jul 23, 2011	U-215			
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 002	5326570	Jul 23, 2011	U-215			
<u>CARBAMAZEPINE - CARBATROL</u>						
N020712 003	5326570	Jul 23, 2011	U-215			
<u>CELECOXIB - CELEBREX</u>						
N020998 001	5760068	Jun 02, 2015	U-672			
<u>CELECOXIB - CELEBREX</u>						
N020998 002	5760068	Jun 02, 2015	U-672			
<u>CELECOXIB - CELEBREX</u>						
N020998 003	5760068	Jun 02, 2015	U-672			
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N021669 001	7935093	Oct 02, 2027	DP U-1022			
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS</u>						
N021441 001	7863287	Feb 28, 2027	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 001	>A> 6011068	Mar 08, 2018	DS DP		I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 002	>A> 6011068	Mar 08, 2018	DS DP		I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N021688 003	>A> 6011068	Mar 08, 2018	DS DP		I-634 M-101 ODE	Feb 25, 2014 Feb 25, 2014 Feb 25, 2018

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N020839 001	4847265	Nov 17, 2011	DS DP		M-61	May 06, 2014
	4847265*PED	May 17, 2012			PED	Nov 06, 2014
	5576328	Jan 31, 2014	U-432	Y		
	5576328*PED	Jul 31, 2014				
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
<u>CLOPIDOGREL BISULFATE - PLAVIX</u>						
N020839 002	4847265	Nov 17, 2011	DS DP		M-61	May 06, 2014
	4847265*PED	May 17, 2012			PED	Nov 06, 2014
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
<u>COLCHICINE - COLCRYS</u>						
N022352 001	7906519	Feb 17, 2029	U-1116			
	7915269	Feb 17, 2029	U-1007			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N021642 001	7879349	Jun 01, 2024	DP U-1152			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		I-578	Oct 21, 2011
	5843946*PED	Jun 01, 2016			NCE	Jun 23, 2011
	6037157	Jun 26, 2016	U-935		PED	Jun 13, 2014
	6037157*PED	Dec 26, 2016			PED	Jun 18, 2012
	6248775	Aug 13, 2014	DS		PED	Apr 21, 2012
	6248775*PED	Feb 13, 2015			PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		I-578	Oct 21, 2011
	5843946*PED	Jun 01, 2016			NCE	Jun 23, 2011
	6037157	Jun 26, 2016	U-935		PED	Jun 13, 2014
	6037157*PED	Dec 26, 2016			PED	Jun 18, 2012
	6248775	Aug 13, 2014	DS		PED	Apr 21, 2012
	6248775*PED	Feb 13, 2015			PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		D-118	Oct 21, 2011
	5843946*PED	Jun 01, 2016			I-578	Oct 21, 2011
	6037157	Jun 26, 2016	U-935		NCE	Jun 23, 2011
	6037157*PED	Dec 26, 2016			PED	Jun 13, 2014
	6248775	Aug 13, 2014	DS		PED	Jun 18, 2012
	6248775*PED	Feb 13, 2015			PED	Apr 21, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	5843946	Dec 01, 2015	DP U-935		D-129	Dec 13, 2013
	5843946*PED	Jun 01, 2016			D-119	Dec 18, 2011
	6037157	Jun 26, 2016	U-935		NS	Dec 18, 2011
	6037157*PED	Dec 26, 2016			NCE	Jun 23, 2011
	6248775	Aug 13, 2014	DS		PED	Jun 13, 2014
	6248775*PED	Feb 13, 2015			PED	Jun 18, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Dec 23, 2011
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	5843946	Dec 01, 2015	DP U-935		D-129	Dec 13, 2013
	5843946*PED	Jun 01, 2016			D-119	Dec 18, 2011
	6037157	Jun 26, 2016	U-935		NS	Dec 18, 2011
	6037157*PED	Dec 26, 2016			NCE	Jun 23, 2011
	6248775	Aug 13, 2014	DS		PED	Jun 13, 2014
	6248775*PED	Feb 13, 2015			PED	Jun 18, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Dec 23, 2011
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
<u>DASATINIB - SPRYCEL</u>						
N021986 005	>A> 6596746	Jun 28, 2020	DS DP U-780			
	>A> 6596746	Jun 28, 2020	DS DP U-748			
	>A> 7125875	Apr 13, 2020	U-780			
	>A> 7125875	Apr 13, 2020	U-779			
	>A> 7153856	Apr 28, 2020	U-780			
<u>DASATINIB - SPRYCEL</u>						
N021986 006	>A> 6596746	Jun 28, 2020	DS DP U-780			
	>A> 6596746	Jun 28, 2020	DS DP U-748			
	>A> 7125875	Apr 13, 2020	U-780			
	>A> 7125875	Apr 13, 2020	U-779			
	>A> 7153856	Apr 28, 2020	U-780			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 007	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	DP U-678		M-80	Oct 17, 2011
	6228398	Nov 01, 2019	DP U-676			
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP U-677			
	6730325	Nov 01, 2019	DP U-676			
	7431944	Dec 04, 2015	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR</u>						
N021802 008	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	DP U-678		M-80	Oct 17, 2011
	6228398	Nov 01, 2019	DP U-676			
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP U-677			
	6730325	Nov 01, 2019	DP U-676			
	7431944	Dec 04, 2015	DP			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	7884095	Feb 24, 2029	U-1111			
	7939518	Feb 24, 2029	U-980			
<u>DICLOFENAC SODIUM - SOLARAZE</u>						
N021005 001	5929048	Jun 17, 2014	U-402			
	5985850	Aug 11, 2015	DP			
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	6133251	Oct 25, 2016	DP U-828	Y		
	6133251	Oct 25, 2016	DP U-112	Y		
	6133251	Oct 25, 2016	DP U-1	Y		
	6884793	Oct 25, 2016	DP	Y		
<u>DORIPENEM - DORIBAX</u>						
N022106 001	5317016	Jun 05, 2015	DS DP U-282			
<u>DORIPENEM - DORIBAX</u>						
N022106 002	5317016	Jun 05, 2015	DS DP U-282			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 001	7915307	Aug 24, 2027	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N022036 002	7915307	Aug 24, 2027	U-620			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N022574 001	5798338	Jul 10, 2015	DP			
	6441168	Apr 17, 2020	DS			
	6958326	Dec 20, 2021	DP			
	7163931	Mar 03, 2022	U-1			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 001	7547719	Jul 13, 2025	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 002	7547719	Jul 13, 2025	DS DP U-930			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 003	7547719	Jul 13, 2025	DS DP U-930			
<u>EPINASTINE HYDROCHLORIDE - EPINASTINE HYDROCHLORIDE</u>						
A090870 001					>A> PC	Oct 29, 2011
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 001					NPP PED	Feb 27, 2011 Aug 27, 2011
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 002					NPP PED	Feb 27, 2011 Aug 27, 2011
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N022101 001					M-86 PED	Jun 18, 2012 Dec 18, 2012
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 001	5714504	Feb 03, 2015	DP U-1053			
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS U-1053			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1053			
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS U-1053			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N022511 002	5714504	Feb 03, 2015	DP U-1053			
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS U-1053			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1053			
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS U-1053			
	7411070*PED	Nov 25, 2018				
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE</u>						
N022262 001	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N021840 001	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE</u>						
N022573 001	5552394	Jul 22, 2014	U-828			
	6667050	Apr 06, 2019	DP U-828			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 001	7887845	Mar 25, 2019	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETRAVIRINE - INTELENCE</u>						
N022187 002	6878717	Nov 05, 2019	U-1016		NCE	Jan 18, 2013
	7037917	Nov 05, 2019	DS DP U-1016			
	7887845	Mar 25, 2019	DP			
<u>EVEROLIMUS - AFINITOR</u>						
N022334 001	>A> 5665772	Sep 09, 2019	DS DP		I-638 ODE	May 05, 2014 Oct 29, 2017
<u>EVEROLIMUS - AFINITOR</u>						
N022334 002	>A> 5665772	Sep 09, 2019	DS DP		I-638 ODE	May 05, 2014 Oct 29, 2017
<u>EVEROLIMUS - AFINITOR</u>						
N022334 003	>A> 5665772	Sep 09, 2019			I-638 NCE ODE	May 05, 2014 Mar 30, 2014 Oct 29, 2017
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 001	>A> 5665772	Sep 09, 2019	DS DP U-1049			
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	>A> 5665772	Sep 09, 2019	DS DP U-1049			
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	>A> 5665772	Sep 09, 2019	DS DP U-1049			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 001	5424286	Dec 01, 2016	U-653			
	5424286	Dec 01, 2016	U-1108			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 002	5424286	Dec 01, 2016	U-653			
	5424286	Dec 01, 2016	U-1108			
<u>EZETIMIBE - ZETIA</u>						
N021445 001	>A> RE42461	Oct 25, 2016	DS DP U-473			
	>A> RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 001	>A> RE37721	Oct 25, 2016	DS DP U-473		Y	
	>A> RE37721*PED	Apr 25, 2017			Y	
	>A> RE42461	Oct 25, 2016	DS DP U-473			
	>A> RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 002	>A> RE37721	Oct 25, 2016	DS DP U-473		Y	
	>A> RE37721*PED	Apr 25, 2017			Y	
	>A> RE42461	Oct 25, 2016	DS DP U-473			
	>A> RE42461*PED	Apr 25, 2017				
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 003	>A> RE37721	Oct 25, 2016	DS DP U-473		Y	
	>A> RE37721*PED	Apr 25, 2017			Y	
	>A> RE42461	Oct 25, 2016	DS DP U-473			
	>A> RE42461*PED	Apr 25, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 004	>A> RE37721	Oct 25, 2016	DS DP U-473	Y		
	>A> RE37721*PED	Apr 25, 2017		Y		
	>A> RE42461	Oct 25, 2016	DS DP U-473			
	>A> RE42461*PED	Apr 25, 2017				
<u>EZOGABINE - POTIGA</u>						
N022345 001					>A> NCE	Jun 10, 2016
<u>EZOGABINE - POTIGA</u>						
N022345 002					>A> NCE	Jun 10, 2016
<u>EZOGABINE - POTIGA</u>						
N022345 003					>A> NCE	Jun 10, 2016
<u>EZOGABINE - POTIGA</u>						
N022345 004					>A> NCE	Jun 10, 2016
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 001					M-98	Jan 31, 2014
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 002					M-98	Jan 31, 2014
<u>FAMCICLOVIR - FAMVIR</u>						
N020363 003					M-98	Jan 31, 2014
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N022519 001					NC	Apr 23, 2014
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N021695 001	7863331	Aug 08, 2020		U-1107		
	7863331	Aug 08, 2020		U-1106		
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N021695 003	7863331	Aug 08, 2020		U-1107		
	7863331	Aug 08, 2020		U-1106		
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418 001	7915247	Aug 20, 2027		U-1061		
	7915247	Aug 20, 2027		U-1059		
	7915247	Aug 20, 2027		U-1000		
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N022418 002	7915247	Aug 20, 2027		U-1061		
	7915247	Aug 20, 2027		U-1059		
	7915247	Aug 20, 2027		U-1000		
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 001	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 002	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 003	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 004	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 005	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - ABSTRAL</u>						
N022510 006	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 001	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 002	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 003	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 004	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 001					>A> NDF	Jun 30, 2014
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 002					>A> NDF	Jun 30, 2014
<u>FERUMOXYTOL - FERAHEME</u>						
N022180 001	7871597	Mar 08, 2020	DS DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	7384980	May 11, 2019	DS DP U-913			
	7855230	May 11, 2019	U-913			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	7384980	May 11, 2019	DS DP U-913			
	7855230	May 11, 2019	U-913			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY</u>						
N020872 007	>A> 5578610	Nov 26, 2013	DS DP U-1160			
	>A> 5578610*PED	May 26, 2014				
	>A> 5855912	Feb 28, 2015	DP			
	>A> 5855912*PED	Aug 28, 2015				
	>A> 5932247	Feb 28, 2015	DP			
	>A> 5932247*PED	Aug 28, 2015				
	>A> 6037353	Mar 14, 2017	U-1160			
	>A> 6037353*PED	Sep 14, 2017				
	>A> 6113942	Feb 28, 2015	DP			
	>A> 6113942*PED	Aug 28, 2015				
	>A> 6187791	May 11, 2012	U-1160			
	>A> 6187791*PED	Nov 11, 2012				
	>A> 6399632	May 11, 2012	U-1160			
	>A> 6399632*PED	Nov 11, 2012				
	>A> 7135571	May 18, 2014	DS U-1160			
	>A> 7135571*PED	Nov 18, 2014				
	>A> 7138524	May 18, 2014	DS			
	>A> 7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY</u>						
N020872 010	>A> 5578610	Nov 26, 2013	DS DP U-1160			
	>A> 5578610*PED	May 26, 2014				
	>A> 5855912	Feb 28, 2015	DP			
	>A> 5855912*PED	Aug 28, 2015				
	>A> 5932247	Feb 28, 2015	DP			
	>A> 5932247*PED	Aug 28, 2015				
	>A> 6037353	Mar 14, 2017	U-1160			
	>A> 6037353*PED	Sep 14, 2017				
	>A> 6113942	Feb 28, 2015	DP			
	>A> 6113942*PED	Aug 28, 2015				
	>A> 6187791	May 11, 2012	U-1160			
	>A> 6187791*PED	Nov 11, 2012				
	>A> 6399632	May 11, 2012	U-1160			
	>A> 6399632*PED	Nov 11, 2012				
	>A> 7135571	May 18, 2014	DS U-1160			
	>A> 7135571*PED	Nov 18, 2014				
	>A> 7138524	May 18, 2014	DS			
	>A> 7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N020872 008	>A> 5578610	Nov 26, 2013	DS DP U-1160			
	>A> 5578610*PED	May 26, 2014				
	>A> 5855912	Feb 28, 2015	DP			
	>A> 5855912*PED	Aug 28, 2015				
	>A> 5932247	Feb 28, 2015	DP			
	>A> 5932247*PED	Aug 28, 2015				
	>A> 6037353	Mar 14, 2017	U-1160			
	>A> 6037353*PED	Sep 14, 2017				
	>A> 6113942	Feb 28, 2015	DP			
	>A> 6113942*PED	Aug 28, 2015				
	>A> 6187791	May 11, 2012	U-1160			
	>A> 6187791*PED	Nov 11, 2012				
	>A> 6399632	May 11, 2012	U-1160			
	>A> 6399632*PED	Nov 11, 2012				
	>A> 7135571	May 18, 2014	DS U-1160			
	>A> 7135571*PED	Nov 18, 2014				
	>A> 7138524	May 18, 2014	DS			
	>A> 7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES</u>						
N020872 009	>A> 5578610	Nov 26, 2013	DS DP U-1160			
	>A> 5578610*PED	May 26, 2014				
	>A> 5855912	Feb 28, 2015	DP			
	>A> 5855912*PED	Aug 28, 2015				
	>A> 5932247	Feb 28, 2015	DP			
	>A> 5932247*PED	Aug 28, 2015				
	>A> 6037353	Mar 14, 2017	U-1160			
	>A> 6037353*PED	Sep 14, 2017				
	>A> 6113942	Feb 28, 2015	DP			
	>A> 6113942*PED	Aug 28, 2015				
	>A> 6187791	May 11, 2012	U-1160			
	>A> 6187791*PED	Nov 11, 2012				
	>A> 6399632	May 11, 2012	U-1160			
	>A> 6399632*PED	Nov 11, 2012				
	>A> 7135571	May 18, 2014	DS U-1160			
	>A> 7135571*PED	Nov 18, 2014				
	>A> 7138524	May 18, 2014	DS			
	>A> 7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N020872 005	>A> 5578610	Nov 26, 2013	DS DP U-1160			
	>A> 5578610*PED	May 26, 2014				
	>A> 5855912	Feb 28, 2015	DP			
	>A> 5855912*PED	Aug 28, 2015				
	>A> 5932247	Feb 28, 2015	DP			
	>A> 5932247*PED	Aug 28, 2015				
	>A> 6037353	Mar 14, 2017	U-1160			
	>A> 6037353*PED	Sep 14, 2017				
	>A> 6113942	Feb 28, 2015	DP			
	>A> 6113942*PED	Aug 28, 2015				
	>A> 6187791	May 11, 2012	U-1160			
	>A> 6187791*PED	Nov 11, 2012				
	>A> 6399632	May 11, 2012	U-1160			
	>A> 6399632*PED	Nov 11, 2012				
	>A> 7135571	May 18, 2014	DS U-1160			
	>A> 7135571*PED	Nov 18, 2014				
	>A> 7138524	May 18, 2014	DS			
	>A> 7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N021909 002	>A> 5578610	Nov 26, 2013	DS DP U-1158			
	>A> 5738872	Feb 28, 2015	DP			
	>A> 6037353	Mar 14, 2017	U-1158			
	>A> 6187791	May 11, 2012	U-1158			
	>A> 6399632	May 11, 2012	U-1158			
	>A> 7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N201373 001	>A> 5578610	Nov 26, 2013	DS DP U-1157			
	>A> 5578610*PED	May 26, 2014				
	>A> 6037353	Mar 14, 2017	U-1157			
	>A> 6037353*PED	Sep 14, 2017				
	>A> 6187791	May 11, 2012	U-1157			
	>A> 6187791*PED	Nov 11, 2012				
	>A> 6399632	May 11, 2012	U-1157			
	>A> 6399632*PED	Nov 11, 2012				
	>A> 7138524	May 18, 2014	DS			
	>A> 7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N020872 006	>A> 5578610	Nov 26, 2013	DS DP			U-1160
	>A> 5578610*PED	May 26, 2014				
	>A> 5855912	Feb 28, 2015		DP		
	>A> 5855912*PED	Aug 28, 2015				
	>A> 5932247	Feb 28, 2015		DP		
	>A> 5932247*PED	Aug 28, 2015				
	>A> 6037353	Mar 14, 2017			U-1160	
	>A> 6037353*PED	Sep 14, 2017				
	>A> 6113942	Feb 28, 2015		DP		
	>A> 6113942*PED	Aug 28, 2015				
	>A> 6187791	May 11, 2012			U-1160	
	>A> 6187791*PED	Nov 11, 2012				
	>A> 6399632	May 11, 2012			U-1160	
	>A> 6399632*PED	Nov 11, 2012				
	>A> 7135571	May 18, 2014	DS		U-1160	
	>A> 7135571*PED	Nov 18, 2014				
	>A> 7138524	May 18, 2014	DS			
	>A> 7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N021909 003	>A> 5578610	Nov 26, 2013	DS DP			U-1158
	>A> 5738872	Feb 28, 2015		DP		
	>A> 6037353	Mar 14, 2017			U-1158	
	>A> 6187791	May 11, 2012			U-1158	
	>A> 6399632	May 11, 2012			U-1158	
	>A> 7138524	May 18, 2014	DS			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N201373 002	>A> 5578610	Nov 26, 2013	DS DP			U-1157
	>A> 5578610*PED	May 26, 2014				
	>A> 6037353	Mar 14, 2017			U-1157	
	>A> 6037353*PED	Sep 14, 2017				
	>A> 6187791	May 11, 2012			U-1157	
	>A> 6187791*PED	Nov 11, 2012				
	>A> 6399632	May 11, 2012			U-1157	
	>A> 6399632*PED	Nov 11, 2012				
	>A> 7138524	May 18, 2014	DS			
	>A> 7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION</u>						
N020786 002	>A> 5578610	Nov 26, 2013	DS DP U-1159			
	>A> 5578610*PED	May 26, 2014				
	>A> 5855912	Feb 28, 2015	DP			
	>A> 5855912*PED	Aug 28, 2015				
	>A> 6037353	Mar 14, 2017	U-1159			
	>A> 6037353*PED	Sep 14, 2017	U-138			
	>A> 6039974	Jul 31, 2018	DP			
	>A> 6113942	Feb 28, 2015	DP			
	>A> 6113942*PED	Aug 28, 2015				
	>A> 6187791	May 11, 2012	U-1159			
	>A> 6187791*PED	Nov 11, 2012	U-138			
	>A> 6399632	May 11, 2012	U-1159			
	>A> 6399632*PED	Nov 11, 2012	U-468			
	>A> 7135571	May 18, 2014	DS U-1159			
	>A> 7135571*PED	Nov 18, 2014				
	>A> 7138524	May 18, 2014	DS			
	>A> 7138524*PED	Nov 18, 2014				
<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION</u>						
N021704 002	>A> 5578610	Nov 26, 2013	DS DP U-1159			
	>A> 5578610*PED	May 26, 2014				
	>A> 6037353	Mar 14, 2017	U-1159			
	>A> 6037353*PED	Sep 14, 2017				
	>A> 6187791	May 11, 2012	U-1159			
	>A> 6187791*PED	Nov 11, 2012				
	>A> 6399632	May 11, 2012	U-1159			
	>A> 6399632*PED	Nov 11, 2012				
	>A> 6613357	Dec 25, 2020	DP U-1159			
	>A> 7138524	May 18, 2014	DS			
	>A> 7138524*PED	Nov 18, 2014				
	>A> RE39069	May 29, 2018	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N201699 001					NCE	May 27, 2016
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N021112 001	7915243	Mar 22, 2026	DP			
	7939516	May 04, 2025	DP			
<u>FULVESTRANT - FASLODEX</u>						
N021344 001	6774122	Jan 09, 2021	U-596		D-126	Sep 09, 2013
	6774122*PED	Jul 09, 2021			M-103	May 17, 2014
	7456160	Jan 09, 2021	U-596		PED	Nov 17, 2014
	7456160*PED	Jul 09, 2021			PED	Mar 09, 2014
<u>GABAPENTIN - GABAPENTIN</u>						
A078974 001					PC	Aug 22, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN - GRALISE</u>						
N022544 001	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
<u>GABAPENTIN - GRALISE</u>						
N022544 002	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 001	6818787	Nov 06, 2022	DS DP		NCE	Apr 06, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 001	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 002	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 003	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 004	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOBUTROL - GADAVIST</u>						
N201277 005	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001	5362475	Nov 08, 2011	DS			
	6676929	May 26, 2015	DP			
	7011815	Feb 01, 2015	U-1112			
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015	U-1112			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002	5362475	Nov 08, 2011	DS			
	6676929	May 26, 2015	DP			
	7011815	Feb 01, 2015	U-1112			
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015	U-1112			
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A077983 001					PC	Jul 24, 2011
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A077983 002					PC	Jul 24, 2011
<u>GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE</u>						
A079183 001					PC	May 14, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 001					M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 002					M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 003					M-102	Apr 29, 2014
<u>GRANISETRON HYDROCHLORIDE - KYTRIL</u>						
N020239 004					M-102	Apr 29, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 001					I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 002					I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 003					I-635	Feb 25, 2014
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N022037 004					I-635	Feb 25, 2014
<u>HYDROXOCOBALAMIN - CYANOKIT</u>						
N022041 001	5834448	Nov 14, 2016	DP		ODE	Dec 15, 2013
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA</u>						
N021945 001					ODE	Feb 03, 2018
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N021903 001	6342530	Nov 14, 2020	DP U-794			
	6342530	Nov 14, 2020	DP U-1127			
	6344479	Mar 20, 2021	DS DP U-794	Y		
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 001					I-636	Mar 24, 2014
<u>INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN</u>						
N020314 001	5384113	Jan 24, 2012	DP			
	5753627	May 19, 2015		U-1125		
	5776894	Jul 07, 2015	DS DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS</u>						
N021081 001	7918833	Sep 23, 2027	DP			
	7918833*PED	Mar 23, 2028				
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N021629 003	7918833	Sep 23, 2027	DP			
<u>INSULIN RECOMBINANT HUMAN - HUMULIN R</u>						
N018780 001					NR	Mar 25, 2014
<u>INSULIN RECOMBINANT HUMAN - HUMULIN R PEN</u>						
N018780 005					NR	Mar 25, 2014
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454 001					NCE	Jan 14, 2016

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	6670384	Jan 23, 2022	DP U-960		NCE	Oct 16, 2012
	6670384	Jan 23, 2022	DP U-959		PED	Apr 16, 2013
	6670384*PED	Jul 23, 2022				
	7022330	Jan 23, 2022	DP U-958			
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	6670384	Jan 23, 2022	DP U-960		NCE	Oct 16, 2012
	6670384	Jan 23, 2022	DP U-959		PED	Apr 16, 2013
	6670384*PED	Jul 23, 2022				
	7022330	Jan 23, 2022	DP U-958			
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 001	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 002	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 003	7919115	Jan 04, 2029	DS DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N022251 004	7919115	Jan 04, 2029	DS DP			
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 001	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 002	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N022074 003	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 001	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LANSOPRAZOLE - PREVACID</u>						
N021428 002	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	7855217	Nov 24, 2024	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	7855217	Nov 24, 2024	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	7855217	Nov 24, 2024	DS DP			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N020517 003					>A> D-132	Jun 17, 2014
					>A> NS	Jun 17, 2014
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 001					I-637	Apr 29, 2014
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 002	6500829	Dec 31, 2019	DS DP		I-637 ODE	Apr 29, 2014 Mar 07, 2015
<u>LEVOLEUCOVORIN CALCIUM - FUSILEV</u>						
N020140 003	6500829	Dec 31, 2019	DS DP		I-637 ODE	Apr 29, 2014 Mar 07, 2015
<u>LINAGLIPTIN - TRADJENTA</u>						
N201280 001	6303661	Apr 24, 2017	U-774		>A> NCE	May 02, 2016
	6890898	Feb 02, 2019	U-493			
	7078381	Feb 02, 2019	U-493			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-493			
<u>LOTEPREDNOL ETABONATE - LOTEMAX</u>						
N200738 001					NDF PED	Apr 15, 2014 Oct 15, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 001	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1131			
	6469035	Mar 15, 2018	U-1130			
	6676967	Sep 20, 2013	U-1132			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 002	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1131			
	6469035	Mar 15, 2018	U-1130			
	6676967	Sep 20, 2013	U-1132			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 003	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1131			
	6469035	Mar 15, 2018	U-1130			
	6676967	Sep 20, 2013	U-1132			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
<u>LOVASTATIN; NIACIN - ADVICOR</u>						
N021249 004	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1131			
	6469035	Mar 15, 2018	U-1130			
	6676967	Sep 20, 2013	U-1132			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 001	7919116	Mar 20, 2018	DP			
<u>METFORMIN HYDROCHLORIDE - FORTAMET</u>						
N021574 002	7919116	Mar 20, 2018	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024 001	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	>A> 7959946	Jul 31, 2026	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N022024 002	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	>A> 7959946	Jul 31, 2026	DP			
<u>METRONIDAZOLE - VANDAZOLE</u>						
N021806 001	7456207	Sep 22, 2024	DP			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 001	7888342	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 002	7888342	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 003	7888342	Nov 05, 2021	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 004	7888342	Nov 05, 2021	U-882			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 001	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 002	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 003	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 004	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 005	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 006	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 007	7919483	Feb 28, 2027	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 008	7919483	Feb 28, 2027	U-1078			
<u>MOMETASONE FUROATE MONOHYDRATE - NASONEX</u>						
N020762 001					M-99	Jan 19, 2014
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N022428 001	7671070*PED	Mar 29, 2020				
<u>MUPIROCIN CALCIUM - BACTROBAN</u>						
N050746 001	6025389	Oct 20, 2014	DP U-1122			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NALTREXONE - VIVITROL</u>						
N021897 001	7919499	Oct 15, 2029	U-1124			
	7919499	Oct 15, 2029	U-1123			
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N201152 001	5366972	Nov 22, 2011	DS DP U-167		NDF	Mar 25, 2014
	5366972*PED	May 22, 2012				
<u>NIACIN - NIASPAN</u>						
N020381 002	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-1145			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1143			
	6676967	Sep 20, 2013	U-1138			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	7011848	Sep 20, 2013	U-1148			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N020381 003	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-1145			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1143			
	6676967	Sep 20, 2013	U-1138			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1141			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	7011848	Sep 20, 2013	U-1148			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN - NIASPAN</u>						
N020381 004	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-1145			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1143			
	6676967	Sep 20, 2013	U-1138			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1141			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	7011848	Sep 20, 2013	U-1148			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 001	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-862			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 002	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-862			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 003	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-862			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 004	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIACIN; SIMVASTATIN - SIMCOR</u>						
N022078 005	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			
<u>NITROGLYCERIN - RECTIV</u>						
N021359 001					>A> NP	Jun 21, 2014
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 001					NPP PED	Dec 04, 2012 Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 002					NPP PED	Dec 04, 2012 Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 003					NPP PED	Dec 04, 2012 Jun 04, 2013
<u>OLANZAPINE - ZYPREXA ZYDIS</u>						
N021086 004					NPP PED	Dec 04, 2012 Jun 04, 2013
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 001	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 002	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021087 003	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N021246 001	5763483	Dec 27, 2016	DS	U-376		
	5763483	Dec 27, 2016	DS	U-1113		
	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	7923536	Dec 09, 2023	U-1117			
	RE41884	Aug 14, 2016	U-1117			
<u>PALIPERIDONE - INVEGA</u>						
N021999 001					NPP PED	Apr 06, 2014 Oct 06, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE - INVEGA</u>						
N021999 002					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 003					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 004					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALIPERIDONE - INVEGA</u>						
N021999 006					NPP PED	Apr 06, 2014 Oct 06, 2014
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N021372 001	7947724	Jan 30, 2024	DP			
	7947725	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N021372 002	7947724	Jan 30, 2024	DP			
	7947725	Jan 30, 2024	DP			
<u>PAROXETINE HYDROCHLORIDE - PAROXETINE HYDROCHLORIDE</u>						
A091427 001					PC	Nov 01, 2011
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 001					M-61 PED	Mar 17, 2014 Sep 17, 2014
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 002					M-61 PED	Mar 17, 2014 Sep 17, 2014
<u>PERFLUTREN - DEFINITY</u>						
N021064 001	5527521	Feb 22, 2015	DP U-665			
	5585112	Dec 17, 2013	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 001	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	7915229	Apr 14, 2023	DP			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	7915229	Apr 14, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PLERIXAFOR - MOZOBIL</u>						
N022311 001	7897590	Jul 22, 2023	U-936			
	RE42152	Dec 10, 2013	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 001					>A> M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 002					>A> M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 003					>A> M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 005					>A> M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 006					>A> M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
N020667 007					>A> M-104	May 13, 2014
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 006	>A> 7695734	Apr 26, 2028	DP		>A> I-623 >A> NDF	Mar 19, 2013 Feb 19, 2013
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N022421 007	>A> 7695734	Apr 26, 2028	DP		>A> I-623 >A> NDF	Feb 19, 2013 Feb 19, 2013
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145 001	7169780	Oct 03, 2023	DS DP			
<u>RANOLAZINE - RANEXA</u>						
N021526 001	6369062	May 27, 2019	DP		Y	
<u>RETAPAMULIN - ALTABAX</u>						
N022055 001	7875630	Feb 14, 2027	DS			
	RE39128	Apr 12, 2021	DS DP U-805			
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7928115	Jul 24, 2029	U-1121			
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N202022 001	6838464	Feb 26, 2021	DS DP		NCE	May 20, 2016
	7067522	Dec 20, 2019	DS DP			
	7125879	Apr 14, 2023	DS DP U-1153			
	7638522	Apr 14, 2023	DP			
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 001	5602162	Feb 11, 2014			Y	
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 002	5602162	Feb 11, 2014			Y	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 001	5602162	Feb 11, 2014	U-240	Y		
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 002	5602162	Feb 11, 2014	U-240	Y		
<u>ROFLUMILAST - DALIRESP</u>						
N022522 001	5712298	Jan 27, 2015	DS DP U-1115		NCE	Feb 28, 2016
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N022008 001	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N022008 002	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N022008 003	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N022008 004	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N022008 005	7927624	Dec 02, 2021	DP U-20			
<u>ROPINIROLE HYDROCHLORIDE - EQUIP XL</u>						
N022008 006	7927624	Dec 02, 2021	DP U-20			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 001	6699498	Nov 27, 2020	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 002	6699498	Nov 27, 2020	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 003	6699498	Nov 27, 2020	DP			
<u>RUFINAMIDE - BANZEL</u>						
N201367 001	6740669	Aug 17, 2020	DS DP		NCE ODE	Nov 14, 2013 Nov 14, 2015
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N022181 001	>A> 7947681	Nov 17, 2024	U-1156			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N022350 001	>A> 7951400	Nov 30, 2028	DP			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N022350 002	>A> 7951400	Nov 30, 2028	DP			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODE</u>						
N201444 001					ODE	Jan 14, 2018
<u>SODIUM OXYBATE - XYREM</u>						
N021196 001	7668730	Jun 16, 2024	U-1110			
	7895059	Dec 17, 2022	U-1110			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N021923 001	7897623	Jan 12, 2020	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SPINOSAD - NATROBA</u>						
N022408 001	5496931	Mar 05, 2013	DS U-1105		NCE	Jan 18, 2016
	6063771	Jun 22, 2019	DP U-1105			
	6342482	Jun 22, 2019	DP U-1105			
	7030095	Jul 02, 2021	DP U-1105			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	7776007	Nov 28, 2026	DP			
	7901385	Jul 31, 2026	DP			
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 001	>A> 6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 002	>A> 6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 003	>A> 7125905	Feb 15, 2021	DS DP		I-639	May 20, 2014
<u>SUNITINIB MALATE - SUTENT</u>						
N021938 004	>A> 6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
<u>TECHNETIUM TC-99M MERTIATIDE KIT - TECHNESCAN MAG3</u>						
N019882 001	5573748	Nov 12, 2013	DP			
<u>TELAPREVIR - INCIVEK</u>						
N201917 001					NCE	May 23, 2016
<u>TELBIVUDINE - TYZEKA</u>						
N022011 001	7858594	Sep 11, 2023	DS DP U-999			
<u>TESTOSTERONE - ANDROGEL</u>						
N022309 001	6503894	Aug 30, 2020	U-1103		NP	Apr 29, 2014
<u>TESTOSTERONE - FORTESTA</u>						
N021463 001	6319913	Nov 09, 2018	U-490			
	6579865	Nov 09, 2018	DP			
<u>TESTOSTERONE - TESTIM</u>						
N021454 001	7935690	Apr 21, 2023	U-1009			
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	>A> 7959566	Oct 23, 2020	U-1155			
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	>A> 7959566	Oct 23, 2020	U-1155			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	>A> 7959566	Oct 23, 2020	U-1155			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	>A> 7959566	Oct 23, 2020	U-1155			
<u>TIGECYCLINE - TYGACIL</u>						
N021821 001	7879828	Feb 05, 2029	DP			
<u>TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA</u>						
N021395 001	6908928	Sep 24, 2021	DS DP U-762			
	6908928	Sep 24, 2021	DS DP U-566			
	7309707	Sep 24, 2021	DS DP			
	7694676	Mar 12, 2027	DP			
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N022430 001	7947739	Mar 04, 2025	DP			
<u>VANDETANIB - VANDETANIB</u>						
N022405 001	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	RE42353	Sep 23, 2017	DS DP		ODE	Apr 06, 2018
<u>VANDETANIB - VANDETANIB</u>						
N022405 002	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	RE42353	Sep 23, 2017	DS DP		ODE	Apr 06, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 001	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 002	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 003	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
<u>ZOLEDRONIC ACID - RECLAST</u>						
N021817 001	7932241	Feb 05, 2028	DP			
	7932241*PED	Aug 05, 2028				
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N021223 003	>A> 7932241	Feb 05, 2028	DP			
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A078148 001					PC	Jun 04, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
-----------------	-----------	------------------------------	-----------------	-------------------------------	------------------------	-----------------------------------

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
3. **** The expiration date for U.S. Patent No. 5,608,075 is March 4, 2009.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>